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Homeostasis of the Immune System
Components of the immune system and the dynamics of the T cell response to antigens
The immune system is regulated by 
a complex set of biological processes, 
mediated by a variety of specialized 
molecules; it protects the organism 
against pathogens and against its own 
damaged, potentially dangerous cells. 
The first line of defense consists of 
the components of the innate immune 
system, which provide an immediate but 
non-specific response.  This defense 
is provided principally by phagocytes 
(macrophages, dendritic cells and 
neutrophils) (Medzhitov et al., 2007).  In 
addition to identifying and eliminating 
pathogens, innate immune cells are 
important mediators in the activation of 
the adaptive immune response.  This 
second type of response is triggered 
by pathogens that successfully escape 
the control of the innate system, and 
is characterized by high specificity for 
antigens.  The adaptive immune response 
can be classified on the basis of the 
immune components that participate in 
it, which consist of the cellular immune 
response (mediated by CD4+ and 
CD8+ T cells) and the humoral immune 
response (mediated by B cells).
The T cells of the adaptive immune 
system play a crucial role in defending 
the organism against pathogens.  Initial 
stimulation by foreign antigens presented 
by antigen-presenting cells (APC) 
induces activation and clonal proliferation 
of T cells, to generate effector cells that 
clear pathogen from the body.  This 
process, termed clonal expansion, is 
needed to produce a sufficient number 
of pathogen-specific effector T cells.  The 
effector functions of CD4+ T cells consist 
of cytokine and chemokine production, 
which augment the immune response 
at the focus of infection.  Based on the 
pattern of cytokines produced, CD4+ 
T cells can be classified as Th1 (type 1 
T helper cells), which secrete IL-2 and 
IFNγ, Th2 (type 2 T helper cells), which 
secrete IL-4 and IL-5 and Th17 (T helper 
17 cells), which produce IL-17 and IL-
22.  In addition to these populations, 
whose effector functions are directed 
toward pathogen elimination, another 
CD4+ T cell subtype has been identified, 
the CD4+ regulatory T cells (Treg). 
These cells (phenotypically defined as 
CD4+CD25+CD127lowFoxp3+) produce 
suppressor cytokines such as IL-10 and 
TGF-β, and suppress T cell functions to 
avoid chronic activation and autoreactivity 
of T cells in the periphery (Aluvihare et 
al., 2006; Bluestone et al., 2003).
At difference from CD4+ T cells, 
whose effector mechanisms are based 
mainly on cytokine secretion, CD8+ T 
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cells act as cytotoxic T cells that directly 
kill target cells infected with virus or 
intracellular microorganisms.
After antigen clearance, the clonally 
expanded activated T cell population 
must be eliminated to maintain T cell 
homeostasis and to prevent development 
of autoimmunity and hyperproliferative 
diseases; this process is called the 
contraction phase (Krammer et al., 2007; 
Strasser et al., 2004).  Although Fas-
mediated apoptosis was considered the 
main mechanism involved in this process, 
in vivo regulation of the contraction 
phase and the contribution of the distinct 
death pathways (Fas- and Bim-driven) is 
still poorly understood (McKinstry et al., 
2010).  Due to the absence of pathogen-
derived antigens, T cells stop receiving 
activation and survival signals from 
the APC.  Only a few T cells previously 
exposed to antigen are able to survive 
and develop into memory T cells, which 
provide a more rapid response after 
secondary challenge with the same 
antigen (Murali-Krishna et al., 1998; 
Blattman et al., 2002; Sprent et al., 2002; 
Surh et al., 2006).
T cell homeostasis is mediated by the 
balance between cell death and prolifer-
ation.  This balance is characterized by 
rapid clonal expansion of antigen-reac-
tive lymphocytes, followed by apoptosis 
of activated cells.  The misregulation of 
apoptosis or proliferation of apoptosis-
surviving T cells can lead to a number of 
immune diseases (Arias et al., 2007).
One characteristic of the immune 
system is its capacity to recognize and 
respond only to external antigens.  The 
absence of a response to the organism’s 
own antigens is called self tolerance; loss 
of the ability to distinguish between self 
and non-self leads to immune responses 
against autoantigens and to development 
of autoimmune diseases.
Self tolerance is maintained through 
central and peripheral mechanisms. 
Central tolerance, which takes place dur-
ing the maturation process in the thymus, 
ensures elimination of lymphocytes able 
to recognize high affinity autoantigens 
presented in the thymus.  This selection 
process is termed negative selection. 
There is also positive selection, which 
ensures that the TCR (T cell receptor) 
is able to recognize its cognate ligand, 
the peptide-binding major histocompat-
ibility complex (MHC).  T cells whose 
TCR does not fulfill this requirement and 
thus do not receive survival signals are 
eliminated through apoptosis in a pro-
cess called “death by neglect”.  Positive 
and negative selection together allow the 
thymus to produce self-tolerant, function-
ally competent T cells, in order to estab-
lish immunity against foreign pathogens 
(Sprent et al., 2002; Gascoigne et al., 
2011; Metzger et al., 2011).  Recent stud-
ies nonetheless suggest that not all thy-
Tolerance and autoimmunity
INTRODUCTION 11
mocytes with high affinity for self antigen 
are deleted by negative selection in the 
thymus; some survive and undergo non-
deletional central tolerance that leads to 
generation of immunosuppressor CD4+ T 
cells known as naturally-occurring regula-
tory T cells (Treg; Sakaguchi et al., 2003; 
Liu et al., 2006).
The majority of autoreactive T 
cells is eliminated during the central 
tolerance process.  However, not all 
endogenous autoantigens are present 
in the thymus and a small percentage 
of T cells with autoreactive capacity is 
thus released to the periphery (Burns 
et al., 1983).  Here, the second level 
of control permits limitation of the 
autoreactive T cell response during 
encounter with autoantigens in tissues 
outside the thymus; this is peripheral 
tolerance.  This process is based on a 
variety of complex mechanisms, such 
as immunological ignorance, deletion, 
inhibition or suppression of autoreactive 
clones (Walker et al., 2002; Abbas et al., 
2003; 2004).
Immunological ignorance is caused by 
the physical separation between T cells 
and antigens, such as that seen in the 
blood-brain barrier, or by antigen levels 
insufficient to activate T lymphocytes. 
Another mechanism is clonal anergy, 
which consists of antigen presentation in 
the absence of necessary costimulation. 
The failure of full T cell activation leads 
to functional inability to respond, or to cell 
death by apoptosis.
The mechanisms of immunosuppres-
sion include several immunoregulatory 
cell populations whose basic charac-
teristic is the ability to secrete immu-
nosuppressor cytokines, such as IL-4, 
IL-10 and TGF-β.  Naturally-occurring 
Treg (CD4+CD25+CD127lowFoxp3+) are 
among these cells, but there are also oth-
er immunoregulatory subsets, including 
NK-T cells, CD8+CD28- T cells, Tδγ cells, 
and DN (double negative; CD4-CD8-) T 
cells.
Another important mechanism that 
aborts T cell activation after autoantigen 
recognition is the programmed death 
of T cells by apoptosis.  It has become 
evident that elimination of activated T 
cells is the main mechanism for ensuring 
tolerance in the periphery (Krueger et 
al., 2003).  Apoptosis mediated by Fas, 
a member of the tumor necrosis factor 
(TNF) receptor family, is fundamental 
for T cell homeostasis and tolerance 
induction.  This apoptosis system was 
considered the major death pathway in 
the termination of immune response, and 
is well established in vitro in human and 
murine systems (Dhein et al., 1995; Suda 
et al., 1997).  Nevertheless, some in vivo 
studies questioned the prominence of 
its function in this process (Strasser and 
Pellegrini, 2004; Lohman et al., 1996; 
Pellegrini et al., 2003).  In addition to Fas/
FasL signaling, various reports indicated 
that Bim has a central role in T cell death 
induction (Pellegrini et al., 2003; Hughes 
et al., 2008).  
Activation-induced cell death (AICD) 
is the in vitro process of cell death induc-
tion of already-activated T cells by restim-
ulation of the TCR.  In this experimental 
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model, naïve T cells are first activated 
with antigens or mitogens, expanded in 
culture medium containing IL-2, and re-
stimulated in a TCR-dependent manner 
(Scheme 5, Material and Methods).  As a 
consequence, the majority of reactivated 
T cells die through apoptosis.  Extensive 
studies demonstrated that Fas can drive 
the AICD observed in vitro.  Following 
restimulation, upregulation of Fas ligand 
(FasL) takes place, and the Fas/FasL in-
teraction triggers activation of initial and 
effector caspases that lead to cell death 
(Krammer et al., 2000; Green et al., 
2003; Strasser et al., 2000; Nagata et al., 
1995).  Sensitivity to AICD is strictly con-
trolled by the activation status of T cells 
(Klas et al., 1993; Peter et al., 1997).  Its 
initiation requires IL-2 exposure prior to 
secondary TCR stimulation (Walker and 
Abbas, 2002).  Apart from leading to 
AICD sensitization, IL-2 is also an essen-
tial factor in T cell proliferation (Lenardo 
et al., 1991).
The Fas/FasL apoptotic system
Fas was initially characterized as 
a cell membrane receptor with the 
capacity to induce cell death of cells 
treated in vitro with monoclonal anti-Fas 
antibodies (Ogasawara et al., 1993). 
Fas, also known as CD95, TNFR6, 
DR1 or APO-1, is expressed on the 
plasma membrane as a pre-associated 
homotrimer.  As mentioned above, Fas is 
a member of the TNF family, as it has the 
three extracellular cysteine-rich domains 
characteristic of this superfamily (Krammer 
et al., 2000; Green et al., 2003; Krueger 
et al., 2003).  A common feature of death 
receptors, including TNF family members, 
is the presence in their cytoplasmic tail 
of the death domain (DD), a conserved 
80-amino-acid region that serves as a 
platform for death-inducing signaling 
complex (DISC) formation (Wajant et al., 
2003; Delalande et al., 2008).
FasL (CD95L, APO-1L, CD178) is a 
TNF family ligand and is also assembled 
at the plasma membrane in homotrimer 
form (Li-Weber et al., 2003).  Proteolysis 
can generate soluble forms of this 
ligand composed of extracellular protein 
fragments, but a recent report indicated 
that only the membrane-bound FasL 
form is essential for apoptosis induction 
(O’Reilly et al., 2009).
Following binding of FasL, Fas under-
goes conformational changes that allow 
recruitment of the adaptor molecule FADD 
(Fas-associated death domain protein) 
through homotypic interaction of death 
domains present in both molecules.  This 
in turn leads to the recruitment of initia-
tor caspase-8 and formation of the DISC 
(Kischkel et al., 1995; Peter et al., 2003). 
The interaction of FADD and caspase-8 
is mediated through binding of death ef-
fector domains (DED) found in both pro-
teins (Tibbetts et al., 2003; Bernhart et al., 
2003).  A number of trimeric Fas receptor 
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units, each in association with DISC, form 
aggregates called SPOTS (signaling pro-
tein oligomeric transduction structures; 
Siegel et al., 2004).  The oligomerized 
receptors must be internalized through 
clathrin-dependent endocytosis; this al-
lows further recruitment of DISC compo-
nents and permits the local caspase-8 
concentration necessary for its autopro-
cessing.  The receptor internalization is an 
obligatory step, since its inhibition impairs 
full DISC formation and apoptosis (Lee et 
al., 2006).  As a result of auto-cleavage, 
the capase-8 large (p18) and small sub-
units (p10) are released, and reassemble 
to form heterotetramers that consist of two 
large and two small subunits; this is the 
enzymatically active caspase-8 form.  This 
activated caspase-8 is released into the 
cytoplasm, where it targets downstream 
effector caspases such as caspase-3 and 
-7, and triggers apoptosis (Boatright et al., 
2003; Chang et al., 2003).  Interestingly, 
the whole (unprocessed) caspase-8 form 
is associated with lymphocyte prolifera-
tion (Lamkanfi et al., 2007; Bidere et al., 
2006a, Scheme 1).
FLIP (FLICE-inhibitory protein) is one 
of the potent negative regulators of the 
Fas signaling pathway, at the level of 
DISC; it is a caspase-8-like protein that 
has two death effector domains and a 
pseudo-caspase-8-like domain, but lacks 
enzymatic activity (Budd et al., 2006).  In 
low concentrations, cFLIP (cellular FLIP) 
acts as a positive regulator of caspase-8 
activation.  Increased amounts of cFLIP 
nonetheless inhibit caspase-8 activation, 
probably by replacing caspase-8 in the 
DISC and thus dampening apoptosis 
(Chau et al., 2011; Chang et al., 2002; 
Irmler et al., 1997; Katoka et al., 1998).
zVAD
Fas
FasL
FADD
 caspase-8
whole form
 Cleaved
caspase-8
Activation of effector
 caspases-3 and -7
Apoptosis
Bid CBid
Mitochondria
Proliferation
DISC
Scheme 1.  Apoptotic pathway
Binding of Fas by FasL induces Fas con-
formational changes that lead to FADD 
recruitment, which in turn recruits caspase-8 
and results in formation of DISC (death-
inducing signaling complex).  Within DISC, 
caspase-8 is autoprocessed, and active 
cleaved caspase-8 is released to the cyto-
plasm, where it can target downstream 
effector caspases and induce apoptosis.  
Caspase-8 can also amplify the apoptotic 
signal by cleaving Bid.  The cell death inhi-
bitor zVAD blocks apoptosis at the level of 
DISC, impeding caspase-8 autoprocessing.
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Autoimmune disease development in 
B6/lpr mice
B6/lpr (from lymphoproliferation) mice 
show Fas deficiency due to spontane-
ous retrotransposon insertion into intron 
2 of the Fas gene.  This leads to defec-
tive apoptosis signaling and develop-
ment of autoimmune disease, character-
ized by lymphadenopathy and spleno-
megaly.  These abnormalities originate 
from the accumulation of DN T cells 
(TCRab+CD4-CD8-B220+), which are 
rare components of the peripheral T cell 
repertoire.  Accumulation of CD4+ mem-
ory T cells (CD44high/CD62Llow) and 
IgG+ B cells is also observed.  In addi-
tion, Fas-deficient mice have elevated 
levels of anti-DNA antibodies in serum, 
immune complex formation in tissues, 
and mild glomerulonephritis.  This auto-
immune phenotype is much more severe 
in mice on the MRL background (MRL/
lpr), in which kidney failure and death 
are the final consequence of the disease 
(Walker and Abbas, 2002).
Lack of Fas-triggered apoptosis in 
activated T cells of B6/lpr mice was sug-
gested to be a direct cause of lymphade-
nopathy development (Watanabe-Fuku-
naga et al., 1992).  However, the etiol-
ogy of autoimmune disease and lymph-
adenopathy development in B6/lpr mice 
remains elusive, since the in vitro T cell 
apoptotic defect is not always associated 
with reduced apoptosis in vivo (Walker 
and Abbas, 2002).  Moreover, cell death 
defects themselves do not explain the 
B6/lpr phenotype.  In the absence of oth-
er apoptotic pathway components such 
as FADD (as in FADD-/- mice and trans-
genic mice that overexpress a dominant 
negative form of FADD) and caspase-8 
(in humans with an inherited genetic de-
ficiency of caspase-8 and in mice with 
caspase-8 deficiency in T cells), lack of 
apoptosis is accompanied by immunode-
ficiency (Zhang et al., 1998; Newton et 
al., 1998; Newton et al., 2001; Chun et 
al., 2002; Salmena et al., 2003).  On the 
other hand, transgenic mice that over-
express the caspase-8 inhibitor CrmA in 
T cells, and thus lack apoptotic signaling, 
show no phenotypic abnormalities and 
do not develop lymphadenopathy (Smith 
et al., 1996, Scheme 2).
Mouse models with abnormal FADD 
and caspase-8 expression or function 
showed that the origin of autoimmune 
disease associated with impaired Fas 
signaling is more complex than simply 
the result of defective cell death.  Lack 
of FADD and caspase-8 in various 
mouse models and human pathologies 
does not reproduce the phenotype of 
Fas deficiency, although there is a clear 
resistance to apoptosis in vitro.  These 
observations question the apoptosis 
defect due to Fas deficiency as the direct 
cause of autoimmunity development, 
and reveal a gap between the known in 
vitro properties of Fas and the in vivo 
phenotypic abnormalities observed in 
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Fas
FasL
FADD
 caspase-8
whole form
 Cleaved
caspase-8
Activation of effector
 caspases-3 and -7
Apoptosis
no Fas
no FasL
no FADD
 no caspase-8
lpr
gld
DN-FADD
FADD
CrmA
caspase-8 -/-
-/-
No Apoptosis
Autoimmunity
and Lymphadenopathy
Immunodeficiency
or no proliferative defect (CrmA)
Phenotype:
Scheme 2.  Summary of the immunological consequences associated with absence of 
Fas, FasL, FADD or caspase-8
its absence, including lymphadenopathy 
development and lupus-like disease. 
In addition to autoimmune disease 
development in B6/lpr mice, T cells from 
their lymph nodes hyperproliferate in vivo 
(Balomenos et al., 1997; Fortner and 
Budd, 2005); this characteristic of Fas-de-
ficient mice also remains unexplained.  A 
similar hyperproliferative T cell phenotype 
is observed in patients with ALPS (auto-
immune lymphoproliferative syndrome; 
Straus et al., 1999), an autoimmune dis-
ease also characterized by defects in 
Fas-mediated apoptosis, accompanied 
by lymphadenopathy, splenomegaly, 
DN T cell accumulation, elevated serum 
IgG and autoantibodies, and high risk of 
lymphoma development.  Glomerulone-
phritis, autoimmune hemolytic anemia 
and autoimmune neutropenia are also 
found in some patients.  In most cases, 
development of this disease takes place 
early in life, usually before five years of 
age (Biedere et al., 2006b; Neven et al., 
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2011).  Understanding the nature of the 
T cell hyperproliferation observed in B6/
lpr mice would thus be of great value in 
the context of ALPS and of other autoim-
mune diseases characterized by uncon-
trolled lymphocyte expansion.
The importance of T cell hyperprolif-
eration in the development of lymhade-
nopathy and lupus-like disease was pre-
viously shown by our lab (Arias et al., 
2007).  Mice deficient in the cell cycle in-
hibitor p21 develop autoimmunity, indicat-
ing the relevance of lymphoproliferation 
in autoimmune disease development.  In 
this thesis, we show that inhibition of in 
vivo T cell hyperproliferation by p21 over-
expression greatly reduces lymphade-
nopathy in B6/lpr mice.
NF-κB activation after TCR 
stimulation depends on whole 
caspase-8 molecule
The intracellular aspartic-specific 
cysteine protease caspase-8 initiates 
death signaling for the extrinsic apoptotic 
pathway, which is triggered by several 
death receptors of the TNF receptor 
family such as TNFR1, CD95, TRAIL, 
DR3 and DR6 (Ashkenazi et al., 1998). 
Caspase-8 can also amplify the apoptotic 
signal by activating the intrinsic apoptotic 
pathway through the cleavage of BID 
(BH3-interacting domain death agonist) 
(Luo et al., 1998, Scheme 1).
It is now well established that, in 
addition to promoting apoptosis, active 
casapse-8 is essential for T cell activation 
and proliferation after TCR stimulation, 
and that its activity is necessary for NF-
κB activation (Chun et al., 2002; Salmena 
et al., 2003; Siegel 2006; Lamkanfi et al., 
2007).  In its cleaved form, caspase-8 acts 
as a pro-apoptotic molecule, whereas 
its role in lymphocyte proliferation is 
associated with the activity of the whole 
form of the molecule (Lamkanfi et al., 
2007; Bidere et al., 2006a, Scheme 4). 
Inhibition of caspase-8 activity in vivo 
and in vitro in human and murine CD4+ 
T cells leads to reduced proliferation 
and IL-2 production after primary TCR 
stimulation (Kennedy et al., 1999; Falk 
et al., 2004; Mistra et al., 2005), making 
caspase-8 indispensable for a normal 
lymphocyte proliferation.
After T cell-APC contact, receptors 
and intracellular proteins implicated in a 
number of molecular pathways assemble 
into the immunological synapse (IS), 
where the supramolecular activation 
cluster (SMAC) is formed.  The TCR 
is located within the central zone of the 
cluster (cSMAC), where other signaling 
molecules including PKCθ and CARMA-1 
are also found (Saito et al., 2010; Sun 
et al., 2000; Altman and Villalba 2003). 
In this context, PKCθ phosphorylates 
CARMA1, which induces BCL10 and 
MALT1 recruitment and formation of 
the CBM (CARMA1, BCL10, MALT1) 
complex (Matsumoto et al., 2005; 
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Sommer et al., 2005).  Recruitment of 
caspase-8 leads to formation of the 
receptor-induced signalosome (ARIS), 
where caspase-8 interacts physically 
with BCL10 and MALT1 and acquires 
the catalytically active conformation that 
promotes recruitment of TRAF6 and the 
IKK complex (Su et al., 2005; Bidere 
et al., 2006a,b; Lemmers et al., 2006; 
Misra et al., 2007, Scheme 3).  In the 
absence of caspase-8, IKK recruitment 
to the CBM complex is diminished (Su 
et al., 2005).  Although MALT1 was 
reported to activate caspase-8 directly 
through heterodimerization (Kawadler et 
al., 2008), how caspase-8 is activated to 
mediate NF-κB signaling remains poorly 
understood (Du, 2011).
 The IKK complex is composed of two 
catalytic subunits, IKKα and IKKβ, and a 
regulatory subunit, IKKγ (NEMO) (Li and 
Verma 2002).  Activation of this complex 
is a key step in NF-κB signaling and T cell 
proliferation.  In unstimulated cells, IκB 
inhibitors bind to NF-κB p50/p65 dimers 
and thus sequester them in the cytosol. 
These inhibitors were originally thought 
to retain p50/p65 dimers in the cytoplasm 
ZAP70
LAT
Lck
Fas
FasL
FADD
 caspase-8
whole form
 Cleaved
caspase-8
Activation of effector
 caspases-3 and -7
Apoptosis
NF-κB activation
Proliferation
PKC
TRAF6CARMA1
BCL10 MALT1
NEMO
IKKβIKKα
ARIS
DISC
TCR
Scheme 3. Involvement of the uncleaved caspase-8 in TCR-triggered NF-κB activation
Following TCR stimulation, PKCθ is activated and phosphorylates CARMA1, which induces 
BCL10 and MALT1 recruitment as well as formation of the CBM (CARMA1, BCL10, MALT1) 
complex.  Recruitment of whole form of caspase-8 leads to formation of the receptor-induced 
signalosome (ARIS), where caspase-8 interacts physically with BCL10 and MALT1, and 
acquires the catalytically active conformation that promotes TRAF6 and IKK complex re-
cruitment.  Activation of the latter leads to NF-κB translocation to the nucleus, where multiple 
pro-proliferative genes are activated, resulting in T cell proliferation.
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by masking their nuclear localization 
sequences (NLS), although some 
reports indicate that IκB inhibitors shuttle 
between the nucleus and cytoplasm, 
transporting p50/p65 from target DNA 
sites back to the cytoplasm (Birbach 
et al., 2002).  IκB protein expression is 
directly regulated by NF-κB; this feedback 
regulation is believed to contribute to the 
rapid shutdown of NF-κB signaling.  In the 
classical pathway, an upstream signaling 
event induces activation of IKKβ, which 
then phosphorylates IκB, releasing it 
from the p50/p65 dimer and targeting it 
for polyubiquitination and proteosomal 
degradation.  The p50/p65 NF-κB dimer 
is then released and translocates to the 
nucleus to bind to DNA and regulate 
gene transcription (Li and Verma 2002; 
Su et al., 2005).
Upstream TCR signaling events and 
receptor internalization
Triggering of the TCR at the T cell 
surface by APC or monoclonal antibodies 
initiates a signaling cascade of well-
regulated intracellular events that leads to 
cell activation, proliferation, and immune 
functions (Cheng et al., 2011; Bécart et 
al., 2009; Ullman et al., 1990; Weiss et al., 
1994), as well as receptor internalization 
and downmodulation of the TCR (Krangel 
1987; Minami et al., 1987; Telerman et 
al., 1987, Boyer at al., 1989; Boyer et al., 
1991).  TCR internalization contributes 
to receptor desensitization, leading to 
transient or long-term anergy to antigen. 
Cai et al. suggested that the most likely 
function of TCR downmodulation is to 
protect cells from overstimulation (Cai et 
al., 1997); Schonrich et al. also showed 
that TCR downmodulation is an effective 
means of tolerance induction (Schonrich 
et al., 1991).
The TCR/CD3 complex is composed 
of the TCR-αβ heterodimer, which is re-
sponsible for recognition of the antigen 
as a peptide presented by MHC (Bjork-
man et al., 1987), and of the CD3 trans-
duction complex (Clevers et al., 1988). 
The latter is composed of CD3-γ, -δ, -ε 
subunits, which are noncovalently asso-
ciated to the TCR as CD3-δε and CD3-γε 
doublet forms (Koning et al., 1990; Hera 
et al., 1991).  The second transduction 
molecule required for surface expression 
of the TCR/CD3 complex is the ζ com-
ponent (Klausner et ai., 1990; Irving and 
Weiss 1991; Wegener et al., 1992), a 
member of a related family of molecules 
that includes CD3-ζ, CD3-η and FcεRIγ 
(Weissman et al., 1988; Blank et al., 
1989).  TCR-ζ and other CD3 signaling 
subunits have a characteristic sequence 
motif for tyrosine phosphorylation, known 
as ITAM (immunoreceptor tyrosine-based 
activation motif).  The cytoplasmic seg-
ment of CD3-γ, CD3-δ and CD3-ε has a 
single ITAM, whereas that of the TCR-ζ 
subunit bears three ITAM copies.  As a 
result, each αβTCR heterodimer is func-
tionally coupled to ten ITAM (Malissen, 
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2008).  In addition, three protein tyrosine 
kinases (PTK) are associated to the TCR/
CD3 complex, 1) the Src family member 
p56lck, which interacts selectively with 
CD4 and CD8 coreceptors (Veillette et al., 
1988), 2) the Src family member p59fyn, 
which is associated at low stoichiometry 
with the TCR/CD3 complex (Samelson et 
al., 1990), and 3) the syk-related ZAP70, 
which is uniquely associated with the ty-
rosine-phosphorylated TCR-ζ (Chan et 
al., 1991).
The TCR signaling cascade is 
initiated by TCR binding of the MHC-
bound peptide.  This allows members 
of the Src family (Lck and, to a lesser 
degree, Fyn) to initiate T cell activation 
by phosphorylating tyrosine residues 
located within CD3 ITAM, and permits 
ZAP70 recruitment in close proximity to 
the activated TCR.  By phosphorylating 
the tyrosine residue in the ZAP70 
activation loop, Lck increases the kinase 
activity of ITAM-bound ZAP70, which in 
turn recruits and phosphorylates adaptor 
molecules such as LAT, SLAP, SLP-76, 
and possibly Vav1, Cbl and PLC-γ1.  This 
leads to activation of multiple pathways, 
including ERK (extracellular signal-
regulated kinase), JNK (c-Jun N-terminal 
kinase), NF-κB and NFAT (nuclear factor 
of activated T cells), which ultimately 
induce cell effector functions (Davis 
2002; Coombs et al., 2002; Okkenhaug 
and Vanhaesebroeck 2004, Scheme 4).
One of the crucial processes in turn-
ing off TCR signaling is TCR internaliza-
tion and its subsequent degradation.  The 
TCR/CD3 complex is internalized through 
clathrin-coated vesicles (Telerman et al., 
1987; Boyer et al., 1991), a pathway used 
by most surface receptors, including nu-
ZAP70
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LAT
PLCγ
SLP-76
Grb2
Sos
Ras
Raf
MEK
ERK
IP3
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NFAT
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PKC
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caspase-8
P
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γ
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Scheme 4. Simplified 
scheme of TCR signaling
TCR binding results in Lck 
phosphorylation of tyrosine 
residues of the TCR.  This 
leads to recruitment and 
phosphorylation of ZAP70, 
which in turn recruits and 
phosphorylates adaptor 
molecules such as LAT, 
SLP-76, PLC-γ1 and Grb2.  
Multiple downstream sig-
naling pathways, including 
NF-κB, NFAT and ERK are 
subsequently activated and 
ultimately induce cell effec-
tor functions.
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trient receptors such as transferrin (Iaco-
petta et al., 1988; Damke at al., 1994).  In 
this endocytosis pathway, ligand binding 
leads to receptor recruitment to clathrin 
(present in clathrin-coated pits) through 
adaptors such as AP2 (CD2-associated 
protein) or β-arrestin1.  Clathrin then 
polymerizes, driving infolding of the pit, 
which is eventually released into the cy-
toplasm (Doherty and McMahon, 2009). 
After internalization, receptors are routed 
to early endosomes, from which they can 
either be recycled to the plasma mem-
brane or directed to the late endosomes, 
multivesicular bodies, lysosomes and 
afterwards degraded (Stenmark 2009). 
In the course of the last process, recep-
tors are ubiquitinated by the Cbl family of 
ubiquitin ligases (c-Cbl and Cbl-b) prior 
to degradation (Naramura et al., 2002; 
Schmidt and Dikic 2005).
In resting T cells, the TCR/CD3 com-
plex is continuously internalized and re-
cycled to the cell surface (Krangel, 1987; 
Minami et al., 1987; Liu et al., 2000). 
This constitutive cycling depends on the 
di-leucine-based receptor-sorting motif in 
the CD3-γ subunit (Minami et al., 1987; 
Menne et al., 2002).  Once the TCR is 
activated by peptide bound to MHC, anti-
TCR antibody or other ligands, it under-
goes downmodulation (Cai et al., 1997; 
Valitutti et al., 1997; Liu et al., 2000). 
There are at least two distinct pathways 
for endocytosis of triggered TCR.  One is 
dependent on protein tyrosine kinase ac-
tivity, leading to TCR ubiquitination (Vali-
tutti et al., 1997; D’Oro et al., 1997; Wang 
et al., 2001); the other is dependent on 
protein kinase C (PKC)-mediated activa-
tion of the di-leucine motif in the CD3-γ 
subunit and leads to receptor recycling 
(Menne et al., 2002; Dietrich 1998).  In 
addition, unengaged TCR are endocy-
tosed (co-modulated) by the PKC/CD3γ-
dependent pathway; this might attenuate 
signaling and/or ensure an internal store 
of TCR that can be rerouted to the immu-
nological synapse during encounter with 
an APC (San Jose et al., 2000; Monjas et 
al., 2004).
In the PKC/CD3γ-dependent pathway 
of receptor downmodulation, following 
TCR triggering, PKC is activated and 
phosphorylates Ser126 of CD3γ, which 
renders the di-leucine motif accessible to 
binding by AP2 clathrin adaptor protein. 
AP2 binding to CD3γ leads to TCR 
endocytosis (Dietrich et al., 1994; 1996; 
1997).
The TCR/CD3 downmodulation path-
way leading to receptor degradation is 
intimately linked to TCR signaling, and 
in particular to the PTK Lck and Fyn.  In-
hibition or absence of Src family kinases 
prevents TCR endocytosis (Thuillier et 
al., 1991; Luton et al., 1994; D’Oro et al., 
1997).  Phosphorylation events initiated 
by these kinases lead to recruitment of 
adaptor molecules, including SLAP and 
SLAP2, which bring Cbl proteins into 
close proximity with Src kinases as well 
as LAT, ZAP70 and TCR-ζ.  The Cbl is 
further integrated into the complex by 
binding to the central adaptor molecule 
SLP76.  Src kinases in the complex acti-
vate Cbl proteins that in turn ubiquitinate 
ZAP70, Lck and TCR-ζ and target them 
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for internalization and degradation (Wang 
et al., 2001).
Crotzer and colleagues offered another 
regulatory mechanism that links TCR to 
endocytosis; they suggested that TCR 
internalization after receptor engagement 
involves inducible phosphorylation of 
clathrin heavy chain (CHC; Crotzer et 
al., 2004).  They showed that Lck is the 
enzyme responsible for this process 
and that its activity is influenced by the 
function of active ZAP70.
The half-life of the interaction between 
pMHC and the TCR modulates the extent 
to which the TCR is phosphorylated.  Lee 
et al. demonstrated that unphosphorylat-
ed or partially phosphorylated TCR (cor-
responding to the p21 form) is returned 
to the cell surface after internalization, 
whereas fully phosphorylated TCR (the 
p23 form) is degraded and removed from 
the system after internalization (Lee et 
al., 2003).  These observations added 
to the ongoing debate regarding the 
role of cSMAC in TCR downmodulation. 
By clustering TCR, cSMAC facilitates full 
phosphorylation by Lck; because only 
fully phosphorylated receptors are sub-
ject to degradation, cSMAC thus both 
enhances and limits TCR signaling.  This 
regulatory function of cSMAC on TCR ac-
tivation also takes into account the anti-
gen concentration.  At low peptide-MHC 
concentrations, cSMAC enhances T cell 
activation by clustering engaged TCR, 
however at high peptide-MHC concentra-
tion, cSMAC can become a site of TCR 
downmodulation and degradation.  In ad-
dition, Lee and colleagues demonstrated 
that AP2 recruitment is critical for the 
degradation of activated TCR/CD3 com-
plexes, and that T cells deficient in this 
protein show impaired TCR downmodu-
lation (Lee et al., 2003).
The role of Fas in T cell activation
Evidence to date suggests that, in 
addition to its proapoptotic effect, Fas/
FasL signaling has other important cell or 
tissue-dependent properties (Strasser et 
al., 2009).  The non apoptotic or costimu-
latory consequences of Fas engagement 
have been described for different cell 
types during liver regeneration, neurite 
outgrowth, development and functional 
recovery of the central nervous system, 
and also proliferation of growth factor-
deprived fibroblasts (Peter et al., 2007). 
Fas affects proliferation, differentiation 
and migration processes as well as cy-
tokine production in various hematopoi-
etic and non-hematopoietic cell types.
Fas binding might be very relevant in 
the modulation of TCR/CD3 signaling in 
primary T cells, and most reports identify 
Fas as a costimulatory molecule for T 
cells.  Alderson et al. provided the first 
evidence for this function of Fas showing 
that the presence of a functional Fas/
FasL system enhances proliferation and 
cytokine production in the activation 
of human T cells (Alderson et al., 
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1993).  A later study demonstrated the 
costimulatory function of Fas in murine 
naïve T cells, and that Fas costimulation 
is controlled by NF-κB signaling and 
caspase activity (Maksimow et al., 2006). 
It was also shown that Fas might have a 
role in mature T cell activation, although 
Fas-mediated T cell proliferation was 
observed only with a full mitogenic dose 
of anti-CD3, in contrast to the effect of 
CD28 costimulation, which is observed 
even at suboptimal concentrations of 
anti-CD3 (Chun et al., 2000).
As shown above, several reports 
demonstrate a potent regulatory function 
of Fas in T cell activation.  The precise 
molecular mechanism of Fas  costimula-
tion, however, had never been elucidated 
in detail.  Understanding of these addi-
tional Fas functions was further compli-
cated by reports that identified Fas as a 
silencer of T cell activation.  The authors 
showed that crosslinking of the Fas anti-
gen on preactivated human T cells inhib-
its early TCR/CD3 signaling events such 
as intracellular Ca2+ mobilization (Kovacs 
and Tsokos, 1995).  These results were 
subsequently completed by the same 
investigators, who showed impaired as-
sociation of ZAP70 with TCR-ζ in Jurkat 
cells after Fas crosslinking (Kovacs et al., 
1999).
In accordance with these data, 
others reported that CD95 triggering 
during priming of naïve human T cells 
interfered with proximal TCR signaling 
by inhibiting ZAP70, PLC-γ1 and PKC 
recruitment into lipid rafts, as well as 
mutual tyrosine phosphorylation of these 
proteins.  Subsequent Ca2+ mobilization 
and nuclear translocation of NF-κB, 
NFAT, and AP1 were greatly reduced, 
resulting in impaired cytokine production 
and cell proliferation.  In addition, these 
cells were partially non-responsive after 
secondary T cell stimulation (Strauss 
et al., 2009).  In line with these data, 
Paulsen et al. reported that high CD95 
agonist concentrations block activation 
of human naïve T cells by inhibiting TCR 
signaling (Paulsen et al., 2011), although 
they demonstrated dual Fas modulator 
function during TCR/CD3 activation of 
primary human T cells.  Fas can have 
opposite effects depending on the agonist 
concentration, ranging from complete 
activation blockade at high doses to a 
prominent costimulatory role at lower 
concentrations.  T cell activation induced 
by the phorbol ester PMA (phorbol 12-
myristate 13-acetate) and ionophore 
(ionomycin) was unaltered by Fas binding 
at either high or at low concentration, 
indicating that Fas affects TCR signaling 
upstream or independently of PKC 
and Ca2+ mobilization.  Moreover, Fas 
crosslinking was shown to promote TCR 
internalization (Paulsen et al., 2011).
These reports describe the impact 
of Fas engagement on T cell activation. 
The functional TCR complex was recently 
observed to have an essential role in Fas 
mediation of apoptosis (Akizhanov et al., 
2010), suggesting that the interaction be-
tween Fas and TCR signaling pathways is 
bidirectional.  Using  immunoprecipitation 
assays, Akizhanov et al. showed that Fas 
interacts directly with the TCR complex 
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proteins Lck and PLC-γ1, which suggests 
that the unengaged TCR complex can 
act as a direct regulator of Fas signaling. 
The strong dependence of Fas-induced 
cell death on the presence of active Lck 
was reported previously by Sharif-Askari 
et al., who also showed Lck preassocia-
tion with the Fas signaling complex in un-
treated T cells (Sharif-Askari et al., 2007). 
Direct Fas association with another Src 
family member, Yes, and with the PI3K 
p85 subunit was also described in glio-
blastoma cells (Kleber et al., 2008).  Fyn, 
another T cell-associated tyrosine kinase, 
was also found to interact physically with 
Fas in activated lymphocytes (Atkinson et 
al., 1996).  This last report describes the 
presence of the tyrosine-containing mo-
tif YXXL within the CD95 DD sequence, 
similar to canonical ITAM or ITIM (immu-
noreceptor tyrosine inhibitory motif) found 
in the TCR/CD3 complex, opening up the 
possibility of Fas interaction with SH2-
containing proteins.
Considerable effort has been made 
to understand Fas functions in addition 
to its known role in apoptosis induction. 
As shown above, some reports indicated 
a role for Fas as a potent modulator in 
T cell activation, although the underlying 
molecular mechanism has not been 
explained in detail.  Published data on 
Fas costimulation are inconsistent, since 
Fas was described as both an enhancer 
and a silencer of primary T cell activation. 
In addition, these results define Fas 
functions mainly in human primary cells. 
As study of these Fas characteristics 
in effector/memory T cells has been 
limited, the overall biological function 
of Fas signaling remains unknown.  In 
this thesis, we examined the nature of 
hyperproliferating Fas-deficient T cells 
and studied their involvement in lupus-
like disease in B6/lpr mice.  We show 
that reduction of T cell hyperproliferation 
indeed attenuates disease manifestations 
in these animals, and identify Fas as a 
potent negative regulator of proliferation 
in preactivated T cells.  Our data indicate 
that Fas associates with the TCR complex 
and affects its internalization.  Based on 
these findings, we propose a mechanism 
of T cell homeostasis that implicates this 
alternative to the proapoptotic function of 
Fas.
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OBJECTIVES
As an apoptosis-inducing factor, Fas plays an important role in T cell homeostasis 
(Watanabe-Fukunaga et al., 1992).  This healthy state is achieved through a balance in 
cell proliferation, survival and apoptosis.  When one of these processes is impaired, the 
balance is destabilized.  This can lead to accumulation of autoreactive and activated 
T cells and, ultimately, to autoimmune disease development; this is the case of Fas-
deficient B6/lpr mice.  These mice show a lymphoproliferative lupus-like syndrome with 
severe consequences, including kidney failure and death (Walker et al., 2002).  Although 
this autoimmune disease is extensively studied, its etiology remains elusive.  In vitro 
death defects, which seem to be the most logical explanation, do not justify the B6/lpr 
phenotype, as the absence of other proteins involved in apoptosis, such as FADD and 
caspase-8, do not lead to this autoimmune phenotype (Newton et al., 1998; Newton et 
al., 2001; Zhang et al., 1998; Chun et al., 2002; Smith et al., 1996).  Hyperproliferation 
of T cells from B6/lpr mice is also poorly understood and reports suggest that this 
hyperproliferation is essential for lymphadenopathy development (Balomenos et al., 
1997; Fortner et al., 2005; Katagiri et al., 1988).  Thus, we considered that alternative 
yet unknown Fas properties might account for the B6/lpr phenotype, in addition to its 
pro-apoptotic function. With these observations in mind, we studied the role of Fas in T 
cell homeostasis, which appears to be more complex than simply apoptosis induction. 
Furthermore, we analyzed the effect of the cell cycle inhibitor p21 overexpression on 
the B6/lpr hyperproliferation.
We established the following objectives:
To analyze a possible proliferative advantage of Fas- and FasL-deficient T cells 1. 
over control T cells and their NF-κB activation status 
To study the importance of the Fas-FasL interaction and the molecular mechanism 2. 
underlying the Fas inhibitory effect on secondary T cell proliferation
To determine where in the activation/proliferation signaling Fas exhibits its 3. 
inhibitory role
To identify the relationship of Fas with TCR in T cell activation and proliferation4. 
To attempt to inhibit B6/5. lpr hyperproliferation
To analyze the 6. in vivo effect of p21 overexpression in B6/lpr mice 
25
Objectives
Introduction
Material and Methods
Results
Discussion
Conclusions
Resumen en español
References
Supplement
MATERIAL AND METHODS
 Mice
Control C57BL/6 mice were from Har-
lan Interfauna Ibérica; C57BL/6-lpr (B6.
MRL-Tnfrsf6lpr), C57BL/6-gld, MRL-mp 
and MRL-lpr were from Jackson Labo-
ratories. C57BL/6-p21tg mice were a 
kind gift from Arun Fotedar (Sidney Kim-
mel Cancer Center, San Diego, CA). 
C57BL/6-lpr-p21tg mice were generated 
from C57BL/6-lpr and C57BL/6-p21tg 
mice.  MRL-lpr-p21tg mice were generat-
ed by backcrossing C57BL/6-p21tg with 
MRL-lpr mice over more than nine gen-
erations.  In both C57BL/6-lpr-p21tg and 
MRL-lpr-p21tg, transgene expression 
was restricted to T cells by the proximal 
Lck promoter (Fotedar et al., 1999).  All 
mice were maintained at the CNB animal 
facility.  For most experiments, we used 
mice of less than eight weeks of age to 
study molecular and cellular events that 
precede autoimmune disease develop-
ment.  All animal experiments were per-
formed in accordance with European reg-
ulations, and were approved by the CNB 
Bioethics Committee.
 T cell purification and culture
 Isolation of CD4+ T cells
Mouse CD4+ T cells were obtained 
from a single-cell spleen suspension by 
negative selection (Mouse CD4 Negative 
Isolation Kit, Dynal Biotech) with magnetic 
beads coated with antibodies Tib 105, 
3F12, RA3-6B2, as well as PK136 and 
CD11b, to bind CD8+ cells, B cells, NK 
cells and macrophages, respectively. 
After 30 min incubation, a magnetic 
field was applied and CD4+ cells were 
separated.  Purity was confirmed by flow 
cytometry and was routinely >90%.
 Cell culture
CD4+ T cells were cultured in RPMI-
1640 medium (Gibco) supplemented 
with 100 U/ml penicillin-streptomycin, 
10 mM HEPES pH 7.4,  50 mM 
β-mercaptoethanol, 2 mM L-glutamine, 
1 mM sodium pyruvate, 0.1 mM 
nonessential amino acids (all from Gibco) 
and 10% FCS (fetal calf serum; Harlan 
Bioproducts).
 Repeated cell stimulation protocol
Activation-induced cell death (AICD) 
was induced using repeated cell stimula-
tion protocols.  Purified CD4+ T cells (106 
cells/ml) were stimulated in vitro with 3 
µg/ml concanavalin A (ConA; Sigma), and 
the culture was supplemented with 20 
ng/ml human recombinant interleukin-2 
(rIL-2; PeproTech) for 3 days (Scheme 5). 
In some experiments, cells were stimulat-
ed with plate-bound anti-CD3 (0.5 µg/ml; 
PharMingen) in 0.1 M Tris-HCl and sol-
uble anti-CD28 (1 µg/ml; PharMingen), 
or with ionomycin (0.5 µg/ml; Sigma) and 
PMA (20 ng/ml; Calbiochem).  Cells were 
then washed and resuspended in fresh 
culture medium supplemented with 20 
ng/ml IL-2 for 6 days.  During this time, 
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medium was changed once to avoid nu-
trient and IL-2 depletion.  Cell concentra-
tion during IL-2 expansion was 0.5 x 106 
cells/ml.  Cells (106/ml) were then restim-
ulated with 3 µg/ml ConA and 20 ng/ml 
IL-2 for 3 days.
Some cells were cultured with the cell 
death inhibitor benzyloxycarbonyl-Val-Ala-
Asp-fluoromethlketone (zVAD; Bachem), 
used at the indicated concentrations.
For the apoptosis-free conditions 
system, after 48 h of secondary ConA 
stimulation, cells were washed and live 
cells separated on a Ficoll gradient (800 
x g, 20 min; Lympholyte, Cedarlane 
Laboratories).  Propidium iodide staining 
(PI; DNA-Prep reagent Kit, Beckman 
Coulter) and cell cycle analysis ensured 
that after Ficoll treatment, >80% of cells 
were alive and cycling.  After separation, 
control and B6/lpr T cells were plated at 
the same concentration and restimulated 
for 72 h.  Alternatively, after separation 
cells were expanded in IL-2-containing 
medium (Scheme 6).
In the repeated stimulation experiments 
with B6/gld T cells, we used 150 ng/
1    stimulationst 2     stimulationnd 
6 days
gradient purification
     of live cells
AICD
IL-2
IL-2
3    stimulationrd 
3 days
No Apoptosis
Scheme 6. Apoptosis-free conditions protocols. After 48 h of secondary stimulation, live 
CD4+ cells were gradient-separated from apoptotic cells and were either ConA-restimulated 
(3rd stimulation) or cultured with IL-2. In these conditions, apoptosis does not occur.
spleen
Isolation of CD4+ T cells
by negative isolation kit
1    stimulationst 2     stimulationnd IL-2 expansion
3 days 6 days
AICD
B6
B6/lpr
LIVE
APOPTOTIC
3 days
Scheme 5.  In vitro AICD protocol
After extraction of CD4+ T cells from murine spleen using a negative isolation kit, cells were 
ConA-stimulated (3 days), IL-2-expanded (6 days) and ConA-restimulated (3 days).
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ml recombinant FasL and 50 ng/ml 
crosslinking enhancer (both from Alexis 
Biochemicals).
Flow cytometry (fluorescence 
activated cell sorting, FACS)
All staining was performed by incuba-
tion of cells in 50 µl of appropriate anti-
body mixture (depending on experimental 
context) for 20 min at 4ºC, in the dark. An-
tibodies were resuspended in PBS stain-
ing buffer (1x PBS, 5% FCS, 1% BSA, 
5 mM EDTA).  After incubation, cells were 
washed twice with PBS staining buffer 
and analyzed on an LSR cytometer (Bec-
ton Dickinson).  Experiments were ana-
lyzed using FlowJo software (Tree Star). 
Freshly isolated CD4+ T cells were stained 
to determine memory phenotype with an-
ti-CD4-PE (Beckman-Coulter), -CD8-PE-
cy7 (Biolegend), -CD44-FITC (Beckman) 
and -CD62L-APC (Beckman-Coulter) an-
tibodies.  For T cell activation analysis, 
cells were stained with anti-CD4-FITC, 
-CD25-PE (both from PharMingen) and 
-CD69-Pecy7 (eBioscience).  For double 
negative population analysis, cells were 
stained with anti-CD4-PE, -CD8-PEcy7, 
-B220-APC (Beckman-Coulter), -TCR-
FITC (PharMingen) and -Thy1.2-APC 
(PharMingen) antibodies.
BrdU was detected with an anti-
BrdU-FITC antibody (Becton Dickinson) 
in combination with anti-CD4-Pecy7 
(eBioscience), -CD8-SPRD (Beckman-
Coulter), -CD44-biot (PharMingen), Av-
SPRD (Beckman-Coulter), -CD62-PE 
(Southern) and -TCR-PE antibodies.
Proliferation assays
 [3H]thymidine incorporation
T cell proliferation was measured 
by culturing cells in 96-well plates for 
indicated times and quantifying [3H]
thymidine uptake (1 mCi/150 ml; 
Amersham Bioscience) in the last 16 h 
of culture.  Incorporated radioactivity was 
measured using a beta-plate counter 
(b1205 Wallac, Perkin Elmer) after 
transferring cells onto fiber filters (Wallac) 
with a semi-automatic cell harvester.
CFSE fluorescence dilution assay
Cells were washed with PBS and re-
suspended in PBS + 0.1% BSA at a final 
concentration of 2 x 106 cells/ml and incu-
bated with 2.5 µM of the fluorescent dye 
carboxyfluorescein diacetate succinimidyl 
ester (CFSE; Molecular Probes) for 15 
min at 37ºC.  The reaction was terminat-
ed by incubating cells on ice.  Cells were 
washed three times with cold RPMI-1640 
medium and stimulated according to the 
requirements of each experiment.  CFSE 
fluorescence decay at the indicated time 
points was measured by flow cytometry, 
gating live PI-negative cells.
Cell cycle analysis
For cell cycle analysis, cells were 
washed with PBS at the times indicated, 
resuspended in 50 µl of detergent (DNA-
Prep Reagent Kit, Beckman Coulter) 
and 10 mg/ml PI was added (DNA-Prep 
reagent Kit; 30 min, 37ºC) before flow 
cytometry analysis.
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  Ki-67 proliferation marker staining
After surface marker staining, cells 
were washed with PBS and fixed and 
permeabilized with 100 µl Cytofix/Cytop-
erm (BD Biosciences; 20 min, 4ºC).  After 
incubation, cells were washed once with 
Perm/Wash buffer (BD Biosciences) and 
blocked with 150 µl Perm/Wash buffer 
+ 1% BSA (30 min, room temperature). 
Anti-Ki-67 antibody (1/100, Abcam) was 
added; the permeabilized cells were in-
cubated (1 h, 4°C) and washed twice in 
Perm/Wash before flow cytometry analy-
sis.
  Trypan blue exclusion test 
of cell viability
The number of live cells as determined 
by counting Trypan blue-stained cells was 
also used to measure proliferation ratio.
 In vivo BrdU administration
Mice were given bromodeoxyuridine 
(BrdU, 0.8 mg/ml; Sigma) in drinking 
water, freshly prepared every 2 days for 
a 9-day period, and BrdU incorporation 
was determined in lymph node T cells 
(Balomenos et al., 1997).  Cells were 
stained with appropriate combinations 
of labeled anti-CD4, -CD8 and -CD44, 
-CD62L, -TCR, -Thy1.2 and -B220 
antibodies and anti-BrdU antibody (for 
antibody sources, see flow cytometry 
section).
Apoptosis assay
For annexin-V and PI double staining, 
cultured cells at the indicated time were 
stained using an anti-annexin-V antibody 
kit (PharMingen, 5 µl/100 µl; 15 min, 
4ºC).  To distinguish live from apoptotic 
and necrotic cells, 10 µl of 50 µg/ml PI 
stock solution was added before flow 
cytometry analysis.
 Sorting of DN and memory T cells
Mouse CD4+ T cells were isolated 
from spleen using the Negative Isolation 
Kit and stained with anti-TCR-FITC, 
-CD4-PE and -CD8-SPRD for the DN 
T cell population, and with anti-CD4-
PE, -CD44-FITC and -CD62L-APC 
for the memory T cell population.  Cell 
populations of interest were sorted on an 
Epics Altra sorter (Beckman-Coulter).
 Intracellular cytokine staining
For intracellular cytokine staining, 
cells were isolated from spleen, then 
plated (5 x 106 cells/ml) and stimulated 
(1 h, 37°C) in culture medium containing 
PMA (50 ng/ml), ionomycin (2 µg/ml). 
Brefeldin A (GolgiPlug, 10 µl/ml; BD 
Pharmingen) was added and cells were 
further incubated (3 h, 37°C).  After 
surface marker staining (CD4, CD8, 
CD44, CD62L, Thy1), cells were washed 
with PBS, fixed, and permeabilized with 
100 µl Cytofix/Cytoperm (20 min, 4ºC). 
Cells were then washed once with Perm/
Wash buffer and blocked with 150 µl 
Perm/Wash buffer + 1% BSA (30 min, 
room temperature).  Anti-IL-17-PE (1/100, 
PharMingen) and anti-IFNγ-PE (1/100, 
PharMingen) antibodies were added; the 
permeabilized cells were incubated (20 
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min, 4°C) and washed twice in Perm/
Wash before FACS analysis.
 Internalization and recycling 
assays using cell surface 
fluorescence quenching
For TCR internalization, cells following 
the first or second stimulation or during 
the IL-2 expansion phase were incubated 
(45 min, on ice) with 2 µg/ml Alexa488-
conjugated anti-TCRβ (Invitrogen), which 
binds the TCR stably.  Cells were washed 
three times in medium and pulsed for 
indicated times at 37°C.  Internalization 
was terminated by placing samples on 
ice.  Cells were divided into two groups; 
one was fixed with 2% formaldehyde and 
the other incubated (1 h, on ice) with 25 
µg/ml rabbit anti-Alexa488 quenching 
antibody (Molecular Probes) prior to fixing 
and flow cytometry analysis (Scheme 7).
Mean fluorescence intensity was 
quantified for 6 x 103 viable cells by flow 
cytometry, and internalized fluorescence 
was calculated from quenched and non-
quenched samples, as described (Austin 
et al., 2004) (Scheme 8).  Surface anti-
body and TCR endocytic rate constants 
were determined by generating internal-
ization plots.
In some experiments, cells at the end 
of the IL-2 expansion phase were ConA 
restimulated (1 h) to trigger internalization. 
Cells were then incubated (37°C) with 
Alexa488-transferrin (Molecular Probes) 
for indicated times. Cells were washed 
and divided into two groups; one 
group was fixed directly and the other, 
incubated with quenching antibody prior 
to fixing and FACS analysis.  Data are 
representative of two experiments.
For TCR recycling, cells were pre-
incubated (15 min, 37°C) with 2 µg/ml 
Alexa488-anti-TCRβ antibody.  Cells 
were chilled rapidly, washed twice in cold 
medium and surface-quenched (15 min, 
on ice) with 25 µg/ml anti-Alexa488 an-
tibody.  Cells were then warmed to 37°C 
(chased) in the continuous presence of 
Scheme 7.  
Internalization assay
Surface TCR was 
stained with Alexa488-
conjugated antibody. 
Cells were pulsed at 37°C 
to internalize receptor and 
were then divided into 
two groups; one group 
was fixed and the other 
incubated with quenching 
antibody prior to fixation 
and FACS analysis.
Internalization
TCR
1. 4°C, 1h + A488-TCR
TCR
A488
2. Wash, 2x
3. 37°C for indicated times points
       (0h keep on ice)
4. Split into two halves
a) 4°C, 1h + anti-A488 b) unquenched control
Q
TCR
A488anti-A488
Quenching
5. Fix and facs
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the quenching agents for the indicated in-
tervals, chilled rapidly, fixed and analyzed 
by flow cytometry (Scheme 9).
The percentage of internalized and 
recycled fluorescence (pulsed) remaining 
at each chase time point was calculated 
as the difference between pulsed and 
unpulsed cell fluorescence, normalized to 
this value at chase time = 0, as described 
(Austin et al., 2004).
 
Calcium (Ca2+) mobilization assay
Cells were washed with PBS and 
resuspended in cold Tyrode’s solution 
(Sigma), after which 20 µl 10 mM Fluo-2 
(AM) (Teflabs) was added and incubated 
(15 min, room temperature).  Cells 
were centrifuged, resuspended in 5 ml 
Tyrode’s solution and incubated (30 min, 
room temperature).  The baseline was 
established by collecting events for 100 
s on an LSRFortessa cell analyzer (BD 
Biosciences).  These cells were then 
stimulated (5 µg/ml CD3 and 1 µg/ml 
CD28, or 0.5 µg/ml ionomycin and 20 ng/
ml PMA) and further events collected on 
the same equipment.
 Western blot
Cells were lysed in 0.2% NP-40 lysis 
buffer supplemented with Phosphatase 
Inhibitor Cocktail (PhosStop) and Com-
plete Protease Inhibitor Cocktail (both 
from Roche).  Protein concentration was 
determined using the Bradford method. 
Lysates (40 µg) of freshly isolated or cul-
tured cells were resolved on 12% acryl-
amide gels and transferred to a nitrocellu-
lose membrane (Bio-Rad).  After blocking 
with 5% low fat milk (or BSA) in 0.05% 
Tween 20, membranes were incubated 
with appropriate primary antibodies.  After 
incubation with appropriate peroxidase-
conjugated secondary antibodies (all 
(F1 - E1 )
T = 0
A0
C0
B0
T = t1
D1
B1
C1
E1
A1
= quenched surface
= unquenched surface
    (background fluorescence)
= unquenched internal
B1 = A1 - C1 = F1 - E1
A1 (1-      ) = F1 - E1
A1 =
assume          =         and substitute:
A1 = C0
A0
F1 - E1
D1 = F1 - A1 = F1 -  (1-     )C0A0
F1 - E1
C1
A1
(1-      )C1A1
C0
A0
C1
A1
(1-      )
F1
Scheme 8. Calculation 
of internalized receptor 
amount from raw FACS 
data. The amount of internal 
signal (D1) is calculated at 
different time points.  Surfa-
ce fluorescence (A1), which 
consists of quenched fluo-
rescence (B1) and nonquen-
chable background fluores-
cence (C1), is subtracted 
from total unquenched 
fluorescence (F1) at each 
time point.  Background fluorescence as well as the ratio of quenched and total unquenched 
fluorescence at time 0 (1-C0/A0; quenching efficiency) are assumed to be the same at all 
time points.
32
MATERIAL AND METHODS
Scheme 9.  Recycling assay. Cells were stained with Alexa488-anti-TCRβ antibody at 37°C 
to internalize the labeled receptor.  Cells were then incubated on ice with quenching anti-
Alexa488 antibody and warmed to 37°C in the continuous presence of the quenching agent. 
Recycling of Alexa488-labeled TCR induced quenching of surface fluorescence.
from Dako), proteins of interest were de-
tected by chemiluminescence (ESL, Am-
ersham) according to manufacturer’s in-
dications.  Primary antibodies were from 
Cell Signaling (anti-pSrk, -pZAP70, -pAkt, 
-pPKCα, -pPKCθ, -pLAT, -pIκBα, -pERK, 
-Lck, -ZAP70, -ERK, -MALT1, -Bcl10, 
-acetyl coA), Santa Cruz Biotechnology 
(anti-p21, -CDK2, -TCRγ, -Fas, -TRAF6, 
-LAT), Millipore (anti-phosphotyrosine), 
Alexis (anti-caspase-8), MBL (anti-cFLIP, 
-FADD), ProSci (anti-CARMA1) and Sig-
ma (anti-β-actin).
Phosphotyrosine 
immunoprecipitation
Untreated and ConA-restimulated (15 
min) B6 and B6/lpr T cells were lysed 
in modified RIPA buffer (50 mM Tris-
HCl pH 7.4, 1% NP-40, 0.25% sodium 
deoxycholate, 150 mM NaCl, 1 mM 
EDTA, 1 mM PMSF, 1mg/ml aprotinin, 
leupeptin, pepstatin, 1 mM Na3VO4, 1 mM 
NaF).  Protein (250 µg) was incubated 
(overnight, 4°C) with 20 µ l  4G10 
Platinum Anti-Phosphotyrosine agarose 
conjugate (50% slurry; Millipore); beads 
were then separated from supernatant by 
microcentrifugation (4010 x g, 4 min) and 
washed three times with PBS.  Proteins 
were dissociated from beads with SDS-
PAGE sample buffer, resolved on 12% 
acrylamide gels and transferred to a 
nitrocellulose membrane.  Immunoblotting 
was performed with a protein-specific 
antibody.
TCR
1. 37°C, 15min + A488-TCR
2. Wash, 2x
3. 4°C, 15min + anti-A488
Q
anti-A488
Q
Q
4. 37°C for indicated times points
Q Q
Q
Recycling
Q
Q
Q
Q
5. Fix and facs
Quenching
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 Biotin-VAD-fmk caspase 
precipitation assay
T cells were incubated with 10 mM 
biotin-VAD-fmk (bVAD; MP Biomedicals; 
30 min, 37ºC).  Cells were lysed with 0.2% 
NP-40 lysis buffer (10 mM Tris pH 7.5, 
150 mM NaCl) containing an additional 20 
mM bVAD (20 min, on ice).  After protein 
quantification, cell lysates (400-600 µg 
protein) were pre-cleared by incubation (2 
h, 4°C) with Sepharose 6B beads (30 ml; 
Pierce), followed by incubation (overnight, 
4°C) with 40 ml immobilized streptavidin 
beads.  Beads were washed 5 times 
with lysis buffer without protease inhibitor 
cocktail and boiled with loading buffer (5 
min).  Proteins were separated on 12% 
polyacrylamide gels and precipitated 
caspase-8 was detected by western blot.
 Caspase-8 colorimetric 
activity assay
Caspase-8 activity was determined by 
measuring fluorescence originating from 
a cleaved tetrapeptide (IETD) substrate 
linked to a fluorogenic group (pNA) 
using the FLICE/Caspase-8 Colorimetric 
Assay Kit (BV-K113, 3 MBL).  Viable cells 
were lysed and treated according to the 
manufacturer’s protocol.  Caspase-8 
recognizes the IETD sequence, and 
cleavage of the tetrapeptide substrate by 
active caspase-8 in cell lysates releases 
the pNA group; light emission is quantified 
at 400-405 nm by spectrofluorometry 
to determine the increase in caspase-8 
activity.
RNAi transfection of T cells
Small interfering RNA (RNAi) specific 
for caspase-8 bearing two different 
targeting sequences (sc-37226; Santa 
Cruz) and the non-specific control (sc-
37007; Santa Cruz) were used to transfect 
lpr T cells at the IL-2 expansion stage, 
using the Amaxa Nucleofector system 
for mouse lymphocytes (VPA-1002). 
Cells were then incubated overnight 
and cultured with IL-2 for 2 days prior to 
secondary ConA stimulation.
 Confocal analysis
Cells were cultured overnight on colla-
gen-I-covered chamber slides (Lab-Tek) 
and left untreated or stimulated with 3 µg/
ml ConA, 20 ng/ml IL-2 and 30 µM zVAD 
(1 h, 37°C).  Cells were then placed at 
4°C to terminate stimulation, fixed, and 
permabilized with Cytofix/Cytoperm solu-
tion (BD Biosciences; 30 min, 4°C).  Cells 
were washed twice with Perm/Wash so-
lution (BD Biosciences) and incubated 
with blocking solution (PBS + 1% BSA + 
10% goat serum; 45 min, room tempera-
ture) in a humid chamber.  After washing 
with Perm/Wash, anti-TCRg and -Fas 
(A-20) antibodies (both from Santa Cruz 
Biotechnology) were added and cells in-
cubated (45 min, room temperature) in a 
humid chamber.  For some experiments, 
cells were incubated with anti-caspase-8 
antibody (Alexis Biochemicals).  After 1 h, 
cells were washed three times with PBS 
to remove unbound primary antibody; 
anti-goat IgG (Santa Cruz Biotechnol-
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ogy) and -rabbit IgG (Molecular Probes) 
secondary antibodies were added (1 h, 
room temperature).  After mounting cells 
with DAPI-containing mounting medium 
(Vectashield; Vector Laboratories), fluo-
rescence was documented on a confocal 
microscope (Olympus).
 NF-κB activation assays
 Electrophoretic mobility 
shift assay (EMSA)
Nuclear extracts were obtained by 
lysing cells in Buffer A (see table below; 
5 min, 4°C).  After centrifugation (4010 x 
g, 4 min), supernatant (cytosolic extract) 
was separated from the pellet (containing 
nuclei), which was washed with Buffer B 
(see table).  After centrifugation (4010 x 
g, 4 min), supernatant was removed and 
the pellets incubated (30 min, 4°C) with 
Buffer C (see table).  Subsequent centrif-
ugation (4010 x g, 15 min) completed nu-
clear extraction.  The nuclear extracts (10 
µg) were incubated in binding buffer (0.45 
µg/µl BSA, 20 mM Hepes, 1 mM EDTA, 
20% glycerol, 1 M DTT, 0.5 mM PMSF, 
1 M MgCl, 0.5 M EDTA pH 7, 2 M NaCl, 
100 mM Tris-HCl pH 7.5, poly(dI-dC) with 
1 µl [γ-32P]-ATP-labeled probe containing 
the NF-κB consensus sequence (sense: 
5´-AGTTGAGGGGACTTTCCCAGGC-3´, 
a n t i s e n s e  3 - T C A A C T C C C C T-
GAAAGGGTCCG-5´, Promega).  The 
labeling reaction was catalyzed by T4-
polynucleotide kinase and incubated in 
10x kinase buffer (30 min, 37°C).  Nucle-
ar extracts were incubated (20 min, room 
temperature) with radiolabeled probe 
and resolved on 5% acrylamide gels.  As 
a loading control, probe containing the 
NF-Y consensus sequence was used. 
Gels were dried and exposed to X-ray 
film (Kodak BioMax MR) for up to 3 days 
at -80°C.  After development of the au-
toradiographs, band intensity of radiola-
beled NF-κB-DNA complexes was used 
to measure NF-κB activation.
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Table 1.  Lysis buffer composition
Buffer A
(100 ml)
Buffer B
(25 ml)
Buffer C
(20 ml)
Hepes (1 M) 1000 µl 250 µl 200 µl
NaCl (5 M) 1000 µl 250 µl 1400 µl
Saccharose (100 mM) 500 µl - -
EDTA (500 mM) 200 µl 5 µl 4 µl
Spermidine (500 mM) 100 µl - 20 µl
Spermine (500 mM) 30 µl - 6 µl
Triton X-100 (100%) 500 µl - -
Glycerol - 6.25 ml 5 ml
ddH2O 97 ml 18.25 ml 13.4 ml
 TransAM ELISA-based kit
This kit contains 96-well plates to 
which an oligonucleotide containing an 
NF-κB consensus binding site has been 
immobilized.  Activated NF-κB homo- 
and heterodimers in nuclear extracts 
(obtained according to manufacturer’s 
protocol with reagents provided) bind 
specifically to the oligonucleotide.  The 
activated NF-κB subunit bound to the 
oligonucleotide is detected with an 
anti-NF-κB p65 antibody. Addition of 
a secondary antibody conjugated to 
horseradish peroxidase (HRP) provides 
sensitive colorimetric readout easily 
quantified by spectrophotometry.
 IN Cell Analyzer 2000 cell 
imaging system
The percentage of cells positive for 
NF-κB translocation was defined with an 
IN Cell Analyzer 2000 (GE Healthcare) 
high-content analysis system.  The 
software localizes the nuclei based 
on AAD nuclear stain (Invitrogen) and 
defines the nuclear space.  The algorithm 
then defines a collar space around the 
nuclei.  Signal intensity for NF-κB (NF-
κB, p65, Santa Cruz) is then measured in 
the nuclei and in the peri-nuclear space, 
as a surrogate for cell staining.  NF-κB 
activation status is defined by its nuclear 
versus cytoplasmic localization.  Data are 
expressed as the ratio between nuclear 
and cytoplasm staining intensity.
 Detection of anti-DNA antibodies
The relative levels of anti-DNA anti-
bodies in serum were detected by en-
zyme-linked immunosorbent assay (ELI-
SA).  The 96-well plates were first coated 
with calf thymus DNA (2.5 µg/ml; Sigma 
Aldrich).  IgG was detected with peroxi-
dase-conjugated anti-mouse antibody 
(Jackson ImmunoResearch).  Relative 
absorbance levels were measured at 492 
nm in a Labsystems Multiskan Plus Plate 
Reader.
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Kidney cryosections and 
immunofluorescence analysis
Kidneys were isolated, embedded in 
inclusion solution (Jung Tissue Freezing 
medium, Leica Microsystems) and fro-
zen individually in liquid nitrogen.  Cryo-
sections (7 µm) were prepared in a cry-
ostat (Leica CM1900), placed on Fischer 
slides (Fisherbrand Superfrost/Plus) and 
allowed to dry (2 h, room temperature). 
Sections were then treated with 100% ac-
etone (10 min, 4°C), dried (30 min, room 
temperature) and blocked with PBS + 2% 
BSA + 10% goat serum (45 min, room 
temperature).  After washings (3 times 
in PBS), sections were incubated (1 h, 
room temperature) with combinations 
of anti-IgG-FITC, -CD4-PE (both from 
PharMingen), and -F4/80-FITC primary 
antibodies (Serotec).  After washing (3 
times in PBS) and mounting with mount-
ing medium (Vectashield, Vector Labora-
tories), fluorescence was documented on 
a fluorescence microscope (Leica).
 Glomerulonephritis evaluation
Glomerulonephritis grade was evalu-
ated on kidney sections according to the 
Berden scale (Berden et al., 1983): (0) no 
glomerular lesions, (1) minimal thickening 
of the mesangium, (2) lesions with notice-
able increases in mesangial and glomer-
ular cellularity, (3) lesions characterized 
by the preceding conditions with super-
imposed inflammatory exudates and cap-
sular adhesions, and (4) the glomerular 
architecture was obliterated in >70% of 
glomeruli, and tubular cast formation 
was extensive.  Results were evaluated 
by Dr. Juana Flores, Animal Biology De-
partment, School of Veterinary Medicine 
(Universidad Complutense de Madrid).
 Statistical analysis
Student’s t test was used for all statis-
tical analyses; p values <0.05 were con-
sidered significant.
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RESULTS
Hyperactivation of the immune system 
in B6/lpr mice 
B6/lpr mice show Fas deficiency that 
leads to defective apoptosis signaling and 
an autoimmune phenotype, characterized 
by development of lymphadenopathy 
and splenomegaly.  These processes 
originate from the accumulation of double 
negative (DN) T cells (TCRab+CD4-
CD8-B220+), which are otherwise rare 
components of the peripheral T cell 
repertoire. The accumulation of CD4+ 
memory T cells (CD44high/CD62Llow) 
and of IgG+ B cells was also detected in 
Fas deficient mice. 
We observed that CD4+ T cells in 
these animals showed an activated 
phenotype, as they overexpressed the 
activation markers CD25 and CD69 (Fig. 
1A).  In addition, CD4+ memory T cells 
(Fig. 1B) and DN T cells (Fig. 1C) were 
characterized by higher in vivo production 
of the proinflammatory cytokines IL-17 
and IFNγ.  In concordance with reports 
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Figure 1.  In vivo hyperproliferation and hyperactivation of the B6/lpr mouse immu-
ne system. A. Cell surface expression of activation markers CD25 (left) and CD69 (right) 
in spleen-derived CD4+ T cells from 2-month-old control and B6/lpr mice.  Representative 
histograms are shown (n = 3).  B, C. Intracellular staining for IL-17 and IFNγ production by 
memory (CD44highCD62Llow) (B) and DN (Thy1+CD4-CD8-) T cells (C).  Single cell sus-
pensions from B6 and B6/lpr mouse spleens were prepared, plated (5 × 106 cells/ml), and 
stimulated with PMA/calcium ionophore and brefeldin A for 4 h.  Cells were then collected, 
fixed and permeabilized, surface markers stained, and cytokine production was measured by 
intracellular cytokine staining.  Values show mean ± SD (n = 4).  D. CD4+, CD8+ and DN T 
cells from B6/lpr mice showed higher in vivo BrdU incorporation than B6 control mice.  Two-
month-old mice were given BrdU in drinking water for 9 days, after which they were sacrificed 
and cell suspensions prepared from cervical lymph nodes for staining and FACS analysis.  
Values are mean ± SD (n = 4).  
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showing T cell hyperproliferation in 
B6/lpr mice (Balomenos et al., 1997; 
Fortner et al., 2005), we also observed, 
using a BrdU incorporation assay, 
that CD4+, CD8+ and DN T cells in 
these mice hyperproliferated in vivo 
compared to control T cells (Fig. 1D). 
This hyperactivation state leads to an 
autoimmune phenotype with elevated 
production of anti-DNA antibodies, with 
deposits of immune complexes in the 
kidneys and mild glomerulonephritis, 
finally leading to kidney damage.
Overall, autoimmune disease in B6/lpr 
mice is the result of severe deregulation 
of immune homeostasis.  Since apoptosis 
defects due to the Fas deficiency cannot 
explain lymphadenopathy development, 
hyperactivation or hyperproliferation 
of T cells from these animals (see 
Introduction), the aim of this thesis is to 
show that, in addition to the apoptosis 
induction, Fas has other functions 
in immune homesostasis, which are 
associated with control of T cell activation 
and proliferation.
Hyperproliferation and 
hyperactivation of Fas-deficient 
T cells after repeated stimulation
In the process of an in vivo immune 
response, the first encounter of T cells 
with antigen is accompanied by a rapid 
clonal proliferation, followed by a decline 
in cell number and achievement of a 
balanced state.  Cells that survive form 
a pool of memory T cells.  The second 
encounter with antigen by circulating T 
cells is thought to induce apoptosis via 
Fas interaction with FasL.  Deregulation of 
T cell proliferative response or apoptosis 
can have severe consequences in the 
immune system homeostasis.
We found that T cells from B6/lpr mice 
hyperproliferate in vivo.  We therefore 
studied whether Fas is directly implicated 
in T cell proliferation control in an apop-
tosis independent manner.  To analyze 
the proliferative response of B6/lpr CD4+ 
T cells, we used a classical protocol for 
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Figure 2.  Similar proliferation ratio by 
B6 and B6/lpr T cells after primary sti-
mulation. A. Purified CD4+ T cells from B6 
and B6/lpr mice were ConA-stimulated and 
PI-stained 24 h later for cell cycle analysis.  
The proliferation ratio was similar for B6 and 
B6/lpr CD4+ T cells. Representative histo-
grams are shown (n >7).  B. CFSE dilution 
rate of gated PI-negative T cells following 
primary ConA stimulation (72 h).  Represen-
tative histograms are shown (n = 3).  
C. Similar proliferation of B6 and B6/lpr T 
cells after primary ConA stimulation, detec-
ted by [3H]thymidine uptake at 24, 48 and 72 
h after first challenge.  Values show mean ± 
SD (n = 4).  
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activation-induced cell death (AICD), in 
which naïve T cells are antigen stimu-
lated, expanded with interleukin-2 (IL-2) 
and afterwards restimulated through 
their TCR (T cell receptor).  This pro-
tocol mimics the in vivo situation when 
autoreactive T cells are exposed to the 
continuous presence of specific autoan-
tigens.  To simulate repeated T cell chal-
lenge in in vitro conditions, we stimu-
lated B6/lpr CD4+ T cells repeatedly 
with concanavalin A (ConA), separated 
by stages of IL-2 expansion (Scheme 
1, Materials and Methods).  B6/lpr and 
B6 T cells responded similarly after pri-
mary ConA treatment, as determined by 
cell cycle analysis, CFSE dilution analy-
sis and [3H]thymidine incorporation (Fig. 
2A-C).  Following the second challenge, 
B6/lpr T cell proliferation appeared to be 
higher than that of control cells, which 
underwent extensive apoptosis as de-
tected by cell cycle analysis (Fig. 3A, 
top).  This increased B6/lpr T cell pro-
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Figure 3. B6/lpr T cells hyperproliferate after secondary stimulation. A. Purified CD4+ 
T cells from B6 and B6/lpr mice were ConA-stimulated and received a secondary ConA 
challenge after an IL-2 expansion phase.  The proliferation of B6/lpr T cells at 24 h post-
restimulation was notably higher than that of control T cells, which underwent apoptosis, as 
measured by cell cycle analysis after PI staining (top).  Addition of zVAD (50 µM) efficiently 
inhibited apoptosis of B6 T cells, although proliferation of B6/lpr T cells remained elevated 
(bottom).  Representative data are shown (n = 7).  B. [3H]thymidine uptake 24 h and 48 h 
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liferation ratio could nonetheless be due 
to accumulation of live apoptosis-surviv-
ing Fas-deficient cells compared to B6 
T cells.  To overcome these differences 
in cell death between control and B6/lpr 
T cells, we used the cell death inhibitor 
zVAD, a broad-spectrum caspase inhibi-
tor that blocks caspase-8 processing at 
the DISC and thus inhibits transduction 
of apoptotic signaling (Scheme 2, Intro-
duction).  Cell cycle analysis showed that 
in the presence of this inhibitor, B6/lpr 
T cells still hyperproliferated compared to 
controls (Fig. 3A, bottom). This was also 
demonstrated by increased [3H]thymidine 
uptake (Fig. 3B) and accumulation of live 
cells in the culture (Fig. 3C).
To further confirm that B6/lpr T cell 
hyperproliferation after secondary stimu-
lation was due to lack of proliferation con-
trol by Fas rather than to the increased 
number of live T cells in B6/lpr vs. B6 
cultures, we examined division rates of 
CFSE-labeled B6/lpr vs. B6 T cells.  In 
this assay, incorporated fluorescent mark-
er is reduced by half the initial intensity 
after each cell division and can be moni-
tored by flow cytometry.  CFSE dilution of 
propidium iodide-negative (PI-) live B6/lpr 
cells was greater compared to B6 coun-
terparts (Fig. 3D, top).  zVAD treatment 
(50 µM) had no effect on the proliferative/
division potential of B6 T cells (Fig. 3D, 
bottom).  The CFSE dilution data showed 
total population fluorescence shifts, rath-
er than typical sequential dilution peaks. 
This is probably an inherent characteristic 
of CFSE labeling of repeatedly stimulated 
cells, as CFSE staining of naïve T cells 
after the first stimulation showed sequen-
tial dilution peaks (Fig. 2B).  We also ana-
lyzed expression of the Ki-67 proliferation 
marker in CD4+ T cells (Katzman et al., 
2010), and found a notable increase in 
expression of this marker 24 h after sec-
ondary stimulation (Fig. 3E).  Restimulat-
ed Fas-deficient T cells thus divided at an 
increased rate compared to apoptosis-
surviving B6 T cells, supporting the prem-
ise that Fas has a proliferation-regulating 
effect on T cells after repeated stimula-
tion.
Hyperproliferation of B6/lpr T cells 
might reflect an increased cell activation 
after secondary ConA challenge.  Values show mean ± SD, (n = 6, p<0.0001).  C. Increased 
generation of B6/lpr T cells after secondary stimulation compared to B6 T cells, determined 
by dye exclusion based on trypan blue staining.  Values show mean ± SD (n = 4; p<0.0005).  
D. CFSE dilution rate of gated PI-negative cells shows increased B6/lpr T cell proliferation 
after secondary stimulation compared to B6 T cells (top).  zVAD addition did not affect B6 T 
cell proliferation (bottom).  Representative histograms are shown (n = 4).  E. Upregulation of 
the Ki-67 proliferation marker on B6/lpr T cells at 24 h after secondary ConA stimulation, as 
determined by flow cytometry.  A representative experiment is shown (n = 3).  F. High IL-2 
levels detected in culture supernatant from B6/lpr T cells at 24 h post-restimulation.  Values 
show mean ± SD (n = 4).  G. Elevated surface expression of CD25 and CD69 activation mar-
kers on B6/lpr T cells at 24 h post-restimulation, as compared to B6 T cells.  Representative 
histograms are shown (n = 4).
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status; we therefore examined the impact 
of Fas deficiency on T cell activation. 
In accordance with the observed 
enhanced proliferation of B6/lpr T cells, 
we detected more IL-2 production (Fig. 
3F), used as a surrogate for active 
proliferative signaling (Bécart et al., 2007; 
Alshamsan et al., 2011).  Finally, we found 
that at 24 h after second stimulation in the 
presence of zVAD, these cells showed 
greater expression of CD25 (Fig. 3G, top) 
and CD69 (Fig. 3G, bottom).  
These results thus indicate that after 
secondary stimulation, B6/lpr T cells reach 
higher activation status than B6 T cells, 
and this justify their hyperproliferative 
phenotype.
Fas controls rechallenged T cell 
proliferation independently of its pro-
apoptotic function
To confirm that Fas control of prolif-
eration is independent of AICD-inducing 
potential and to exclude possible second-
ary effects of zVAD, we analyzed prolif-
eration of restimulated B6 and B6/lpr T 
cells in apoptosis-free conditions.  We es-
tablished in our laboratory two apoptosis-
free protocols for the analysis of T cell 
proliferation after repeated stimulation 
(Scheme 6, Materials and Methods).  
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Figure 4.  Fas controls T cell 
proliferation independently 
of its AICD potential. A.  Live 
cells were gradient-separated 
48 h after secondary challen-
ge, ConA-restimulated and 
annexin-V and PI double stai-
ning was performed at indicated 
times; similar cell death ratios 
were observed for B6 and B6/
lpr T cells.  Representative data 
are shown (n = 2).  B. Cell cycle 
analysis at 24 h after the third 
stimulation showed elevated 
proliferation of B6/lpr T cells 
compared to controls in similar 
conditions of cell death.  Repre-
sentative histograms are shown 
(n = 2).  C. Hyperproliferation of 
B6/lpr T cells in apoptosis-free 
conditions, measured by [3H]
thymidine uptake at 24 h after 
the third challenge.  Values 
show mean ± SD (n = 4).  
D. Dilution rate of CFSE-labeled 
PI-negative control and B6/lpr T 
cells at 48 h and 72 h after the 
third stimulation. Representati-
ve data are shown (n = 2).
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In the first system, at 48 h after sec-
ondary stimulation, B6 and B6/lpr T cells 
were gradient-purified to separate live 
from apoptotic cells (>90% efficiency) 
and live cells were immediately restimu-
lated with ConA.  This restimulation did 
not induce apoptosis in B6 or B6/lpr T 
cells, as determined by Annexin V and 
PI staining (Fig. 4A), but led to marked 
B6/lpr T cell hyperproliferation 24 h after 
the third ConA stimulation (Fig. 4B).  En-
hanced proliferation was also evident in 
[3H]thymidine  incorporation assays (Fig. 
4C) and CFSE dilution experiments (Fig. 
4D).  These data confirm that B6/lpr T cell 
hyperproliferation is not a direct result of 
an apoptosis defect, but a consequence 
of each cell’s greater capacity to divide.
In the second protocol, restimulated 
and gradient-purified cells were cultured 
with IL-2.  Cell cycle analysis showed that 
cell death was also minimal in this case 
and was the same for both cell groups 
(Fig. 5A).  In contrast, B6/lpr T cells hy-
perproliferated compared to controls, as 
shown by [3H]thymidine incorporation 
(Fig. 5B) and CFSE dilution (Fig. 5C). 
These observations indicate that hyper-
proliferative characteristics of B6/lpr T 
cells are maintained, even for prolonged 
periods post-restimulation, and show 
that Fas-deficient cells have greater divi-
sion capacity, which permits them to ex-
tend the proliferative response beyond 
the immediate reaction to TCR stimula-
tion.  Overall, data from apoptosis-free 
systems demonstrate that Fas regulates 
T cell proliferation independently of its 
AICD-inducing potential.
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Figure 5.  B6/lpr T cell hyperproliferation in an apoptosis-free proliferation system
A. Live cells were gradient-separated at 48 h after secondary stimulation and expanded with 
IL-2 for another 48 h.  PI staining and cell cycle analysis showed enhanced proliferation of 
B6/lpr T cells compared to controls.  B. Proliferation of live B6 and B6/lpr T cells in an apop-
tosis-free system was measured by [3H]thymidine incorporation at 24 h and 48 h after gra-
dient separation and the third stimulation (mean ± SD, n = 4).  C. CFSE dilution experiments 
confirmed elevated B6/lpr T cell proliferation compared to controls in minimal cell death 
conditions.  In all cases, representative data are shown (n = 2).
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Fas-dependent control of T cell 
proliferation requires interaction with 
Fas ligand
As Fas interaction with its ligand is 
necessary to induce the apoptosis signal-
ing pathway, we analyzed whether this 
interaction is needed for Fas-dependent 
control of cellular proliferation.  We used 
B6/gld T cells that express fully functional 
Fas, but lack Fas ligand and develop au-
toimmune disorders similar to those of 
B6/lpr mice (Lynch et al., 1994; Ramsdell 
et al., 1994).  We subjected CD4+ T cells 
from B6/gld mice to the repeated stimu-
lation protocol and observed by means 
of [3H]thymidine incorporation and CFSE 
dilution experiments that, like B6/lpr T 
cells, they hyperproliferated compared to 
controls (Fig. 6A).  These results indicat-
ed that Fas-FasL interaction is important 
in proliferation control.  Similar to B6/lpr T 
cells, B6/gld cells did not undergo apop-
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Figure 6.  Fas interaction with 
its ligand directly attenuates 
T cell proliferation
A.  FasL-deficient B6/gld T 
cells, like B6/lpr T cells, hy-
perproliferate after secondary 
stimulation, as detected by 
[3H]thymidine incorporation and 
CFSE dilution assys.  B. Cell 
cycle and apoptosis analysis 
of ConA-restimulated B6/gld T 
cells treated with recombinant 
(r)FasL (150 ng/ml) or rFasL + 
zVAD (150 ng/ml and 50 µM, 
respectively). Representative 
histograms are shown (n = 4).  
C. FasL treatment of restimu-
lated B6/gld T cells decreased 
their hyperproliferation 
([3H]thymidine incorporation, 
top) and as a result, the number 
of live cells in culture (trypan 
blue staining, bottom).  Values 
show mean ± SD (n = 4). 
D. Reduced proliferation of 
FasL-treated B6/gld T cells after 
second stimulation, as deter-
mined by CFSE dilution (top).  
Addition of zVAD (50 µM) had 
no effect on restimulated B6/
gld T cell proliferation (bottom).  
Representative data are shown 
(n = 4).  
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tosis, as determined by PI staining (Fig. 
6B, top).
To test whether restored Fas-FasL 
interaction can reduce proliferation, we 
treated Fas-expressing B6/gld T cells 
with 150 ng/ml of recombinant FasL 
(rFasL) and tested whether hyperprolifer-
ation was reduced after the second chal-
lenge.  As rFasL addition induced apop-
tosis of ConA-restimulated B6/gld T cells 
(Fig. 6B, bottom left), we used the inhibi-
tor zVAD (50 µM) to avoid cell death and 
to allow observation of the Fas effect on 
cell proliferation alone.  zVAD treatment 
efficiently inhibited rFasL-induced apop-
tosis (Fig. 6B, bottom right), and rFasL 
addition notably decreased B6/gld cell 
hyperproliferation after secondary stimu-
lation (Fig. 6B, bottom right). This result 
was confirmed in a [3H]thymidine incor-
poration assay and by counting live cell 
numbers (Fig. 6C).  CFSE dilution experi-
ments also showed a decreased division 
rate for B6/gld T cells treated with rFasL, 
indicating that Fas-FasL interaction has 
a direct effect on the proliferation of re-
stimulated T cells (Fig. 6D, top); a control 
showed that 50 µM zVAD had no effect 
on T cell proliferation (Fig. 6D, bottom).  
Overall, these data demonstrate that, 
independently of its AICD-inducing effect, 
Fas interaction with FasL directly attenu-
ates restimulated B6/gld T cell hyperpro-
liferation.
Hyperproliferation of Fas-deficient 
cells is not due to higher number of 
memory T cells entering the second 
stimulation
To rule out the possibility that B6/lpr T 
cell hyperproliferation characterizes dis-
tinct initial activation/memory status be-
tween B6 and B6/lpr cells or that culture 
conditions favor selection of Fas-deficient 
cell clones with the initial high proliferative 
capacity, we sorted spleen naïve (CD44-
low/CD62Lhigh) and memory (CD44high/
CD62Llow) CD4+ T cells from B6 and B6/
lpr mice (Fig. 7A).  Cells were subjected 
to the standard AICD protocol.  Follow-
ing the first stimulation, proliferation of 
B6/lpr  CD44low/CD62Lhigh T cells (the 
term “naïve” can not be use at this stage, 
as “naïve” refers to cells that have nev-
er seen antigen) was in fact lower than 
that of control T cells, as determined by 
cell cycle analysis (Fig. 7B).  This finding 
concurs with reports that Fas provides 
necessary costimulation for naïve T cells 
(Alderson et al., 1993; Maksimow et al., 
2006; Rethi et al., 2008).  In addition, 
there were no differences between B6 
and B6/lpr T cells in expression of activa-
tion markers CD25 and CD69 (Fig. 7C).
Following the second stimulation, 
however, CD44low/CD62Lhigh B6/lpr T 
cells showed much higher CD25 expres-
sion than control T cells.  This was also 
the case of CD44high/CD62Llow B6/
lpr T cells, although here the difference 
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was less notable (Fig. 8A, top).  Surface 
CD69 expression was also consider-
ably higher in CD44low/CD62Lhigh B6/
lpr T cells, which was not the case for 
CD44high/CD62Llow B6/lpr T cells (Fig. 
8A, bottom).  
We analyzed proliferation of both 
cell subsets by testing expression of the 
proliferation marker Ki-67 and by cell 
cycle analysis.  Ki-67 was upregulated 
in CD44low/CD62Lhigh B6/lpr T cells 
(Fig. 8B).  In agreement with this result, 
cell cycle analysis showed markedly 
higher proliferation of B6/lpr CD44low/
CD62Lhigh T cells compared to this 
subset in B6 mice (Fig. 8C, left), indicating 
that these cells have a greater intrinsic 
proliferative capacity.  The proliferation 
rate of CD44high/CD62Llow was also 
increased in B6/lpr compared to B6 mice 
(Fig. 8C, right); in both B6/lpr and B6 T 
mice, CD44high/CD62Llow proliferation 
was lower than that of CD44low/
CD62Lhigh T cells.  
Overall, these results exclude the pos-
sibility that B6/lpr T cell hyperproliferation 
is due to differences in activation/mem-
ory status before second stimulation, or 
to artifactual culture conditions that fa-
vor selection of Fas-deficient cell clones 
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Figure 7. Proliferative response of sorted naïve and memory T cells after first stimula-
tion. A. Spleen-derived cells from B6 and B6/lpr T mice were stained for CD4, CD44, CD62L 
surface markers, and naïve (CD44lowCD62Lhigh) and memory T cells (CD44highCD62Llow) 
were sorted.  B. Cell cycle analysis at 24 h after primary stimulation showed similar proli-
feration ratios between B6 and B6/lpr CD44low/CD62Lhigh cells and between B6 and B6/
lpr CD44high/CD62Llow T cells. C. Surface expression of CD25 and CD69 activation mar-
kers on sorted B6 and B6/lpr T cell populations.  In all cases, representative data are shown 
(n=3).
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with initial high proliferative capacity.  B6/
lpr T cells hyperproliferate following re-
stimulation even when they show naïve T 
cell status at the beginning of the culture 
period, which confirms the role of Fas in 
direct control of T cell proliferation after 
repeated antigenic stimulation.
p21 overexpression in B6/lpr mice 
reduces in vivo T cell hyperproliferation 
and lymphadenopathy development
Our in vitro data thus far indicated that 
Fas negatively controls T cell prolifera-
tion.  As the etiology of the B6/lpr mouse 
phenotype has not been explained to 
date, we considered that the lack of Fas 
control of proliferation might modulate the 
B6/lpr phenotype.  We therefore explored 
the physiological relevance of T cell hy-
perproliferation in autoimmunity develop-
ment in Fas-deficient mice.  We used an 
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Figure 8.  Hyperactivation and hyperproliferation of sorted naïve and memory B6/lpr T 
cells after secondary stimulation. A. Increased surface expression of CD25 on CD44low/
CD62Lhigh and CD44high/CD62Llow B6/lpr T cells (top) and increased CD69 expression on 
CD44low/CD62Lhigh B6/lpr T cells (bottom).  B. Enhanced proliferation of CD44low/CD62L-
high B6/lpr T cells compared to CD44low/CD62Lhigh B6 T cells, determined by Ki-67 ex-
pression.  C. Cell cycle analysis of sorted populations showed hyperproliferation of CD44low/
CD62Lhigh and CD44high/CD62Llow B6/lpr T cells, as well as notable differences in the 
proliferation ratio between sorted populations from each mice genotype.  In all cases, repre-
sentative data are shown (n = 3).
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in vivo model generated in our laborato-
ry in which the cell cycle inhibitor p21 is 
overexpressed in the B6/lpr mouse T cell 
compartment.
We previously described p21 as a 
suppressor of autoimmunity (Balome-
nos et al., 2000; Arias et al., 2007), and 
showed that it does not affect primary 
T cell proliferation, but controls prolifera-
tion of apoptosis-surviving T cells after 
secondary antigen challenge (Arias et 
al., 2007).  This led us to speculate that 
p21 overexpression in B6/lpr mice might 
reduce the autoimmune disorder in these 
animals, since their T cells hyperprolifer-
ate after restimulation.
B6/lpr-p21tg mice were generated from 
C57BL/6-p21tg mice (B6-p21tg); p21 
transgene expression in these animals is 
restricted to T cells by the proximal Lck 
promoter.  B6-p21tg mice show normal 
T cell development and differentiation 
(Fotedar et al., 1999). 
In vivo T cell proliferation is similar to 
that of B6 mice (Fig. 9A), as determined by 
BrdU incorporation by lymph node CD4+, 
CD8+ and DN T cells.  We found that 
although the p21 transgene had no effect 
on B6 T cell proliferative characteristics, 
it greatly inhibited (>2-fold) CD4+, CD8+ 
and DN T cell hyperproliferation in B6/lpr-
p21tg mice (Fig. 9B).
These results indicated an antiprolif-
erative effect of p21 overexpression on 
peripheral B6/lpr-p21tg T cells.  To rule 
out a possible p21 transgene effect on 
selection events and development in the 
thymus, we examined the T cell profiles 
in B6, B6/lpr, B6-p21tg and B6/lpr-p21tg 
mouse thymus.  The similarity of frequen-
cies for all thymocyte subsets in all geno-
type groups supports the view that p21 
transgene function is manifested in pe-
ripheral B6/lpr-p21tg T cells (Fig. 10).
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Figure 9.  p21 overexpression inhibits in vivo hyperproliferation of B6/lpr T cells
A. In vivo BrdU incorporation by lymph node T cells from 2-month-old B6, B6-p21tg and B. 
B6/lpr, B6/lpr-p21tg mice shows decreased proliferation for B6/lpr-p21tg CD4+, CD8+ and 
DN T cells.  Values are mean ± SD (n = 4).
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Reduced lymphadenopathy 
and autoimmune manifestations
in B6/lpr‑p21tg mice
B6/lpr mice develop lymphadenopathy 
and splenomegaly, which originate 
from accumulation of DN (Fig. 11A, 
left) and CD4+ memory T cells (Fig. 
12A).  Expansion of these cell subsets 
is evident at two months of age and 
increases with time.  We found that p21 
overexpression led to a clear reduction 
of the DN T cell population in B6/lpr-
p21tg mice (Fig. 11A, top), probably as a 
result of the reduced in vivo proliferation 
of DN T cells in B6/lpr-p21tg mice (Fig. 
9B, bottom).  The DN T cell population 
in B6-p21tg mice was unaffected by 
overexpression of the transgene (Fig. 
11A, bottom).  In accordance with these 
results, we observed a notable reduction 
in lymphadenopathy in B6/lpr-p21tg mice 
(Fig. 11B).  We detected no endogenous 
p21 expression in DN T cells; this 
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Figure 11.  Decreased DN T cell accumulation and reduced lymphadenopathy in 
B6/lpr-p21tg mice. A. Decreased proportions of DN T cells in lymph nodes of 5-month-old 
B6/lpr-p21tg compared to B6/lpr mice.  Values are mean ± SD (n = 8). B. Decreased size 
(top) and weight (bottom) of cervical lymph nodes in 8 month-old female B6/lpr-p21tg vs. 
B6/lpr mice.  Values are mean ± SD (n = 10, p<1 x 106). C. Western blot reflecting expression 
of transgenic p21 in DN T cells from 2-month-old mice.  Endogenous p21 is not expressed in 
DN T cells compared to control CD4+ T cells cultured in vitro in the presence of IL-2.  β-actin 
was used as a loading control.
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lack of p21 probably explains the 
hyperproliferation of these cells, whereas 
expression of the p21 transgene reduces 
this elevated proliferation (Fig. 11C).
In addition to decreasing lymphade-
nopathy, p21 overexpression also amelio-
rated manifestations of the autoimmune 
disease; it considerably reduced the 
expansion of both subsets (CD44high/
CD62Lhigh or low) of effector/memory T 
cells in B6/lpr-p21tg mice (Fig. 12A) and 
led to a notable drop in serum anti-DNA 
antibody levels in B6/lpr-p21tg mice com-
pared to B6/lpr controls (Fig. 12B).
T cell-directed expression of the 
p21 transgene therefore has a dual 
effect in B6/lpr mice; on the one hand, 
it reduces DN T cell expansion and 
lymphadenopathy, and on the other, it 
ameliorates autoimmune manifestations.
p21 overexpression diminishes lupus-
like autoimmunity and death incidence 
in MRL/lpr mice
Our results demonstrated that p21 
overexpression in B6/lpr-p21tg T cells 
effectively limits the autoimmunity 
symptoms and lymphadenopathy of B6/
lpr mice.  We next tested whether p21 
hyperexpression had similar potential 
to inhibit the severe, death-inducing 
autoimmunity features in the MRL/lpr 
mice; the phenotype of these animals is 
a result of the combined autoimmunity-
prone MRL background and the lpr 
mutation.
We found that T cell-directed p21 
hyperexpression reduced the proportion 
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Figure 12. p21 overexpression reduces manifestations of autoimmune disease
A. Proportions of lymph node memory T cells (CD44high, CD62Lhigh/low) from 2 month-old 
B6/lpr, B6/lpr-p21tg, B6 and B6-p21tg mice.  p21 overexpression greatly reduces age-related 
memory T cell accumulation in B6/lpr mice. Values are mean ± SD (n = 5 mice/group or ge-
notype). B. Relative levels of anti-DNA IgG detected by ELISA in 4-month-old B6, B6/lpr and 
B6/lpr-p21tg mice.  Values are mean ± SD (n = 9 mice/group or genotype, p=1 x 105).
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(Fig. 13A) and absolute number (Fig. 
13B) of lymph node DN T cells, as 
well as lymphadenopathy in MRL/lpr-
p21tg compared to MRL/lpr mice (Fig. 
13C).  The weight of lymph nodes from 
transgenic mice was markedly decreased, 
and dropped to levels similar to those of 
MRL-MP mice, which are not prone to 
autoimmunity.
Compared to controls, MRL/lpr-p21tg 
mice also showed a reduction in the pro-
portion (Fig. 13D) and absolute number 
(Fig. 13E) of effector/memory T cells in 
lymph nodes, and a strong decrease in 
serum anti-DNA antibody levels, which 
decreased almost to the level of the MRL-
MP controls (Fig. 13F).  As MRL/lpr mice 
have much higher levels of anti-DNA an-
tibodies than B6/lpr mice, it appears that 
p21 overexpression is able to control the 
predisposition of MRL/lpr mice to severe 
autoimmunity.  Indeed, when compared 
to MRL/lpr mice, MRL/lpr-p21tg mice 
showed clear improvement in critical as-
pects of lupus-like kidney disease, such 
as lower immune complex deposition, 
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Figure 13.  Decreased DN and memory T cell accumulation, lymphadenopathy and 
anti-DNA IgG production in MRL/lpr-p21tg mice. A. Percentage of lymph node DN T cells 
normalized to CD4+ T cells in 4- to 6-month-old MRL/lpr and MRL/lpr-p21tg mice.  Values are 
mean ± SD (n = 10, p=4,24 x 105). B. Absolute number of DN T cells in lymph nodes of 4- to 
6-month-old MRL/lpr and MRL/lpr-p21tg mice.  Values are mean ± SD (n = 10, p=1 x 104). 
C. Decreased size and weight of cervical lymph nodes in 4- to 6 month-old female MRL/lpr-
p21tg vs MRL/lpr and MRL-MP mice. Values are mean ± SD (n = 10, p=1.7 x 106).
D. Percentage of memory T cells (CD44high, CD62Llow) in 4- to 6 month-old MRL/lpr-p21tg 
and MRL/lpr mice normalized to CD4+ T cells.  Values are mean ± SD (n = 8, p=0.24 x 104).
E. Absolute number of memory (CD44high, CD62Llow) T cells in lymph nodes of 4- to 
6-month-old MRL/lpr and MRL/lpr-p21tg mice. Values are mean ± SD (n = 8, p=0.43 x 104).
F. Relative levels of anti-DNA IgG detected by ELISA in 4-month-old MRL-MP, MRL/lpr and 
MRL/lpr-p21tg mice.  Values are mean ± SD (n = 9 mice/group or genotype, p<9 x 105).
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diminished inflammatory infiltration of 
CD4+ T cells and F4/80+ macrophages 
in kidney (Fig. 14A), and reduced glom-
erulonephritis development (Fig. 14B). 
The ameliorating effect of the p21 trans-
gene on disease manifestations in MRL/
lpr mice is translated into survival of MRL/
lpr-p21tg mice (Fig. 14C).
Overall, these data show that p21 is a 
potent suppressor of autoimmunity, as it 
can restrain the autoimmune symptoms 
and death in the MRL/lpr mouse models 
that develop accelerated, severe lupus-
like disease.
p21 overexpression does not restore 
apoptosis defect in death-deficient 
B6/lpr T cells
To further analyze the role of p21 as 
a proliferation-attenuator of B6/lpr-p21tg 
T cells, we performed in vitro stimulation 
and proliferation studies.  Previous work 
from our laboratory with p21-deficient 
mice attributed a role to p21 in controlling 
the expansion of effector/memory T cells, 
but not of naïve T cells (Arias et al., 2007).
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Figure 14.  Diminished lupus-like autoimmunity and death in MRL/lpr-p21tg mice
A. Anti-IgG, -CD4 and -F/480 immunostaining of kidney cryosections from 6-month-old MRL/ 
lpr and MRL/lpr-p21tg mice. B. Analysis of glomeruli in representative kidney sections from 
6-month-old MRL-MP, MRL/lpr and MRL/lpr-p21tg mice.  Glomerulonephritis grade (based on 
the Berdem scale) is shown. C. Kaplan-Meier survival curves indicating the impact of the p21 
transgene on MRL/lpr-p21tg mouse lifespan.
53
RESULTS
Here we examined whether p21 
overexpression affected B6/lpr-p21tg 
T cell proliferation compared to B6/lpr 
controls after primary and secondary 
stimulation.  Spleen-derived T cells from 
B6/lpr-p21tg and B6/lpr mice were ConA-
stimulated, expanded briefly in IL-2 (2 
days), and then restimulated.  PI staining 
and cell cycle analysis showed that p21 
overexpression had no effect on T cell 
proliferation following primary stimulation 
(Fig. 15A, left), whereas it clearly reduced 
cell cycle progression of B6/lpr-p21tg 
T cells at 24 and 48 h after secondary 
stimulation compared to B6/lpr T cells 
(Fig. 15A, right).
Following primary ConA stimulation, 
IL-2-dependent culture, and secondary 
activation of T cells, the Fas/FasL system 
is activated and apoptosis proceeds. 
Fas-deficient B6/lpr T cells have a defect 
in apoptosis after secondary T cell 
stimulation.  The observed reduction in 
B6/lpr-p21tg T cell proliferation in vivo, 
and in vitro post-restimulation, might 
be caused by a proliferation inhibitory 
effect of p21.  Alternatively, this reduction 
could be due to p21 transgene-induced 
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Figure 15.  Apoptosis defect in B6/lpr T cells is unaffected by p21 overexpression
A. Cell cycle analysis at 24 h after the first (left) and the second (right) stimulation showed 
decreased proliferation of B6/lpr-p21tg T cells after secondary stimulation compared to con-
trols in similar conditions of cell death.  Representative histograms are shown (n = 3).
B. Annexin-V and PI double staining at various times after second stimulation showed the 
same cell death defect in B6/lpr and B6/lpr-p21tg T cells.  Representative histograms are 
shown (n = 2).
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restoration of defective apoptosis in B6/
lpr T cells.  Nonetheless, the absence 
of an apoptotic hypodiploid peak in cell 
cycle profiles after secondary stimulation 
of both B6/lpr-p21tg and B6/lpr T cells 
indicated that p21 overexpression does 
not restore the B6/lpr apoptotic defect 
(Fig. 15A, right).  To further rule out a role 
for p21 as an apoptosis inducer in B6/
lpr T cells after secondary stimulation, 
we analyzed apoptosis induction in B6/
lpr and B6/lpr-p21tg T cells by annexin-V 
and PI double staining.  The annexin-V(+)
PI(-) population represents apoptotic T 
cells and the annexin-V(+)PI(+) subset 
indicates post-apoptotic, dead T cells. 
We found that p21 overexpression did 
not interfere with the defective apoptosis 
of B6/lpr T cells, as annexin-V staining 
showed similarly deficient apoptosis for 
B6/lpr and B6/lpr-p21tg T cells, at both 
early and late times post-secondary 
simulation (Fig. 15B).
These results therefore exclude a 
possible apoptosis-inducing effect of 
the p21 transgene in the reduction of 
T cell proliferation observed in B6/lpr-
p21tg mice.  The data therefore suggest 
that p21 overexpression has an anti-
proliferative effect on B6/lpr-p21tg T 
cells, and limits B6/lpr-dependent T cell 
hyperproliferation without altering the 
apoptosis defect.
Reduced B6/lpr-p21tg T cell 
proliferation after secondary 
in vitro stimulation
The observed reduction in B6/lpr-
p21tg T cell proliferation only after sec-
ondary stimulation (Fig. 15A) was further 
confirmed by [3H]thymidine uptake at 48 
h after the first and second ConA stimu-
lation.  Following primary challenge, we 
found similar proliferation rates for B6/
lpr and B6/lpr-p21tg T cells (Fig. 16A). 
In contrast, after secondary stimulation, 
we observed a sharp decrease (>50%) 
in [3H]thymidine uptake by B6/lpr-p21tg 
compared to B6/lpr T cells (Fig. 16A). 
The capacity of p21 overexpression to 
reduce cell cycle progression of restimu-
lated B6/lpr-p21tg T cells was further vali-
dated by the decreased expression of the 
Ki-67 proliferation marker by B6/lpr-p21tg 
vs. B6/lpr T cells (>3-fold) after second-
ary stimulation (Fig. 16B).
To further confirm that p21 overexpres-
sion reduced the capacity of T cells to di-
vide, we performed CFSE dilution experi-
ments.  Fluorescence intensity dilution of 
CFSE-labeled B6/lpr-p21tg and B6/lpr T 
cells established that p21 overexpression 
did not affect primary proliferation of T 
cells (Fig. 16C, left).  In accordance with 
previous data, we nonetheless observed 
decreased fluorescence intensity dilu-
tion of CFSE-labeled B6/lpr-p21tg T cells 
compared to B6/lpr T cells, which was 
detectable at 48 h and became clear 72 
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h after secondary stimulation (Fig. 16C, 
right).  Restimulated B6/lpr-p21tg T cells 
thus divided at a decreased rate com-
pared to B6/lpr T cells.  The CFSE dilu-
tion results were supported by the severe 
reduction (>5-fold) in the absolute num-
ber of live T cells in B6/lpr-p21tg vs. B6/
lpr T cell cultures at 48 h post-secondary 
activation (Fig. 16D).  As anticipated, we 
detected comparable numbers of these 
two cell types at the termination of pri-
mary stimulation (Fig. 16D).  These data 
indicate that the p21 transgene has a 
regulatory role in the expansion of B6/lpr-
p21tg T cells after in vitro secondary, but 
not after primary challenge.
To further evaluate the effect of p21 
overexpression on T cell proliferation af-
ter secondary stimulation, we examined 
expression of the p21 transgene and of 
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Figure 16.  p21 overexpression decreases in vitro B6/lpr cell hyperproliferation after 
secondary stimulation. A.  Purified CD4+ T cells from B6/lpr and B6/lpr-p21tg mice were 
ConA-stimulated (1st stimulation) or restimulated with ConA after an IL-2 expansion phase 
(2nd stimulation). The p21 transgene reduced T cell responses only after secondary stimula-
tion.  Proliferation was measured by [3H]thymidine uptake at 48 h after first or second cha-
llenge.  Values show mean ± SD (n = 4). B. B6/lpr-p21tg T cells showed reduced expression 
of the Ki-67 proliferation marker compared to B6/lpr T cells at 24 h after secondary stimula-
tion, as assessed by flow cytometry analysis.  Representative histograms are shown (n = 2).
C. CFSE dilution rate of gated PI-negative T cells, following the first (left) and the second 
(right) ConA stimulation.  Representative histograms are shown (n = 3). D. Decreased gene-
ration of B6/lpr-p21tg CD4+ T cells compared to B6/lpr T cells after secondary stimulation, as 
determined by Trypan blue dye exclusion.  Values show mean ± SD (n = 4). E. Western blot 
reflecting the expression of endogenous and transgenic p21 in CD4+ T cells from 2-month-
old B6/lpr and B6/lpr-p21tg mice.  Spleen cells were isolated, ConA stimulated, IL-2 expan-
ded and restimulated for indicated times.  β-actin was used as a loading control.
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endogenous p21 by Western blot.  We 
found that, at the end of the IL-2 expan-
sion step (0 h, Fig. 16E), endogenous p21 
was minimally expressed in B6/lpr and B6/
lpr-p21tg T cells, whereas p21 transgene 
expression was high in the latter.  After the 
second activation step, endogenous p21 
was greatly induced in B6/lpr T cells, sug-
gesting that p21 is critical for the control 
of proliferation in restimulated T cells.  In 
B6/lpr-p21tg T cells, we observed a reduc-
tion in p21 transgene expression following 
secondary stimulation; this indicates that 
the high p21 transgene levels at the be-
ginning of restimulation might condition 
cells to a lower proliferative response dur-
ing the course of the secondary response 
(Fig. 16E).
We found that although p21 overex-
pression inhibits in vivo hyperproliferation 
of B6/lpr T cells (Fig. 9B), it does not af-
fect in vivo proliferation of B6 T cells (Fig. 
9A).  Concurring with these results, the 
p21 transgene differentially affected the 
in vitro proliferation of B6/lpr and B6 T 
cells after secondary stimulation.  B6 and 
B6-p21tg T cell cultures showed similar 
[3H]thymidine uptake 48 h after both pri-
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Figure 17.  p21 overexpression does not affect proliferation or cell death of control T 
cells. A. Purified CD4+ T cells from B6 and B6-p21tg mice were ConA-stimulated 
(1st stimulation) or restimulated with ConA after an IL-2 expansion phase (2nd stimulation).  
Proliferation was measured by [3H]thymidine uptake at 48 h after first or second challenge. 
Values show mean ± SD (n = 4). B. Similar generation of B6 and B6-p21tg CD4+ T cells 
after primary and secondary stimulation, as determined by Trypan blue dye exclusion.  
Values show mean ± SD (n = 3). C. Cell cycle analysis at 24 h after the second stimula-
tion showed similar proliferation and cell death of B6 and B6-p21tg T cells.  Representative 
histograms are shown (n = 3). D. Annexin-V and PI double staining at 24 h after the second 
stimulation showed the same cell death in B6 and B6-p21tg T cells.  Representative histo-
grams are shown (n = 2). E. Western blot showing endogenous and transgenic p21 expres-
sion in CD4+ T cells from 2 month-old B6 and B6-p21tg mice.  Spleen cells were isolated, 
ConA stimulated, IL-2 expanded and restimulated for indicated times.  β-actin was used as a 
loading control.
57
RESULTS
mary and secondary challenge (Fig. 17A) 
and absolute numbers of live cells were 
similar (Fig. 17B), whereas B6/lpr-p21tg 
T cells showed a reduction in prolifera-
tion and live cell numbers (see above). 
The slightly lower values observed for 
B6-p21tg compared to B6 T cell cultures 
after secondary stimulation were not sig-
nificant.
Cell  cycle analysis at  24 h after 
secondary stimulation of B6 and B6-
p21tg T cells demonstrated similar 
apoptosis levels (hypodiploid cells) 
as well as comparable proliferation of 
the two cell groups (Fig. 17C).  Double 
staining with annexin-V and PI showed 
that a large proportion of B6 and B6-
p21tg T cells underwent apoptosis 
during the first 24 following secondary 
TCR challenge, and that there were no 
differences in the proportion of apoptotic 
cells between the two genotype groups 
(Fig. 17D); p21 overexpression therefore 
does not influence B6 T cell responses 
after secondary stimulation.  Western 
blot analysis confirmed p21 transgene 
expression in B6-p21tg T cells (Fig. 
17E).
Taken together, our in vivo and in vitro 
studies suggest that p21 overexpression 
in control T cells does affect neither 
proliferative responses nor apoptosis, 
although it greatly reduces B6/lpr T 
cell hyperproliferation in vivo and in 
vitro after secondary challenge.  This 
proliferation-attenuating property of 
p21 overexpression is not due to a 
possible apoptosis-inducing effect of 
the p21 transgene, since both B6/lpr 
and B6/lpr-p21tg T cells show the same 
apoptotic defect.  The reduction of B6/
lpr hyperproliferation is relevant to the 
outcome of the lupus-like disease, as 
it ameliorates lymphadenopathy and 
autoimmune manifestations, even in the 
severe lupus-like phenotype of MRL-lpr 
mice.
Hyperproliferation of rechallenged 
B6/lpr T cells is associated with 
NF-κB hyperactivation
The data thus far indicate that Fas 
plays an important role in the control of 
T cell proliferation independently of its 
proapoptotic function.  As restimulated 
B6/lpr T cells acquire hyperactivation sta-
tus and hyperproliferate after secondary 
stimulation, Fas must have an important 
function in the control of T cell prolifera-
tion after TCR reactivation.  Our next ob-
jective was to determine the molecular 
connection between hyperproliferation 
and hyperactivation in B6/lpr T cells.
NF-κB has a fundamental role in 
regulating the immune response, as a 
key factor in transcription of the genes 
essential for cell proliferation and survival. 
We therefore studied the effect of Fas 
deficiency on activation of the NF-κB 
pathway after secondary TCR challenge.
NF-κB dimers are maintained in an 
inactive state in cytoplasm by NF-κB 
inhibitor (IκBα).  Receptor signaling leads 
to rapid activation of a multi-subunit kinase 
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complex (IKK) that phosphorylates IκBα 
inhibitor on two key serines and marks it 
for degradation by the ubiquitin pathway 
(reviewed in Li et al., 2002; Rawilings et 
al., 2006; Ruland et al., 2003).  Although 
the exact molecular events leading to 
NF-κB activation are not yet well defined, 
we know that the CBM complex, formed 
by CARMA-1, BCL-10 and MALT-1, is 
essential for NF κB nuclear translocation 
(Frischbutter et al., 2011; Egawa et al., 
2003; Rueda et al., 2005; Sommer et al., 
2005; Matsumoto et al., 2005; Thome et 
al., 2003).  
In accordance with the B6/lpr T cells 
hyperproliferation already evident at 24 h 
post-restimulation, we detected by EMSA 
analysis that NF-κB in nuclear extracts 
from B6/lpr T cells showed much greater 
binding to the DNA consensus sequence 
than that in control extracts (Fig. 18A). 
In order to confirm and quantify the 
observed difference, we used the IN Cell 
Analyzer 2000, a high-content analysis 
system that quantities data based on 
automated cell imaging.  The integrated 
software localizes nuclei based on 
fluorescence staining, and the algorithm 
defines a collar space around the nuclei. 
Signal intensity for NF-κB (p65) is then 
measured in the nuclei and in the peri-
nuclear space, and data are expressed as 
the ratio between nuclear and cytoplasm 
staining intensity.  In correlation with 
EMSA results, we detected a two-fold 
increase in NF-κB activation in B6/
lpr compared to control T cells at 24 h 
post-secondary stimulation (Fig. 18B, 
left).  We also tested NF-κB activation 
status in both cell groups 24 h after first 
stimulation and detected no difference 
(Fig. 18B, right).  These results indicated 
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Figure 18.  Hyperprolifera-
tion of rechallenged B6/lpr 
T cells is linked to NF-κB 
hyperactivation
A. Enhanced NF-κB ac-
tivation after secondary 
stimulation in B6/lpr T cells 
compared to controls, as 
determined by EMSA.  
Probe containing the NF-Y 
consensus sequence was 
used as a loading control.  
B. Quantification of NF-κB 
activation levels in B6 and 
B6/lpr T cells using the IN 
Cell Analyzer 2000 imaging 
system.  Cells at indicated 
times after second (left) and 
first (right) stimulation were stained for nuclear content (AAD nuclear stain) and NF-κB (p65).  
NF-κB signal intensity was measured in nuclei and the perinuclear space, and NF-κB activa-
tion status was defined by its nuclear vs. cytoplasmic localization.  Values show mean ± SD 
(n = 3).  C. Reduced NF-κB activation after FasL treatment of B6/gld T cells during secondary 
stimulation in the presence of zVAD (50 µM), as determined by EMSA.
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that the hyperproliferation of restimulated 
B6/lpr T cells is a consequence of NF-κB 
hyperactivation.
In another approach we further con-
firmed the functional relationship between 
Fas deficiency and hyperactivation of NF-
κB signaling; we treated reactivated B6/
gld T cells with recombinant FasL (150 
ng/ml) in the presence of zVAD (50 µM). 
Treatment of these FasL-deficient, Fas-
sufficient T cells with rFasL restored the 
Fas signaling pathway and thus led to a 
decrease in NF-κB activation, as detect-
ed by EMSA experiment (Fig. 18C).
NF-κB hyperactivation in B6/lpr T cells 
is associated with caspase-8 whole 
form activity 
Our results established an important 
role for Fas in T cell homeostasis.  We 
found that in the absence of Fas, B6/lpr 
T cells hyperproliferate after secondary 
stimulation and that this hyperprolifera-
tion is due to NF-κB hyperactivation.  In 
order to obtain insights into molecular 
mechanism that leads to NF-κB hyperac-
tivation in the absence of Fas, we studied 
molecular pathway involved in the NF-κB 
signaling.
It is now very clear that, in addition to 
promoting apoptosis, active casapse-8 
is essential for T cell activation and 
proliferation after TCR stimulation and its 
activity is important for NF-κB activation 
(Chun et al., 2002; Salmena et al., 2003; 
Siegel 2006; Lamkanfi et al., 2007). The 
molecular events that lead to caspase-8 
activation and its cell localization in these 
divergent processes remain nonetheless 
unclear.  Some indications support a 
model in which the location of active 
caspase-8 would greatly influence its 
functional capacity as a regulator of cell 
death or proliferative response (Koenig 
et al., 2008).  It was suggested that 
caspase-8 translocation into the lipid 
raft fraction at the plasma membrane 
is important for T cell activation, and 
possibly for preventing active caspase-8 
from accessing substrates that promote 
cell death (Mistra et al., 2007).
Given the importance of its spatial 
location in the mediation of cell growth 
versus cell death, we studied caspase-8 
localization in B6 and B6/lpr T cells 
following TCR restimulation.  Confocal 
microscopy was used to visualize 
caspase-8 and Fas in cells treated with 
zVAD to block apoptosis.  We observed 
that at time 0, caspase-8 localized mainly 
to the plasma membrane in both cell 
groups (Fig. 19A).  At 1 h after secondary 
stimulation, however, caspase-8 staining 
was almost entirely cytoplasmic in 
B6 compared to B6/lpr T cells; in the 
latter, its staining was basically annular, 
indicating that there was no translocation 
into cytoplasm (Fig. 19B).  In addition, 
caspase-8 and Fas co-localized in control 
T cells before and after restimulation. 
We excluded, however, the possibility 
that this interaction was pro-apoptotic, 
since all experiments were performed in 
the presence of the apoptosis inhibitor 
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zVAD.  It is thus tempting to speculate 
that Fas collaborates with caspase-8 in 
the control of T cell proliferation, possibly 
by mediating its translocation from the 
plasma membrane, where the protein 
complex required for TCR-mediated NF-
κB activation, which includes CARMA-1, 
BCL10 and MALT-1, is located.
Our results show that caspase-8 
localizes to distinct cell regions after 
TCR restimulation in Fas-deficient T cells 
compared to controls.  This suggests that 
Fas is required for internalization of the 
pro-proliferative portion of capsase-8.
Although caspase-8 participation in 
cell activation is well documented, the 
precise molecular mechanisms that link 
its activation to TCR-induced proliferation 
are not yet defined.   Following TCR 
activation, caspase-8 is recruited to the 
CBM complex  (CARMA-1, BCL10 and 
MALT-1) (Schme 4, Introduction); in this 
molecular context, caspase-8 contributes 
to degradation of the NF- κB inhibitor 
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Figure 19.  Caspase-8 colocalizes with Fas in B6 T cells before and after restimulation
A.  Confocal analysis of Fas and caspase-8 cell localization before ConA restimulation.  Cells 
in the IL-2 expansion phase were collected on collagen-I-coated chamber slides, fixed and 
permabilized, blocked, and stained with primary antibodies.  After washing, cells were stai-
ned with secondary antibodies to detect Fas (green) and caspase-8 (red) and mounted with 
DAPI (blue)-containing mounting medium for confocal microscopy.  B. Cells after IL-2 expan-
sion were ConA restimulated for 1 h and treated as in (A) for confocal microscopy analysis.  
Representative results are shown (n = 2). 
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IκBα and subsequent translocation of 
NF-κB dimers to the nucleus (Su et al., 
2005; Bidere et al., 2006).  It was also 
established that in caspase-8-dependent 
NF-κB activation, caspase-8 does not 
require cleavage and dimerization to 
be active but its enzymatic activity is 
associated with full-length form (Lamkanfi 
et al., 2007; Bidere et al., 2006a).
As active unprocessed caspase-8 
controls T cell activation and proliferation 
after primary TCR stimulation, and 
its activity is important for NF-κB 
activation, we considered that it might 
also be involved in hyperproliferation 
of restimulated B6/lpr T cells.  To study 
the caspase-8 activation stage after 
secondary stimulation, we used biotin-
VAD-fmk, which binds selectively to 
enzymatically active site of the whole 
caspase molecule.  Caspase-8 was 
precipitated from T cells cultured with 
zVAD, which assures apoptosis-free 
conditions.  zVAD treatment (50 µM) had 
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Figure 20.  Active unprocessed caspase-8 controls the proliferative response of res-
timulated T cells independently of its pro-apoptotic function. A.  Active caspase-8 in its 
full-length form was isolated from B6 and B6/lpr T cells at indicated times after secondary sti-
mulation, using bVAD treatment and precipitation with streptavidin beads, followed by Wes-
tern blot for caspase-8 and coprecipitated molecules.  Endogenously biotinylated acetyl-CoA 
carboxylase served as a loading control.  ConA restimulation was performed in the presence 
of zVAD (50 µM).  Representative data are shown (n = 3).  B. zVAD treatment had no effect 
on the proliferation of restimulated B6 and B6/lpr T cells, as determined by CFSE dilution.  
C. Cell cycle analysis 24 h post-secondary stimulation of B6 and B6/lpr T cells used for bVAD 
precipitation of active caspase-8.  D. B6/lpr T cells showed higher caspase-8 enzymatic ac-
tivity 24 h after secondary stimulation, as determined in a colorimetric assay with IEHD-pNA 
substrate.  Release of the pNA group, which indicates relative caspase-8 activity, was mea-
sured by spectrophotometry.  Values show mean ± SD (n = 3).
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no effect on proliferation (Fig. 20B), but 
efficiently inhibited apoptosis in control 
T cells (Fig. 20C).  Western blot analysis 
showed that consistent with B6/lpr T cell 
hyperproliferation at 24 h post-secondary 
stimulation, we detected major caspase-8 
activation in these cells (Fig. 20A).  We 
also analyzed coimunoprecipitated 
proteins, including members of CBM 
complex and others that were previously 
showed to be associated with active 
caspase-8. The composition of the 
precipitated complex differed for both 
cell groups; the pro-proliferative protein 
Flip was associated with the B6/lpr T 
cell complex at 24 h, whereas it was 
only detected in control T cells at 48 h. 
This was also the case for IKK complex 
member IKKα and for the ubiquitin signal 
transducer TRAF6.  FADD, which is 
essential for proliferative signaling in T 
cells (Newton et al., 1998; Zhang et al., 
1998; Newton et al., 2001), was found 
exclusively in B6/lpr T cells.  CARMA1, 
the CBM complex member that plays a 
central role in NF-κB signaling (Blonska 
et al., 2009), was uniquely detected 
in Fas deficient T cells.  Another CBM 
complex protein, MALT1, was detected in 
both control and B6/lpr T cells, but by 48 
h post-stimulation, larger amounts were 
observed in the B6/lpr T cell precipitates. 
The results indicate major activation of 
full-length caspase-8 and CBM complex 
in B6/lpr T cells compared to controls 
after secondary stimulation. Moreover, 
the active caspase-8 complex tends to 
assemble lymphocyte proliferation-related 
signaling molecules more efficiently 
in B6/lpr T cells.  Our data suggest 
that active, unprocessed caspase-8 
controls CBM complex activation and 
proliferation of restimulated B6 and 
B6/lpr T cells independently of its pro-
apoptotic function.  This justifies NF-κB 
hyperactivation in Fas deficient T cells.
We further confirmed that caspase-8 
was enzymatically active and we as-
sessed this activity by applying a colori-
metric assay with IETD-pNA substrate, 
which has high affinity for caspase-8 (see 
Methods).  We indeed detected higher 
caspase-8 enzymatic activity 24 h af-
ter second stimulation in B6/lpr T cells 
than in controls (Fig. 20D).  This data is 
consistent with B6/lpr T cell hyperprolif-
eration.  As Fas expression is defective 
in these cells, it is evident that the cas-
pase-8 activity needed for T cell prolifera-
tion is independent of cell death signaling 
mediated through Fas.  
Inhibition of caspase-8 activity 
attenuates hyperproliferation in 
rechallenged B6/lpr T cells
Inhibition of caspase-8 activity in vivo 
and in vitro in human and murine CD4+ 
T cells leads to reduced proliferation 
and IL-2 production after primary TCR 
stimulation (Kennedy et al., 1999; Falk 
et al., 2004; Mistra et al., 2005), making 
caspase-8 indispensable for normal 
lymphocyte proliferation.  
In order to demonstrate the relevance 
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of enhanced caspase-8 activity in Fas de-
ficiency-mediated hyperproliferation of re-
stimulated T cells, we inhibited caspase-8 
activity using high zVAD concentrations. 
At 200 µM, zVAD blocked caspase-8 en-
zymatic activity in both B6/lpr and control 
T cells, as assessed by colorimetric as-
say (Fig. 21A).  Addition of the inhibitor to 
cell culture also decreased the amount of 
bVAD-precipitated caspase-8 in B6/lpr T 
cells (Fig. 21B).  We analyzed NF-κB ac-
tivation after B6/lpr T cell restimulation in 
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Figure 21.  Inhibition of caspase-8 activity attenuates hyperproliferation of rechallen-
ged B6/lpr T cells. A.  Caspase-8 enzymatic activity in B6 and B6/lpr T cells determined 24 
h after ConA rechallenge by measuring fluorescence release from the cleaved pNA group in 
the presence of DMSO or zVAD (200 µM).  Values show mean ± SD (n = 4).  B. bVAD preci-
pitation of active caspase-8 from B6/lpr T cells 24 h post-ConA restimulation in the presence 
of DMSO or zVAD (200 µM).  C. NF-κB activation in B6/lpr T cells is reduced by treatment 
with 200 µM zVAD, as assessed by EMSA.  Binding of an NF-Y probe was used as loading 
control.  D. Fluorescence intensity dilution of PI-negative CFSE-labeled ConA-rechallenged 
B6/lpr CD4+ T cells, alone or with zVAD (200 µM).  Representative data are shown (n = 3).   
E. Caspase-8 protein expression levels from B6/lpr T cells transfected with control or capase-
8-specific RNAi (left).  Reduced proliferation 24 and 48 h after secondary ConA stimulation of 
B6/lpr T cells transfected with control or caspase-8-specific RNAi, determined by [3H]thymidi-
ne incorporation (middle).  Decrease in the absolute number of B6/lpr T cells after transfec-
tion with caspase-8-specific RNAi (right).  Values show mean ± SD (n = 3).
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the presence of 200 µM zVAD, and found 
that this caspase-8 activity blockade nota-
bly reduced NF-κB activation (Fig. 21C). 
As predicted, B6/lpr T cell hyperprolifera-
tion was clearly reduced when zVAD was 
present, as determined in CFSE dilution 
experiments, which showed a reduced 
division rate in CFSE-labeled B6/lpr T 
cells (Fig. 21D), and in cell cycle analysis 
(Fig. 22B).
These findings confirm that caspase-8 
activity is necessary for hyperproliferation 
of restimulated B6/lpr T cells due to its 
role in NF-κB activation.  Our results 
indicate that in control T cells that survive 
apoptosis, Fas controls activation and 
proliferation by negative regulation of 
caspase-8-dependent NF-κB activation.
Since zVAD treatment can cause 
autophagy in some cell lines (Yu et al., 
2004), 200 µM zVAD might be thought to 
have adverse effects, including autophagy 
or toxicity.  Nonetheless, single-dose 
100 µM zVAD treatment (Alam et al., 
1999) and 80 µM zVAD daily for six 
days (Su et al., 2005) inhibit primary T 
cell proliferation with no toxic effects or 
autophagic death.   In our assays, we 
used a single zVAD dose (200 µM) during 
secondary stimulation of B6/lpr T cells; 
autophagic death was not induced, as 
double-membrane autophagic vacuoles, 
abundant in autophagic cells (Galluzzi 
et al., 2007), were not detected (not 
shown).  Additional experiments excluded 
zVAD toxicity, since both zVAD (200 µM) 
and DMSO treatment resulted in normal 
cell cycle profiles with low proportions of 
dead cells and no apoptosis induction 
(Fig. 22).
To further validate the observation 
that caspase-8 inhibition leads to reduced 
B6/lpr T cell hyperproliferation after 
rechallenge, we inactivated caspase-8 
in these cells by RNA interference 
(RNAi).  Cells were transfected with 
RNAi ribonucleotides on day 4 of the IL-2 
expansion phase, followed by two days 
in culture with fresh medium and IL-2. 
Caspase-8 protein levels were reduced 
in cells treated with caspase-8-specific 
RNAi, as determined by Western blot 
(Fig. 21E, left).  After secondary ConA 
stimulation of the cells, we observed that 
treatment with specific caspase-8 primers 
substantially reduced proliferation of 
rechallenged T cells compared to the 
effect of treatment with nonspecific 
primers (Fig. 21E, middle), as determined 
by [3H]thymidine incorporation.  The 
absolute number of live cells was also 
higher in control RNAi-treated cells than 
in those treated with caspase-8-specific 
RNAi, since reduction of caspase-8 
44% 21%7%  9%
70%49%
PI
DMSO 200 μM zVAD
2    stimulation (24h)nd 
Figure 22.  High zVAD concentration 
(200 µM) does not induce cell viability
Cell cycle analysis 24 h post-secondary 
stimulation of B6/lpr T cells treaded with 
DMSO or 200 µM zVAD.
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levels decreased T cell proliferation after 
restimulation (Fig. 21E, right).  Our data 
show that reduction of caspase-8 activity 
inhibits B6/lpr T cell hyperproliferation, 
and implicate caspase-8 in the reported 
here regulatory function of Fas in the 
proliferation of apoptosis-surviving T 
cells.  These experiments indicated that 
inhibition of B6/lpr T cell hyperproliferation 
by targeting downstream TCR signaling 
could be a useful approach for the 
study of molecular aspects of the 
hyperproliferative phenotype in B6/lpr 
mice.
Fas deficiency leads to increase in 
early NF-κB activation response
Our results demonstrated that hyper-
proliferating B6/lpr T cells at 24 h after 
the secondary stimulation show NF-κB 
hyperactivation.  We also tested activa-
tion of the NF-κB signaling pathway at 
early times points, since phosphorylation 
events that lead to the NF-κB response 
occur shortly after TCR stimulation.  We 
detected higher phosphorylation of IκBα 
inhibitor in B6/lpr T cells than in controls, 
accompanied by its rapid degradation 
(Fig. 23A, top).  In addition, we analyzed 
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Figure 23.  An early NF-κB activation response in B6/lpr T cells.  A.  Western blot shows 
expression patterns of proteins involved in cell signaling upstream of NF-κB activation after 
secondary stimulation. β-actin served as a loading control.  B. NF-κB activation levels in 
B6 and B6/lpr T cells, measured with an ELISA-based kit for NF-κB activation.  Detection is 
based on binding of activated NF-κB homo- and heterodimers from nuclear extracts obtained 
at indicated times after second (top) and first (bottom) stimulation to the immobilized NF-κB 
consensus binding site.  Jurkat cell nuclear extracts served as a positive controls; wild-type 
consensus oligonucleotide was used as a negative control.  Values show mean ± SD (n = 4).
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the expression pattern of the CBM com-
plex proteins; CARMA-1 was expressed 
earlier in B6/lpr T cells than in controls. 
The magnitude and duration of BCL-10 
and MALT-1 expression was also en-
hanced in B6/lpr T cells (Fig. 23A, bot-
tom).
The early NF-κB activation response 
after the first and the second stimulation 
was quantified using an ELISA-based kit 
to detect nuclear factor activation.  In this 
assay, activated NF-κB dimers in nuclear 
extracts bind the immobilized NF-κB 
consensus binding site; these complexes 
are then detected with anti-p65 primary 
antibody and horseradish peroxidase-
conjugated secondary antibody, allowing 
simple quantification by spectrometry 
colorimetric readout.  In accordance 
with higher IκBα phosphorylation levels 
in B6/lpr T cells compared to controls, 
we detected markedly elevated NF-κB 
activation in nuclear extracts from B6/
lpr T cells at 5, 10 and 15 min post-
restimulation (Fig. 23B, top).  The nuclear 
extract from Jurkat cells activated with 
TPA (12-O-tetrade- canoylphorbol-13-
acetate) and calcium ionophore was 
used as a positive control for NF-κB p65 
activation.  As a negative control, wild-
type consensus oligonucleotide was used 
as a competitor for NF-κB binding.  This 
competition assay confirmed that protein 
subunits that bind to the substrate are 
specific for the NF-κB consensus binding 
side.  Using the same technique, we also 
analyzed rapid NF-κB activation after 
first stimulation, but detected no clear 
differences (Fig. 23, bottom).
These results show that there is 
early NF-κB hyperactivation in B6/
lpr T cells after restimulation, and as 
these cells continue to hyperproliferate, 
this hyperactivation is maintained and 
ultimately support a regulatory role for 
Fas in the proliferation of apoptosis-
surviving T cells.
Fas deficiency affects TCR signaling 
pathways
 
The results thus far indicated that 
Fas deficiency leads to hyperproliferation 
of restimulated B6/lpr T cells.  This 
proliferative advantage was associated 
with NF-κB hyperactivation, elevated 
expression of the activation markers 
CD25 and CD69, and enhanced 
IL-2 production.  All of these cellular 
responses have a positive effect on cell 
activation and proliferation; we therefore 
tested whether ERK1/2 signaling, also 
known for transduction of proliferative 
and survival signals, is affected in the 
absence of Fas during secondary ConA 
stimulation.  Western blot analysis 
showed that phosphorylation of ERK-1 
and ERK-2 was indeed altered in B6/
lpr T cells following second stimulation 
(Fig. 24A).  These results thus imply 
that lack of Fas in restimulated T cells 
permits greater activation of the NF-κB 
and ERK1/2 signaling pathways, in turn 
enhancing the proliferative response of 
B6/lpr T cells.
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As elevated proliferation of B6/lpr 
T cells relies on signaling pathways 
downstream of the TCR, it is possible 
that the TCR triggering is necessary 
for hyperproliferation.  To address this 
question we subjected the cells to 
“spontaneous proliferation” assay in which 
cells were expanded in IL-2, washed, 
resuspended in fresh culture medium 
without addition of IL-2 or ConA, and their 
proliferation rate was tested by PI staining 
and cell cycle analysis.  Proliferation of 
B6/lpr T cells in these conditions was no 
longer higher than that of control T cells 
(Fig. 24B).  Proliferation of both B6/
lpr and B6 T cells decreased gradually 
and cell death increased, reaching an 
apoptotic peak at 12 h.  In an analysis of 
cell surface expression of CD25, CD69 
and FasL, we confirmed that this cell 
death was not AICD, but rather a cell 
response to nutrients and IL-2 withdrawal 
(not shown); we therefore concluded that 
B6/lpr T cell hyperproliferation requires 
a TCR-mediated activation.  Absence of 
Fas during restimulation thus appears 
to potentiate TCR signaling pathways 
necessary for T cell proliferation and 
IL-2 production, through its capacity to 
augment the NF-κB and ERK1/2 signaling 
pathways.
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Figure 24. TCR dependency of the B6/lpr hyperproliferative phenotype
A. Western blot shows ERK1/2 phosphorylation at different times after secondary stimulation 
in B6 and B6/lpr T cells.  B. Hyperproliferation of B6/lpr T cells after secondary stimulation 
is a TCR-mediated phenomenon. Cell cycle and apoptosis analysis of B6 and B6/lpr T cells, 
ConA restimulated, or washed and left untreated.  Representative histograms are shown 
(n = 6).
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Fas afects TCR proximal signaling 
events to control T cell proliferation
To gain more information about the 
nature of B6/lpr T cell hyperproliferation 
and its relationship to TCR-dependent 
signaling, we explored the emplacement 
of the Fas inhibitory action in T cell 
proliferation.  We used  PMA and 
ionomycin, stimuli that bypass TCR 
engagement but trigger normal T cell 
proliferative responses.  In this context, 
PMA acts in the same manner as 
diacyglycerol (DAG) in cell stimulation 
through the TCR and activate protein 
kinase C (PKC); ionomycin induces 
Ca2+/calmodulin-dependent signaling 
pathways and synergizes with PMA to 
enhance PKC activation (Chatila et al., 
1989).  This stimulation induces a high 
proliferative response, accompanied by 
IL-2R expression and IL-2 synthesis.
Cell cycle analysis showed that 
in contrast to TCR triggering-induced 
proliferation, the same Fas-deficient 
CD4+ T cells proliferated normally 
in response to stimulation with PMA 
+ ionomycin (0.5 µg/ml and 20 ng/
ml, respectively; Fig. 25A, top).  Their 
proliferation in response to stimulation 
with ConA + IL-2 (3 µg/ml and 20 ng/
ml, respectively) or with anti-CD3/CD28 
(0.5 µg/ml and 1 µg/ml, respectively) 
was clearly enhanced compared to 
controls (Fig. 25A, middle and bottom). 
These results indicate that Fas acts 
upstream or at the level of PKC and/or 
Ca2+ signaling in the TCR proliferative 
pathway.  Consistent with these data, 
ionomycin and PMA induced an increase 
in free intracellular Ca2+ concentration 
in B6/lpr T cells, which was nonetheless 
lower than that induced in control T cells 
(Fig. 25B, top).  TCR stimulation, which 
in this case was with anti-CD3/CD28, 
lead to an enhanced Ca2+ increase in 
the absence of Fas, indicating that Fas 
participates in TCR proximal signaling 
events (Fig. 25B, bottom).  It is of interest 
to note that T cells from SLE patients can 
regain normal levels of proliferation when 
stimulated with PMA (Sierakowski et al., 
1989), suggesting that signaling defects 
in these cells might also reside in the 
proximal signal transduction molecules 
upstream of PKC (Dayal et al., 1991).
To further characterize the activation 
defects of Fas-deficient T cells, we 
analyzed several TCR-induced signaling 
events.  After secondary stimulation, 
the magnitude and duration of TCR 
expression was consistently elevated 
in B6/lpr compared to control T cells. 
Enhanced phosphorylation of Src 
(sarcoma tyrosine kinase) on residue 
Tyr416, ZAP-70 (ζ chain-associated 
protein kinase 70 kDa), LAT (linker for 
activation of T cells) and PKCα (α protein 
kinase C) (Fig. 25C) was also evident 
in B6/lpr T cells, suggesting that Fas 
deficiency influences early signaling steps 
in the proliferative pathway. Interestingly, 
we detected increased phosphorylation 
of these proteins at time 0 in B6/lpr T 
cells, which suggests that these cells 
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were already in the pre-activation stage. 
This activation status has no functional 
significance, however, since we detected 
no NF-κB activation at time 0 (Fig. 
18A) and only TCR-restimulated T cells 
hyperproliferate (Fig. 24B).
We further characterized early sig-
naling events in the absence of Fas by 
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Figure 25. Fas interacts with TCR proximal signaling events to control T cell 
proliferation. A.  After primary stimulation and IL-2 expansion, control and B6/lpr T cells 
were restimulated with ionomycin (0.5 µg/ml) and PMA (20 ng/ml), with ConA (3 µg/ml) and 
Il-2 (20 ng/ml), or with anti-CD3 (0.5 µg/ml) and anti-CD28 (1 µg/ml), and PI-stained for cell 
cycle analysis.  Representative histograms are shown (n = 3).  B. Calcium flux was measu-
red by flow cytometry with Fluo-2-loaded B6 and B6/lpr T cells.  Basal fluorescence readings 
were taken for 100 s before restimulation with ionomycin (0.5 µg/ml) and PMA (20 ng/ml), or 
with anti CD3 (5 µg/ml) and -CD28 (1 µg/ml) followed by ionomycin/PMA (doses as above).  
Representative results are shown (n = 3).  C. Western blot showing the kinetics of TCRε 
expression and phosphorylation pattern of proteins involved in early T cell proliferative sig-
naling.  Cell lysates were obtained from ConA-restimulated B6 and B6/lpr T cells at indicated 
times. β-actin served as a loading control.  D. Immunoprecipitation of tyrosine-phosphoryla-
ted proteins after restimulation with ConA and IL-2 of B6 and B6/lpr T cells; immunoblotting 
with antibodies specific for indicated proteins indicates their tyrosine phosphorylation levels 
or their association with tyrosine-phosphorylated proteins at time 0 and 15 min post-restimu-
lation.
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immunoprecipitating phosphorylated ty-
rosines from B6/lpr and B6 T cells at time 
0 and 15 min post-restimulation.  Western 
blot with Lck-, ZAP70- and PKCθ-specific 
antibodies showed higher levels of these 
tyrosine-phosphorylated proteins in B6/
lpr T cells (Fig. 25D); again the difference 
was especially obvious at time 0.  
In summary, our findings implicate 
Fas as a regulator of proximal TCR 
signaling events.  These results further 
strengthen our view that in addition to 
inducing apoptosis Fas has another 
fundamental role in the maintenance of T 
cell homeostasis through negative control 
of early events that lead to activation of 
proliferative pathways such as NF-κB 
and ERK1/2.
Fas deficiency affects TCR 
downregulation after second 
stimulation
B6/lpr T cells hyperproliferate fol-
lowing restimulation, and this process 
depends on signaling pathways down-
stream of TCR (NF-κB, ERK1/2).  We 
thus considered that analysis of TCR ex-
pressed on these cells at different stages 
of the AICD protocol could help to clarify 
the mechanism underlying hyperprolif-
eration, and possibly the pathogenesis 
of autoimmune disease in B6/lpr mice. 
We stained cells with anti-TCR antibody, 
followed by flow cytometry analysis, and 
observed a slight decrease in B6/lpr TCR 
expression following the first stimulation; 
TCR expression equalized between the 
two cell groups during the IL-2 expan-
sion phase.  After the second stimulation, 
cell surface TCR expression in B6/lpr T 
cells was not downregulated as it was in 
B6 T cells (Fig. 26A, top).  The dynamics 
of surface TCR expression in both T cell 
groups is better expressed in Fig. 26A 
(bottom), showing that after rechallenge, 
surface TCR expression was downregu-
lated in control T cells and was lower 
than during the IL-2 expansion phase. 
This downregulation could allow control 
T cells to terminate signaling and thus to 
shut down the proliferative response.  In-
deed, TCR/CD3 downmodulation is sug-
gested to be one of the mechanisms that 
contribute to the signaling arrest initiated 
by antigen binding (Valitutti et al., 1996; 
Valitutti et al., 1997; Cai et al., 1997; Liu 
et al., 2000; Davanture et al., 2003).  Per-
sistent TCR expression on B6/lpr T cells 
could otherwise account for enhanced, 
prolonged signaling, whose lack of termi-
nation could lead to the hyperproliferative 
phenotype observed in these cells.
To confirm that this TCR downmodu-
lation defect in B6/lpr T cells was due to 
the Fas deficiency and due to the lack of 
interaction with FasL, we analyzed sur-
face TCR expression in B6/gld T cells in 
which Fas-FasL signaling was restored 
by addition of rFasL (150 ng/ml).  Treat-
ment of B6/gld T cells with FasL in the 
presence of zVAD (50 µM, to avoid FasL-
induced apoptosis) lowered surface TCR 
expression as soon as 1 h after second 
stimulation (Fig. 26B).
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Our data thus indicate that after 
secondary stimulation in the absence of 
Fas, cells show a greater proliferative 
capacity that is associated with enhanced 
cell signaling downstream of the TCR, 
resulting from a Fas deficiency effect on 
TCR expression.  The absence of Fas 
thus impairs TCR downmodulation, which 
can result in prolonged signaling that 
can in turn provoke a hyperproliferative 
phenotype in B6/lpr T cells.
TCR internalization is impaired 
in B6/lpr T cells after secondary 
stimulation
 
We found that B6/lpr T cells do 
not downregulate their TCR by 24 h 
post-restimulation, which prompted 
us to speculate that prolonged signal 
transduction from the T cell surface could 
be the cause of elevated proliferation 
of these cells.  To better understand 
the nature of this TCR downmodulation 
defect in B6/lpr T cells, we stimulated 
B6 and B6/lpr T cells with ConA + IL-2 
in the presence of zVAD (50 µM) and 
analyzed surface TCR expression by flow 
cytometry.  Shortly after restimulation (3 
h), the cell surface TCR level was sharply 
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Figure 26.  Fas deficiency affects TCR downregulation after secondary stimulation
A. Cells at indicated stages in the AICD protocol were stained with anti-TCRβ antibody, and 
surface TCR expression was compared between B6 and B6/lpr T cells (top) and between 
different protocol stages for each genotype (bottom).  Representative data are shown (n = 3 
mice/genoptype).  B. FasL treatment (150 mM) of B6/gld T cells at the time of ConA restimu-
lation reduced surface TCRβ expression after 1 h.  Representative data are shown (n = 4).
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downregulated in B6 T cells, which was 
not the case for B6/lpr T cells (Fig. 27A). 
The apoptosis blockade with zVAD ruled 
out the possibility that the decrease in 
TCR expression in control T cells was 
due to cell death.  This suggests that TCR 
downregulation in normal T cells might 
be a physiological process that leads to 
negative regulation of T cell activation.
To determine the kinetics of TCR 
expression in B6/lpr and B6 T cells, we 
stimulated these cells for the indicated 
times and analyzed TCR expression by 
Western blot.  TCR expression in B6/lpr T 
cells was constant and did not follow the 
kinetics of control TCR, which showed 
initial upregulation and subsequent 
downregulation at 1 h post-stimulation 
(Fig. 27B), in accordance with the 
downmodulation defect detected by flow 
cytometry.
We next studied the reason for 
impaired TCR downregulation in B6/lpr 
T cells.  Various cell processes, such as 
receptor internalization, degradation of an 
internalized  receptor fraction, recycling 
and  production of new receptors, 
contribute to the final pool of surface 
receptors.  To determine whether Fas 
deficiency affected TCR internalization, 
we used a cell surface fluorescence 
quenching technique in which cells at 
distinct stages of the AICD protocol 
were stained with Alexa488-conjugated 
anti-TCRβ (45 min, on ice).  We used 
the anti-TCRβ H57 clone, which is the 
only suitable antibody for this approach, 
as it stably binds the TCR and does 
not dissociate during internalization 
(Davanture et al., 2005).  After washing 
off unbound antibody, we pulsed cells 
at 37°C to trigger internalization, which 
was terminated by placing cells on ice at 
various times.  Cells from each sample 
were divided into two groups, one fixed 
directly with formaldehyde and the other 
treated with anti-Alexa488 quenching 
antibody (25 µg/ml) prior to fixing and flow 
cytometry analysis.  We quantified mean 
fluorescent intensity of all samples and 
calculated internalized fluorescence as 
described (Austin et al., 2004).  To avoid 
pH changes, which mediate internalized 
receptor sorting to distinct endosomal 
compartments, all internalization assays 
were performed in CO2-independent 
culture medium.  The caspase inhibitor 
zVAD was used in all experiments to 
equalize death conditions.  In accordance 
with the defective TCR downregulation 
described above, we detected impaired 
TCR internalization in B6/lpr T cells in 
response to secondary stimulation (Fig. 
27C).  In control T cells, rapid receptor 
internalization began at 10 min, and 
more than 70% of the TCR had been 
internalized by 1.5 h.  In contrast, B6/lpr T 
cells maintained their initial internalization 
level (~20%) throughout the assay, 
with only 30% TCR internalization at 
1.5 h.  These results indicate impaired 
TCR internalization in B6/lpr T cells; 
consequently, Fas is necessary for TCR-
triggered early signaling events.
We   also tested whether Fas affects 
TCR internalization after primary stimu-
lation.  In experiments similar to those 
described above, we found the same de-
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Figure 27. Defective TCR internalization after secondary stimulation in B6/lpr T cells
A. The TCR in B6/lpr T cells is not downregulated after restimulation, as determined by flow 
cytometry analysis for surface TCRβ expression.  Representative results are shown (n = 5). 
B. Western blot showing kinetics of TCRγ expression in B6 and B6/lpr T cells after ConA 
restimulation for indicated times. β-actin served as a loading control.  C. TCR internalization 
ratio in B6 and B6/lpr T cells as determined by cell surface fluorescence quenching.  Cells 
at the end of the IL-2 expansion phase were ConA restimulated for 1 h prior to surface 
staining with Alexa488-anti-TCR antibody, then pulsed at 37°C for indicated times to inter-
nalize receptor, washed, and divided into two groups.  One group was directly fixed and the 
other incubated with quenching antibody prior to fixing and FACS analysis.  Representative 
data are shown (n = 4).  D. Freshly isolated B6 and B6/lpr T cells were stimulated for 1 h 
with ConA and IL-2 (1st stimulation) and TCR internalization was analyzed as in (C).  Repre-
sentative results are shown (n = 3).  E. Surface fluorescence quenching (as in C) was used 
to assess the TCR internalization ratio of B6 and B6/lpr T cells during the IL-2 expansion 
phase.  Representative data are shown (n = 2).  F. Confocal analysis of TCR redistribution 
before and 1 h after ConA restimulation.  Cells during IL-2 expansion were collected on 
collagen-I-coated chamber slides and left untreated (0 h, left) or ConA restimulated (1 h, 
right).  Cells were placed on ice to terminate stimulation-induced internalization, fixed and 
permabilized, blocked, and stained with primary antibody.  After washing, cells were stai-
ned with secondary antibody to detect TCR (red) and mounted with DAPI (blue)-containing 
mounting medium for confocal microscopy.  Representative results are shown (n = 2).
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gree of TCR internalization in B6/lpr and 
B6 T cells at 1 h after the first stimulation 
(Fig. 27D).  Likewise, we detected no dif-
ference in TCR internalization between 
these two cell groups during the IL-2 ex-
pansion phase (Fig. 27E).  Fas thus af-
fects TCR internalization only after the 
second stimulation.
We next used confocal microscopy to 
explore TCR localization in these cells be-
fore and after second stimulation.  In both 
cell groups, TCR staining was distributed 
across the plasma membrane at time 0 
(Fig. 27F, left).  At 1 h after restimula-
tion, control T cells showed TCR staining 
throughout the entire cell, whereas the 
TCR in B6/lpr T cells continued mainly at 
the plasma membrane (Fig. 27F, right). 
This result further supports the finding of 
defective surface TCR downregulation in 
B6/lpr T cells.
TCR internalization is an example of 
clathrin-mediated endocytosis (Krangel 
1987; Minami et al., 1987; Crotzer et al., 
2004).  Transferrin is a major blood glyco-
protein that transports iron to all tissues 
from the liver and the intestine.  All grow-
ing cells bear surface transferrin recep-
tors that bind ferrotransferrin (a transfer-
rin form with two bound Fe3+ ions).  The 
transferrin receptor mediates transferrin 
endocytosis through a clathrin-dependent 
internalization mechanism (Iacopetta et 
al., 1988; Damke at al., 1994).  To test 
whether defective TCR internalization in 
B6/lpr T cells is specific to this receptor or 
whether the entire clathrin-mediated en-
docytosis process is affected by Fas defi-
ciency, we compared the rate and extent 
of transferrin internalization in B6 and B6/
lpr T cells after secondary stimulation.  In 
B6 T cells, ~60% of the cell surface trans-
ferrin receptor underwent endocytosis by 
90 min post-pulse.  This value was es-
sentially identical to that for B6/lpr T cells 
(Fig. 28A), indicating that impaired TCR 
internalization in Fas-deficient T cells is 
specific to the TCR receptor and not to 
the general endocytosis pathway.  We 
also performed a transferrin internaliza-
tion assay at 24 h post-restimulation, and 
detected no difference in internalization 
rates between B6 and B6/lpr T cells (Fig. 
28B).  To follow up TCR internalization, 
we repeated the surface fluorescence 
quenching assay at 24 h after secondary 
stimulation, and continued to observe a 
difference in the TCR internalization rate 
between the two cell groups (Fig. 28C).
As TCR downmodulation also involves 
receptor recycling, we further analyzed 
the nature of the TCR downmodulation 
defect in B6/lpr T cells, by examining 
the TCR recycling process using the 
fluorescence quenching technique. 
In these experiments, cel ls were 
preincubated with Alexa488-anti-TCRβ 
(2 µg/ml, 15 min 37°C), then rapidly 
chilled on ice, washed and surface-
quenched (15 min, on ice) with anti-
Alexa488 quenching antibody (25 µg/
ml).  Cells were pulsed at 37°C in the 
continuous presence of the quenching 
agent, then rapidly chilled at different 
time intervals, fixed, and analyzed by 
flow cytometry.  The percentage of 
internalized and recycled fluorescence 
was calculated as the difference between 
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pulsed/unquenched fluorescence (time 
0) and pulsed/quenched fluorescence 
at each chase time, and normalized to 
time 0.  We detected no difference in the 
TCR recycling ratio between B6 and B6/
lpr T cells (Fig. 28D), which suggests 
that defective internalization rather than 
recycling accounts for the lack of TCR 
downmodulation in B6/lpr T cells.
In summary, the data demonstrate 
that Fas deficiency leads to inhibition 
of TCR internalization after the second 
stimulation.  Defective TCR internalization 
in B6/lpr T cells might result in prolonged 
triggering of the signal transduction 
pathways, leading to enhanced NF-κB 
and ERK1/2 activation, and finally to T cell 
hyperactivation and hyperproliferation.
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Figure 28.  Impaired internalization in Fas-deficient T cells is specific to TCR
A.  B6 and B6/lpr T cells at the end of the IL-2 expansion phase were ConA restimulated for 
1 h to trigger internalization, and cells were incubated at 37°C with Alexa488-transferrin for 
indicated times.  Cells were washed and divided into two groups; one was directly fixed and 
the other, incubated with quenching antibody prior to fixuing and FACS analysis.  Represen-
tative data are shown (n = 3).  B. Transferrin internalization experiment as in (A), in B6 and 
B6/lpr T cells restimulated for 24 h. Representative results are shown (n = 2).  C. TCR inter-
nalization assay (as in Fig. 13C) performed with B6 and B6/lpr T cells restimulated for 24 h.  
Representative data are shown (n = 2).  D. TCR recycling was measured in B6 and B6/lpr T 
cells restimulated with ConA for 24 h.  Cells were stained with Alexa488-anti-TCR at 37°C to 
internalize labeled receptor, then incubated on ice with quenching anti-Alexa488 antibody, 
and warmed to 37°C in the continuous presence of the quenching agent for indicated times.  
Recycling of Alexa488-labeled TCR induced quenching of surface fluorescence.  Represen-
tative results are shown (n = 3).
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Fas direct interaction with the TCR 
complex
Our findings indicated that Fas is 
needed for correct TCR downregulation 
following secondary stimulation, and 
that lack of Fas leads to impaired 
internalization of the TCR.  This prompted 
us to test whether Fas interacts directly 
with the TCR during a second stimulation, 
for which we used confocal microscopy 
localization analysis.  Cells were 
prepared (see Methods) and analyzed 
for Fas and TCR localization at time 0 
and 1 h after secondary stimulation.  In 
control T cells, Fas was distributed over 
the entire plasma membrane, coinciding 
with fluorescence staining for the TCR 
(Fig. 29, top).  In B6/lpr T cells, TCR was 
also located at the plasma membrane at 
time 0; we detected slight Fas staining, 
as although this protein is defective, it 
is expressed in trace amounts in these 
mice (Fig. 29, top).  Sequential analysis 
of Fas and TCR distribution showed that 
these proteins co-localized in control T 
cells at 1 h post-restimulation (Fig. 29, 
B6
B6/lpr
B6
B6/lpr
0h
1h
DAPI Fas TCR merge bright field
Figure 29. Fas colocalizes with TCR before and after secondary stimulation in control 
T cells. Confocal analysis of Fas and TCR redistribution before and 1 h after ConA restimu-
lation.  Cells in the IL-2 expansion phase were collected on collagen-I-coated chamber slides 
and left untreated (time 0, top) or ConA restimulated (1 h, bottom).  Cells were placed on ice 
to terminate stimulation-induced internalization, fixed and permabilized, blocked, and stained 
with primary antibodies.  After washing, cells were stained with secondary antibodies to de-
tect Fas (green) and TCR (red) and mounted with DAPI (blue)-containing mounting medium 
for confocal microscopy.  Representative results are shown (n = 3). 
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bottom).  Both proteins translocated 
from the plasma membrane to the cell 
interior, which might reflect internalization 
triggered by antigen binding.  In B6/lpr T 
cells at 1 h after secondary stimulation, 
the TCR remained mostly membrane-
associated, in accordance with our 
previous results (Fig. 27F, right).  In 
conclusion our findings show that Fas 
co-localizes with the TCR before and 
after secondary stimulation, which 
could allow direct Fas influence on TCR 
internalization and other TCR-dependent 
signaling events.
The confocal data demonstrated only 
that Fas and TCR co-localized in control 
T cells.  To assess a possible physical 
interaction between these two proteins, 
we performed a TCR immunoprecipitation 
assay at various times after restimulation 
in the presence of zVAD.  Fas indeed 
associated with TCR after secondary 
stimulation in B6 T cells (Fig. 30); this 
association was transient and peaked at 
10-15 min following ConA restimulation, 
indicating that the two proteins interact 
directly in the context of repeated 
stimulation.  There were also notable 
differences in the composition of the 
immunoprecipitated complex from the 
two cell types.  At difference from control 
T cells, Lck recruitment was very efficient 
in B6/lpr T cells, and was detected even 
at time 0.  This was also the case for 
ZAP70, whose association with TCR in 
B6/lpr T cells was constant over the 1 h 
course of the stimulation.  In contrast, 
ZAP70 recruitment to TCR in control T 
cells began at 5 min, peaked at 10 min, 
and decreased by 1 h post-restimulation. 
PKCθ association with TCR in Fas-
deficient T cells resembled that of Lck, 
with recruitment at time 0 that remained 
essentially constant throughout the 1 h 
period after the second stimulation.  In 
control T cells, PKCθ binding to TCR 
could barely be detected, and only at later 
time points (30 and 60 min) (Fig. 30).
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Lck
0    5   10 15  30  60  0   5   10 15  30  60 (min)
B6 B6/lpr
Fas
Figure 30. Direct interaction of Fas with 
TCR signaling complex in control T cells
Fas coimmunoprecipitates with TCR in B6 
T cells.  B6 and B6/lpr T cells were ConA 
restimulated for the indicated times and 
immunoprecipitated with anti-TCRγ antibody. 
Western blot with primary and secondary an-
tibodies showed association of the indicated 
proteins with the TCR in B6 and B6/lpr. 
These results indicate that in control T 
cells Fas is recruited to the TCR complex 
after restimulation, which might impede 
aggregation of proteins important in 
TCR-triggered signaling pathways; lack 
of this obstruct could otherwise result in 
hyperactivated proliferative signaling, as 
is the case in Fas-deficient B6/lpr T cells. 
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DISCUSSION
Severe deregulation of immune 
homeostasis in B6/lpr mice
Homeostasis  regulates   total     lym-
phocyte number by balancing cell growth 
and death.  Programmed cell death, re-
ferred to as apoptosis, eliminates activat-
ed or autoreactive lymphocytes, and is 
thus important in immune system homeo-
stasis.  Interaction of Fas with its ligand 
(FasL) after secondary TCR triggering in 
vitro induces apoptosis via activation-in-
duced cell death (AICD).  Fas/FasL inter-
action recruits the adaptor protein FADD, 
which activates caspase-8 and initiates 
the apoptotic cascade.  T cell apoptosis 
is considered central to lymphocyte ho-
meostasis and tolerance induction (Walk-
er and Abbas, 2002); this concept was 
recently confirmed by the observation 
of increased lymphadenopathy in Fas/
Bim double-deficient mice (Green, 2008).
Fas deficiency has a considerable im-
pact on immune system homeostasis in 
B6/lpr mice.  These animals develop an 
autoimmune disease characterized by 
lymphadenopathy and splenomegaly, 
hyperproliferation (Fig. 1D) and accumu-
lation of double negative (DN) T cells, 
accumulation of CD4+ memory T cells 
(Fig. 12A), elevated serum levels of anti-
DNA antibodies (Fig. 12B), immune com-
plex formation, and glomerulonephritis.
Lack of Fas-triggered apoptosis 
in activated T cells of B6/lpr mice 
was suggested to be a direct cause 
of lymphadenopathy development 
and lupus-like disease manifestations 
(Watanabe-Fukunaga et al., 1992).  The 
basis of autoimmune disease in these 
mice nevertheless remains elusive, since 
the in vitro B6/lpr T cell apoptotic defect 
is not always associated with reduced 
apoptosis in vivo (Walker and Abbas, 
2002).  In addition, T cell death defects 
do not completely explain the B6/lpr 
phenotype, since in the absence of other 
components of the apoptotic pathway; 
lack of apoptosis is not accompanied 
by lymphadenopathy development. 
This is the case of transgenic mice that 
overexpress the caspase-8 inhibitor CrmA 
in T cells (Smith et al., 1996); although 
AICD of these T cells was inhibited 
efficiently in vitro, the mice showed no DN 
T cell accumulation or lymphadenopathy. 
This observation suggests that in addition 
to its role in apoptosis, Fas might have 
another function in homeostasis control. 
Similarly, mice with caspase-8 deficiency 
in T cells (Chun et al., 2002; Salmena 
et al., 2003) and transgenic mice that 
overexpress a dominant negative form 
of FADD (Newton et al., 1998; Zhang 
et al., 1998; Newton et al., 2001) show 
defective apoptosis, accompanied not by 
lymphadenopathy development but rather 
by immunodeficiency.  These reports, as 
well as data from our laboratory, indicate 
that in addition to its pro-apoptotic role, 
Fas/FasL signaling has other important 
cell regulatory functions.  Here we 
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examined whether an apoptosis-
independent function of Fas contributes 
to the homeostasis of activated T cells.
Fas negatively controls proliferation 
of repeatedly activated T cells
In this study, we established that 
Fas negatively controls the proliferation 
of restimulated T cells.  Following 
secondary antigen stimulation, B6/lpr T 
cells hyperproliferated in comparison to 
controls (Fig. 3A, top).  Given the role of 
Fas as an apoptosis inducer, we focused 
our efforts on evaluating whether the B6/
lpr T cell proliferative advantage reflects 
greater accumulation of apoptosis-
resistant T cells or an increase in the 
proliferative capability.  We used the 
inhibitor zVAD (50 µM) to equalize cell 
death conditions between Fas-deficient 
and control T cells, and observed that 
B6/lpr T cells still manifested a higher 
proliferation ratio than controls (Fig. 3A, 
bottom).  This increased division rate was 
confirmed by analyzing expression of the 
proliferation marker Ki-67 (Fig. 3E) and 
in CFSE dilution experiments (Fig. 3D). 
These data indicated that enhanced B6/lpr 
T cell proliferation is not a direct result of 
the apoptosis defect, but a consequence 
of a greater proliferative capacity, which 
suggests that Fas negatively controls the 
expansion of apoptosis-surviving T cells.
Further confirmation that the prolifera-
tive differences between control and Fas-
deficient T cells are not associated with 
the cell death defects in B6/lpr T cells 
came from experiments carried out in 
apoptosis-free conditions (Fig. 4, 5).  In 
these circumstances, control T cells did 
not undergo cell death; the proliferative 
advantage of Fas-deficient T cells could 
therefore not be attributed to an increase 
in cell survival.  Moreover, these results 
indicated that lack of Fas permits B6/lpr 
T cells to extend their proliferative re-
sponse beyond the immediate reaction to 
TCR stimulation.
In another approach, we demon-
strated that Fas/FasL interaction directly 
reduced proliferation of Fas-expressing, 
restimulated B6/gld T cells, independent-
ly of the Fas/FasL apoptosis-inducing ef-
fect (Fig. 6).  The data showed that Fas/
FasL interaction is directly responsible for 
reducing T cell proliferation, since FasL-
deficient, Fas-expressing B6/gld T cells 
hyperproliferated after secondary chal-
lenge.  These findings also suggest that 
the Fas pro-apoptotic and anti-prolifera-
tive functions are independent, and ulti-
mately rely on Fas/FasL interaction and 
not the presence of Fas alone.
We ruled out the possibility that B6/lpr 
T cell hyperproliferation is due to differ-
ences in activation/memory status before 
second stimulation, or that culture condi-
tions favor selection of Fas-deficient cell 
clones with initial high proliferative ca-
pacity (Fig. 7, 8).  For that purpose, na-
ïve (CD44low/CD62Lhigh) and memory 
(CD44high/CD62Llow) T cells were sort-
ed and their proliferation and activation 
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was tested.  Fas suppressed proliferation 
of apoptosis-resistant T cells after second-
ary stimulation, but did not affect primary T 
cell responses; in fact, it slightly enhanced 
stimulation of naïve T cells.  The difference 
in the Fas effect on primary and second-
ary stimulation might be due to dissimilari-
ties in the T cell response to activation in 
these two contexts.  The Fas/FasL interac-
tion after primary stimulation contributes to 
the proliferative response, offering neces-
sary costimulation for naïve T cells (Alder-
son et al., 1993; Maksimow et al., 2006; 
Rethi et al., 2008).  Our work shows that 
following secondary stimulation, Fas/FasL 
interaction provides negative regulation of 
the proliferative response.
We also observed that in both B6/
lpr and B6 mice, CD44high/CD62Llow T 
cell proliferation was lower than that of 
CD44low/CD62Lhigh T cells.  Other studies 
also reported that in vivo-generated memory 
T cells show characteristics of senescence, 
with diminished proliferative potential in 
vitro (Shimatani et al., 2009; Effros 2003; 
Di Mitri et al., 2011).  Similarly, T cells 
from patients with chronic inflammation or 
long-standing infections respond poorly 
when stimulated in vitro with antigens 
or mitogens, although the mechanism 
underlying this hyporesponsivness is not 
known (Kiessling et al., 1996).
Overall, these data indicate that, in the 
absence of Fas, T cells show a hyperprolif-
eration profile, and the proliferative advan-
tage is not associated with cell death de-
fects.  In addition to its proapoptotic func-
tion, Fas therefore has another role in T cell 
homeostasis.
Fas regulation of proliferation is 
biologically significant
We generated B6/ lpr-p21tg mice 
that overexpress p21 to test whether 
T cell hyperproliferation is responsible 
for lymphadenopathy development and 
lupus-like disease.  p21 overexpression 
inhibited B6/lpr T cell hyperproliferation 
after secondary stimulation (Fig. 16), but 
had no effect on primary stimulation or on 
the B6/lpr apoptotic defect (Fig. 15).  We 
therefore considered that B6/lpr-p21tg 
mice were an appropriate model to study 
the biological significance of Fas as a 
regulator of T cell proliferation. We found 
that p21 overexpression greatly reduced 
B6/lpr T cell hyperproliferation in vivo (Fig. 
9) as well as lymphadenopathy (Fig. 11C), 
suggesting the biological relevance of the 
hyperproliferative effect of reactivated B6/
lpr T cells.  Our results also showed that 
p21 is a potent autoimmunity suppressor, 
as it can restrain autoimmunity and 
death in MRL/lpr mice, which develop 
an accelerated, severe form of lupus-like 
disease (Fig. 13, 14).
Overall our data indicate that the 
Fas proliferation-regulating effect has 
physiological importance, since p21 
overexpression does not affect the 
B6/lpr apoptotic defect, but reduces 
lymphadenopathy by decreasing B6/
lpr T cell hyperproliferation.  This in vivo 
hyperproliferation suppression function 
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of Fas, together with its proapoptotic 
effect, is necessary for activated T cell 
homeostasis.  Our findings suggest an 
alternative mechanism through which Fas 
deficiency leads to lymphadenopathy, and 
should be considered for understanding T 
cell expansion syndromes and diseases 
associated with Fas expression.
The role of Fas in the control of NF-κB 
and ERK1/2 activation
Fas deficiency leads to hyperprolifera-
tion of T cells after a second stimulation; 
in addition, lack of Fas results in hyper-
activation of restimulated T cells, as de-
termined by analysis of activation mark-
ers CD25 and CD69.  To understand the 
molecular basis that underlies these in-
trinsically connected events, we analyzed 
two major signaling pathways involved in 
T cell proliferation after TCR-dependent 
activation, NF-κB and ERK1/2.
NF-κB has a fundamental role in 
regulating the immune response, as a 
key factor in transcription of the genes 
essential for cell proliferation and 
survival.  We found that hyperproliferation 
of B6/lpr T cells 24 h after restimulation 
is associated with NF-κB hyperactivation 
(Fig. 18).  The signaling pathway leading 
from TCR stimulation to NF-κB activation 
is not well defined, although the CBM 
complex, formed by CARMA-1, BCL-
10 and MALT-1, is essential for NF κB 
nuclear translocation (Frischbutter et al., 
2011; Egawa et al., 2003; Thome et al., 
2003; Rueda et al., 2005; Sommer et al., 
2005; Matsumoto et al., 2005).  Following 
secondary stimulation of T cells, we 
detected enhanced expression of these 
proteins in B6/lpr T cells compared to 
controls (Fig. 23A, bottom).  Caspase-8 
is recruited to the CBM complex after 
TCR activation; in this molecular context, 
caspase-8 contributes to degradation of 
the NF-κB inhibitor IκBα and subsequent 
translocation of NF-κB dimers to the 
nucleus (Su et al., 2005; Bidere et al., 
2006).  NF-κB hyperactivation in B6/lpr 
T cells is caspase-8-dependent, since 
blockade of caspase-8 activity led to 
decreased activation of this transcription 
factor (Fig. 21C).  Inhibition of NF-κB 
activation led to a reduction in the B6/lpr 
T cell proliferation, which confirms that 
hyperproliferation of these cells is, to a 
great extent, NF-κB activation-dependent. 
This was confirmed in the B6/gld model, 
in which inhibition of NF-κB activation by 
FasL treatment resulted in reduced B6/
gld T cell proliferation after restimulation 
(Fig. 18C).
In addition to showing NF-κB hyper-
activation in B6/lpr T cells, we demon-
strated that Fas deficiency enhanced the 
ERK1/2 signaling pathway.  Phospsho-
rylation of ERK1/2 following secondary 
stimulation was earlier and stronger in 
B6/lpr T cells compared to controls, sug-
gesting that ERK1/2 activation promotes 
proliferation after TCR restimulation (Fig. 
24A).  Our findings indicate that, after the 
second stimulation, Fas controls the T 
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cell proliferative response through nega-
tive regulation of the NF-κB and ERK1/2 
signaling pathways.
Involvement of whole form caspase-8 
in the B6/lpr T cell hyperproliferation
Caspase-8 is necessary not only for 
death receptor-mediated apoptosis, but is 
also essential for T cell activation (Chun 
et al., 2002; Salmena et al., 2003; Siegel 
2006; Lamkanfi et al., 2007).  Reports 
indicate the fundamental role of capase-8 
in TCR-mediated NF-κB activation 
(Su et al., 2005; Dohrman et al., 2005; 
Biedre et al., 2006; Misra et al., 2007); 
in accordance with these observations, 
caspase-8 inhibition is associated with 
T cell proliferation defects and immune 
deficiency in humans and mice (Kennedy 
et al., 1999; Falk et al., 2004; Mistra et 
al., 2005).  Both caspase-8-mediated 
NF-κB activation and apoptosis require 
enzymatic activity of caspase-8, although 
the molecular form of the protease that 
shows this activity is distinct for each 
of these processes.  For the apoptotic 
cascade, caspase-8 autoprocessing is 
necessary, whereas the full form of active 
caspase mediates the NF-κB signaling 
pathway (Lamkanfi et al., 2007; Bidere 
et al., 2006).  Some studies also indicate 
that the transition from the inactive to 
the active caspase-8 form does not 
involve Fas signaling (Misra et al., 2007; 
Dohrman et al., 2005a; Dohrman et al., 
2005b).
Following primary TCR triggering, the 
entire caspase-8 molecule is essential 
for proliferative signaling, as this form 
promotes NF-κB activation (Scheme 4, 
Introduction; Bidere et al., 2006).  Here 
we showed that active caspase-8 also 
has an important role in enhancing pro-
proliferative signals after secondary 
stimulation.  Using a biotin-VAD-fmk/
streptavidin precipitation system, we 
detected active, unprocessed caspase-8 
after secondary stimulation in both 
control and Fas-deficient T cells, although 
caspase-8 activation was much higher 
in B6/lpr T cells (Fig. 20A).  Moreover, 
caspase-8 association with the CBM 
complex members was more efficient in 
Fas deficient T cells.  Our experiments 
established that, after the second 
stimulation, full-length caspase-8 is more 
active in B6/lpr T cells than in controls, 
and that caspase-8 forms a part of a 
protein complex that tends to assemble 
lymphocyte proliferation-related signaling 
molecules more efficiently in B6/lpr than 
in B6 T cells.  This complex is composed 
of the proteins known to participate in 
the signal transduction that leads to NF-
κB activation, and includes CARMA1, 
BCL10, MALT1, FADD, Flip, and IKKα 
(Fig. 20A).
We confirmed that caspase-8 was in-
deed enzymatically active; a colorimetric 
assay showed an increase in caspase-8 
enzymatic activity that coincided with 
hyperproliferation following the second 
stimulation in B6/lpr T cells (Fig. 20D). 
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Our results demonstrate that the cas-
pase-8 activity needed for T cell prolifera-
tion is independent of Fas-mediated cell 
death signaling, since Fas expression is 
defective in B6/lpr T cells.
In accordance with these observations, 
we found that capase-8 activity is in fact 
involved in the B6/lpr T cell hyperprolifera-
tive phenotype, as inhibition of its enzy-
matic activity led to reduced NF-κB activa-
tion and decreased cell proliferation (Fig. 
21).  These findings implicate caspase-8 
in Fas regulatory function of apoptosis-
surviving T cell proliferation, due to its role 
in NF-κB activation.
Using confocal microscopy, we local-
ized caspase-8 in B6/lpr T cells at the plas-
ma membrane before and after secondary 
stimulation. In contrast, in B6 T cells cas-
pase-8 staining was almost entirely cyto-
plasmic following restimulation (Fig. 19). 
This cytoplasmic fraction of caspase-8 is 
however not pro-apoptotic, since Lee et al. 
showed that zVAD blocs caspase-8 inter-
nalization and consistently inhibits apopto-
sis (Lee et al., 2006).  This suggests that 
Fas/FasL interaction is required for inter-
nalization of the pro-proliferative portion 
of capsase-8. It is also tempting to specu-
late that Fas collaborates with caspase-8 
in the control of T cell proliferation, pos-
sibly by mediating its translocation from 
the plasma membrane, where the protein 
complex required for TCR-mediated NF-
κB activation, which includes CARMA-1, 
BCL10 and MALT-1, is located (Gaide et 
al., 2002; Dykstra et al., 2003).
TCR dependency of the B6/lpr 
hyperproliferative phenotype
We established that, after secondary 
stimulation, B6/lpr T cells are hyperacti-
vated compared to controls.  This phe-
notype is linked to enhanced activation 
of NF-κB and ERK1/2 and is caused by 
lack of negative control by the Fas/FasL 
interaction.  Elevated proliferation of B6/
lpr T cells is thus dependent on signaling 
pathways downstream of the TCR.
In Scheme 10, we illustrate our 
hypothesis wherein Fas acts in the 
control of proliferation after secondary 
stimulation by inhibiting TCR-dependent 
signaling pathways, or by interacting 
directly with the TCR complex (Scheme 
10).  In the latter case, the interaction 
would have an impact on all downstream 
signaling pathways that lead to T cell 
activation and proliferation.  We found 
TCR
Fas
  NF-κB
activation
   ERK
activation   CD25/CD69   upregulation
?
A
B
Scheme 10. Scheme showing possible 
Fas effects on TCR-dependent signaling
A. Fas might interact directly with the TCR 
complex, thus affecting all TCR-triggered 
pathways, or (B) Fas might have a regula-
tory effect downstream of the TCR complex, 
affecting some or all of the pathways.
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that hyperproliferation of B6/lpr T cells 
is a TCR-mediated phenomenon, since 
after the IL-2 expansion phase, only 
TCR-restimulated Fas-deficient T cells 
hyperproliferated compared to controls. 
Proliferation of B6/lpr T cells without 
TCR restimulation was not higher than 
that of control T cells (Fig. 24B).  These 
data demonstrate that Fas interacts 
with proximal TCR signaling events to 
negatively regulate T cell proliferation. 
Indeed, Fas acts upstream of PKC and/
or Ca2+ signaling in the TCR proliferative 
pathway (Fig. 25A, B), and Fas deficiency 
influences early signaling steps in 
the proliferative pathway, including 
phosphorylation of Src, ZAP70, LAT and 
PKCα (Fig. 25C).  Our results therefore 
indicate that, in the model we propose, 
Fas interacts directly with TCR complex 
and thus affects all downstream signaling 
pathways that lead to T cell activation 
and proliferation (Scheme 11).
Differences in the phosphorylation 
pattern of the proteins analyzed were 
apparent before secondary stimulation. 
These differences appear to have no 
functional significance, however, since 
there was no NF-κB activation, nor was 
proliferation of B6/lpr T cells higher than 
that of control T cells before restimulation 
or during the IL-2 expansion phase. 
This suggests that Fas is a regulator 
of the unengaged TCR complex and 
can therefore control initiation of TCR-
mediated signaling directly.  These 
findings concur with observations that 
showed pre-association of Lck and Fas 
in untreated cells and suggested that the 
unengaged TCR complex acts as a direct 
regulator of Fas signaling (Akimzhanov et 
al., 2010; Sharif-Askari et al., 2007).  Our 
findings thus implicate Fas as a regulator 
of proximal TCR signaling events, and 
show that its deficiency leads to the 
pathological amplification of TCR-induced 
signaling.
To maintain T cell homeostasis, a 
proliferative response should terminate 
once the antigen has been cleared.  One 
mechanism that contributes to the signal 
arrest initiated by antigen binding is TCR 
downmodulation (Valitutti et al., 1996; 
Valitutti et al., 1997; Cai et al., 1997; 
Liu et al., 2000; Davanture et al., 2003). 
We found that TCR downregulation 
was defective in B6/lpr T cells (Fig. 26); 
persistent TCR expression in these 
cells could therefore lead to enhanced, 
prolonged signaling, which would result 
in the hyperproliferative phenotype.  This 
could in turn be implicated in the loss of 
self-tolerance observed in B6/lpr mice. 
In contrast, TCR-induced signaling in 
control T cells is not maintained for such a 
TCR
Fas
  NF-κB
activation
   ERK
activation   CD25/CD69   upregulation
Scheme 11.  Fas affects the TCR complex
Fas interacts directly with the TCR complex 
and negatively regulates early signaling 
events, which influences all downstream 
pathways.
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prolonged period, and thus the functional 
outcome is controlled proliferation 
and self tolerance.  In a recent study, 
Katzman and colleagues indeed showed 
physiological relevance for the duration of 
TCR-induced signals; they reported that 
length of T cell-APC (antigen-presenting 
cell) interaction and concomitant TCR-
mediated signaling are key determinants 
in lymphocyte tolerance vs. activation 
(Katzman et al., 2010).  They suggested 
that loss of self tolerance is caused 
by prolonged T cell-APC interaction, 
which induces enhanced TCR signaling, 
whereas transient interactions and 
signaling lead to abortive activation that 
could account for the tolerant phenotype.
Overall, our data indicate that Fas 
is necessary for the regulation of early 
TCR signaling events, and that the 
greater proliferative capacity of B6/
lpr T cells results from a direct effect 
of Fas deficiency on TCR expression. 
The absence of Fas impairs TCR 
downmodulation; this could result in 
persistent signaling that induces stable, 
prolonged expression of activation 
markers, and could in turn provoke a 
hyperproliferative phenotype and loss of 
self tolerance in B6/lpr T cells.
Fas is necessary for correct TCR 
internalization after secondary 
stimulation
Using a flow cytometry-based ap-
proach, we found that TCR downregula-
tion was defective in Fas-deficient T cells 
after secondary stimulation (Fig. 26A, 
27A).  The TCR downmodulation process 
comprises receptor internalization, recy-
cling, phosphorylation and degradation 
through the ubiquitin pathway (Alcover 
et al., 2000).  We analyzed the TCR re-
cycling ratio, and detected no difference 
between B6 control and B6/lpr T cells 
(Fig. 28D).  In accordance with the similar 
proliferation rates for B6 and B6/lpr T cells, 
we detected no differences in the degree 
of receptor internalization after primary 
stimulation or during the IL-2 expansion 
phase (Fig. 27D, E).  This observation 
supports the hypothesis that correct TCR 
internalization allows T cells to terminate 
signaling, and thus to end the proliferative 
response.  Consistent with this hypoth-
esis, we found that the TCR internalization 
process is impaired in B6/lpr T cells (Fig. 
27C, 28C).  Confocal microscopy analy-
sis further supported the finding of defec-
tive surface TCR downregulation in B6/lpr 
T cells after the second stimulation (Fig. 
27F).  Our finding that B6 control and B6/
lpr T cells have a similar TCR recycling 
ratio also indicates that defective internal-
ization rather than receptor recycling ac-
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counts for lack of TCR downmodulation 
in B6/lpr T cells.  In addition, we demon-
strated that impaired TCR internalization 
in Fas-deficient T cells is specific to the 
TCR and not to the general endocytosis 
pathway, since transferrin internalization 
was unaffected by the absence of Fas af-
ter restimulation (Fig. 28A, B).
In summary, our findings establish 
that Fas deficiency leads to inhibition 
of TCR internalization after secondary 
stimulation; this can result in B6/lpr T cell 
hyperactivation and hyperproliferation 
(Model 1).
Lck
ZAP70
LAT
NF-κB
ERK1/2
CD25   CBM
caspase-8
Lck
ZAP70
LAT
NF-κB
ERK1/2
CD25   CBM
caspase-8
ZAP70
LAT
Lck
ZAP70
LAT
Lck
A
B
TCRFas
TCRFas
Model 1.  Fas is a negative regulator of early signaling events
A. Following secondary stimulation, Fas is recruited to the TCR complex, where it negatively 
regulates activation and further recruitment of signaling molecules involved in early signaling, 
such as Lck, ZAP70 and LAT.  This allows controlled activation of downstream signaling pa-
thways including ERK, CBM complex and NF-κB.  In addition, Fas promotes internalization of 
the activated TCR complex, which results in signal termination and prevents hyperactivation 
of T cells. B. Absence of Fas during T cell restimulation leads, on one hand, to pathological 
amplification of TCR proximal signaling, resulting in hyperactivation of downstream pathways 
such as NF-κB and ERK; on the other hand, it inhibits TCR complex internalization, which 
leads to prolonged signaling and T cell hyperactivation.
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Direct interaction of Fas with the TCR 
complex regulates T cell activation
Our results thus far indicate that 
Fas has an important regulatory role in 
T cell proliferation by interacting with 
signaling molecules involved in early 
events.  We placed Fas action upstream 
of the PKC and/or Ca2+ cascades in the 
TCR signaling pathway, and found that 
TCR stimulation triggered enhanced 
phosphorylation of upstream molecules 
in Fas-deficient T cells.  Finally, we 
established that Fas is needed for correct 
TCR downregulation after secondary 
stimulation, and that lack of Fas leads to 
impaired internalization of the TCR.
In accordance with these data, 
confocal analyses showed that Fas 
co-localizes with the TCR in control 
T cells, before and after restimulation 
(Fig. 29).  Such co-localization would 
allow a direct impact of Fas on TCR 
internalization and other TCR-triggered 
signaling events.  Our data also showed 
that both Fas and TCR translocated 
from the plasma membrane to the cell 
interior after restimulation, which could 
reflect internalization triggered by antigen 
binding, as we did not observe similar 
translocation in B6/lpr T cells, which have 
defective TCR internalization (Fig. 29).
Consistent with Fas and TCR co-
localization in B6 T cells, we detected 
direct interaction of Fas and TCR complex 
after secondary stimulation.  Fas from B6 
control T cells coimmunoprecipitated with 
TCR and with other proteins involved in 
early signaling; in B6/lpr T cells, however, 
Lck, ZAP70 and PKCθ recruitment to 
the TCR were considerably enhanced 
after restimulation in the absence of 
Fas (Fig. 30).  These results are in line 
with the recent report of Akimzhanov 
et al. showing Fas and TCR interaction 
for the init iation of Fas-mediated 
apoptosis (Akimzhanov et al. 2010).  In 
their experiments, Fas bound directly 
to and activated TCR components Lck 
and PLC-γ1, suggesting that TCR is a 
potent regulator of Fas signaling.  Our 
study indicates that this interaction is 
bidirectional, since Fas is a key regulator 
of secondary T cell activation and 
proliferation.
These data suggest a model wherein 
Fas recruitment to the TCR following 
restimulation leads to impairment in the 
assembly of proteins important in TCR-
activated signaling pathways.  Lack of this 
blockade could result in hyperactivated 
proliferative signaling, as is the case 
in Fas-deficient B6/lpr T cells.  Fas 
association with the TCR thus appears 
to be critical in the control of proximal 
TCR signaling events.  It would be of 
interest to define the signaling event(s) 
that triggers Fas/TCR association.  Better 
understanding of the precise molecular 
pathway activated by TCR in Fas-deficient 
mice promises to shed light on various 
unexplained aspects of autoimmunity, as 
well as on normal immune function.
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Final conclusion and Model
In conclusion, we show that Fas at-
tenuates proliferation of apoptosis-surviv-
ing B6 T cells.  Our data establish an es-
sential Fas function in the control of T cell 
proliferation, independent of the apopto-
sis-inducing potential of Fas.  We provide 
evidence that Fas has an important role 
in the regulation of proximal TCR signal-
ing events, including phosphorylation of 
the upstream molecules Lck, ZAP70, LAT 
and PKC, and internalization of the TCR. 
As a consequence, Fas controls down-
stream signaling pathways that mediate 
T cell proliferation and activation, such 
ERK1/2 and NF-κB.
Based on these observations, we 
suggest that Fas/FasL signaling controls 
T cell homeostasis and lymphadenopa-
thy development through two distinct 
functions; first, by promoting apoptosis, 
and second, by regulating proliferation 
of apoptosis-surviving T cells (Model 2). 
This dual function underlies the potent 
homeostatic role of Fas in the immune 
system.
   DISC
Apoptosis No apoptosis
TCRFasL
FasFas
1. Survival of apoptosis-defective T cells 2. Hyperproliferation of apoptosis defective T cells
Lymphadenopathy
ZAP70
NF-κB ERK1/2
Controled proliferation Hyperproliferation
TCR
FasL
FasFas
Lck
LAT
Normal activation Hyperactivation
2    stimulationnd
defective
internalization
Model 2.  Dual role of Fas in the homeostasis of activated T cells
Fas induces apoptosis of reactivated T cells, and its absence leads to accumulation of apop-
tosis-defective T cells.  Moreover, Fas controls proliferation of apoptosis-surviving T cells; 
it promotes activated TCR complex internalization and thus inhibits early signaling, which 
allows controlled T cell activation and proliferation. Fas deficiency leads to inhibition of Fas 
internalization and to amplification of early signaling and downstream pathways, resulting in 
T cell hyperactivation and hyperproliferation.  Defective apoptosis, together with hyperprolfe-
ration of apoptosis-surviving T cells, leads to development of lymphadenopathy.
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CONCLUSIONS
1.  In addition to its pro-apoptotic role, Fas has an alternative function in T cell 
homeostasis by controlling T cell activation and proliferation.  The Fas proliferation-
regulating effect is physiologically relevant, since p21 overexpression does not affect 
the B6/lpr apoptotic defect, but reduces lymphadenopathy by decreasing B6/lpr T cell 
hyperproliferation.
2.  Defective Fas signaling results in hyperproliferation of TCR-rechallenged B6/lpr 
T cells in vitro, suggesting an important anti-proliferative function for Fas after secondary 
stimulation, independent of its proapoptotic role.
3.  Fas interaction with its ligand is essential for the inhibition of hyperproliferation after 
restimulation, but this interaction is independent of apoptosis induction.
4.  Hyperproliferation of B6/lpr T cells results from their hyperactivation.  Fas acts 
as a negative regulator of T cell activation and proliferation by negatively controlling 
proximal TCR signaling events as well as activation of the CBM complex, NF-κB and 
ERK1/2 pathways.
5.  Correct TCR internalization is essential for signaling termination and proliferation 
control.  TCR downregulation in B6/lpr T cells is defective due to impaired TCR 
internalization.
6.  Fas interacts directly with the TCR complex in the negative control of T cell activation 
and proliferation.
7.  The anti-proliferative function of Fas, together with apoptosis induction, are 
fundamental in the control of immunological homeostasis and peripheral tolerance.
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RESUMEN EN ESPAÑOL
          
          Introducción
 En el proceso de una respuesta 
inmune in vivo, el encuentro de las células 
T con un antígeno se ve acompañado de 
una rápida proliferación clonal, seguida 
de una reducción en el número de células, 
alcanzándose finalmente un equilibrio. 
Se pensaba que la apoptosis mediada 
por Fas, un miembro de la familia de 
receptores del factor de necrosis tumoral 
(TNF del inglés Tumor Necrosis Factor), 
es el principal mecanismo de esta 
retracción del sistema inmune, llamada 
fase de contracción. Sin embargo, la 
regulación in vivo de este proceso no 
esta definida en detalle.  Las células que 
sobreviven constituyen la población de 
células T de memoria.  La des-regulación 
de la respuesta proliferativa de las células 
T o de la apoptosis, puede tener severas 
consecuencias en la homeostasis del 
sistema inmune.
 La tolerancia es un elemento 
crítico del sistema inmune ya que asegura 
su capacidad de reconocer y responder 
sólo a antígenos exógenos y no a los 
propios del organismo.   La pérdida de la 
capacidad de distinguir entre lo propio y lo 
no propio conduce a respuestas inmunes 
contra autoantígenos y al desarrollo 
de enfermedades autoinmunes.  La 
tolerancia contra antígenos propios, 
se mantiene a través del proceso de 
tolerancia central que ocurre durante 
el proceso de maduración en el timo y 
procesos periféricos como la “ignorancia” 
inmunológica, delección, inhibición o 
supresión de clones autoreactivos.
 Se sabe que la eliminación de 
las células T activadas es el principal 
mecanismo para asegurar la tolerancia 
en periferia.  La interacción de Fas con 
Fas ligando (FasL), es fundamental para 
la homeostasis de células T y la inducción 
de tolerancia.
 La muerte celular inducida por 
activación (AICD del inglés Activation-
Induced Cell Death) es el proceso in vitro 
de inducción de muerte celular en células 
T activadas por una re-estimulación del 
TCR.  En este modelo experimental, se 
estimula inicialmente las células T nativas 
con antígenos o mitógenos; seguidamente 
estas células son expandidas en un 
medio de cultivo con IL-2 y re-estimuladas 
vía TCR.  Tras la re-estimulación, se da 
una inducción del FasL y su unión a Fas, 
induce cambios conformacionales en el 
receptor que permiten el reclutamiento 
de la molécula adaptadora FADD 
(del inglés Fas-Associated Death Domain 
protein).  Esto conduce al reclutamiento 
del iniciador caspasa-8 y la formación 
del complejo de señalización inductor de 
muerte (DISC del inglés Death Inducing 
Signaling Complex). La internalización 
del receptor asociado a DISC, permite 
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el auto-procesado de la caspasa-8 y su 
activación, disparando la apoptosis.
 La caspasa-8 en su forma comple-
ta (sin procesar) está asociada con la pro-
liferación de los linfocitos tras estimula-
ción del TCR, y su actividad es necesaria 
para la activación de NF-κB.  Se ha des-
crito que la caspasa-8 se recluta al com-
plejo CBM (CARMA1, BCL10, MALT1) y 
en este contexto molecular, contribuye a 
la activación del complejo IKK.  La inhi-
bición in vivo e in vitro de la actividad de 
caspasa-8 en las células T CD4+ tanto 
humanas como de ratón, conduce a una 
menor proliferación y producción de IL-2 
después de una estimulación por TCR, 
constituyendo así la caspasa-8 un ele-
mento indispensable para la proliferación 
normal de los linfocitos.
 La activación de células T, su pro-
liferación y sus funciones inmunológicas 
son el resultado de eventos de señaliza-
ción que se originan a partir de la estimu-
lación del receptor de células T (TCR del 
inglés T Cell Receptor).  Cuando el TCR 
reconoce su ligando, se activa la fosfori-
lación de residuos de tirosina en los mo-
tivos ITAMs (del inglés Immunoreceptor 
Tyrosine-based Activation Motifs) de las 
cadenas TCR-ζ y CD3-γ, -δ y –ε, por las 
kinasas de la familia src, Lck y en menor 
grado Fyn.  Esto conduce al reclutamien-
to y fosforilación de ZAP70, que a su vez, 
recluta y fosforila a moléculas adaptado-
ras como LAT, SLAP, SLP-76, PLC-γ1 y 
Cbl.  Seguidamente, se activan múltiples 
cascadas de señalización incluyendo 
ERK, JNK, NF-κB y NFAT, que en último 
término inducen las funciones efectoras.
 Uno de los procesos cruciales en 
el apagado de la señalización por TCR es 
su propia internalización y subsecuente 
degradación.  El complejo TCR se 
internaliza a través de vesículas cubiertas 
por clatrina y existen al menos dos rutas 
distintas de endocitosis del TCR.  Una 
es dependiente de la actividad tirosina 
kinasa, que conduce a la ubiquitinación 
del TCR; la otra, es dependiente de la 
activación mediada por la proteína kinasa 
C (PKC) del dominio di-leucina de la 
subunidad CD3-γ, que origina el reciclado 
del receptor. Se ha sugerido que la 
función más probable de la reducción del 
TCR en la superficie celular, es proteger 
a las células de una sobre-estimulación y 
que este proceso de modulación es una 
eficiente manera de inducir tolerancia.
 Una deficiente señalización me-
diada por Fas/FasL en ratones B6/lpr y 
en pacientes con síndrome linfoprolifera-
tivo autoinmune (ALPS del inglés Autoim-
mune LymphoProliferative Syndrome) 
origina el desarrollo de linfoadenopatías 
y autoinmunidad caracterizadas por la 
acumulación de células T Dobles Nega-
tivas (DN), células T de memoria, niveles 
elevados en suero de IgGs y auto-anti-
cuerpos, formación de complejos inmu-
nes en tejidos y glomerulonefritis leve.
 La pérdida de apoptosis inducida 
por Fas en las células T activadas, se 
ha sugerido como causa directa de los 
fenotipos mostrados por ratones B6/lpr y 
en los pacientes del ALPS. Defectos en 
apoptosis sin embargo, son insuficientes 
para justificar la linfoadenopatía y la 
autoinmunidad observada en ratones B6/
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lpr, ya que la ausencia de otras moléculas 
pro-apoptóticas como FADD y caspasa-8 
originan un defecto en apoptosis pero no 
manifestaciones patológicas como las 
descritas anteriormente.  Además, a pesar 
del bien conocido papel en la muerte 
celular de Fas in vitro, la relevancia in 
vivo de la apoptosis inducida por Fas es 
materia de debate.
 Además del desarrollo de la en-
fermedad autoinmune en pacientes con 
ALPS y ratones B6/lpr, las células T de 
sus ganglios linfáticos hiper-proliferan 
in vivo, lo cual está aún por explicar.  Tal 
y como se mostrará en esta tesis, esta 
hiper-proliferación es relevante fisiológi-
camente, ya que su inhibición origina una 
reducción de la linfoadenopatía; como 
en el caso de los ratones B6/lpr que so-
breexpresan el inhibidor de ciclo celular 
p21en sus células T.
         
 
         
          Objetivos
 La enfermedad autoinmune en los ratones B6/lpr es el resultado de una 
alteración severa de la homeostasis inmune.  Ya que defectos en apoptosis debidos a 
la deficiencia de Fas no pueden explicar el desarrollo de la linfoadenopatía, la hiper-
activación o la hiper-proliferación de las células T de estos animales, el objetivo de esta 
tesis es mostrar que, además de la inducción de apoptosis, Fas tiene otras funciones 
en la homeostasis inmune, que están asociadas con el control de la activación de 
células T y su proliferación.  Además, analizamos el efecto de la sobre-expresión del 
inhibidor de ciclo celular p21 en la hiper-proliferación observada en los ratones B6/
lpr.
Establecimos los siguientes objetivos:
1. Analizar la capacidad proliferativa de las células T deficientes en Fas y FasL y su 
estatus de activación de NF-κB
2. Estudiar la importancia de la interacción Fas-FasL y el mecanismo molecular que 
subyace en el efecto inhibitorio de Fas en la proliferación secundaria de las células T
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3. Determinar en qué punto de la señalización implicada en la activación / proliferación, 
ejerce Fas su papel inhibidor
4. Identificar la relación de Fas con el TCR en la activación y proliferación de las 
células T
5. Intentar inhibir la hiper-proliferación mostrada en ratones B6/lpr 
6.Analizar el efecto in vivo de la sobre-expresión de p21 en las células T de ratones 
B6/l
          
          Resultados
 En esta tesis mostramos que 
además de su efecto pro-apoptótico, 
Fas es un regulador crítico de la 
activación y proliferación de las células 
T que sobreviven a la apoptosis.  Tras 
re-estimulación, las células T B6/lpr 
alcanzan un mayor estado de activación 
e hiper-proliferan comparadas con las 
células control.  Esta hiper-proliferación 
es biológicamente relevante, ya que 
su inhibición por la sobre-expresión 
de p21 reduce la linfoadenopatía y las 
manifestaciones autoinmunes de ratones 
deficientes en Fas.
 El control por Fas de la prolifera-
ción es independiente de su potencial in-
ductor de AICD, ya que el fenotipo hiper-
proliferativo se observa también en con-
diciones sin apoptosis.  Además, la inte-
racción de Fas con FasL recombinante 
atenúa directamente la hiper-proliferación 
de células T B6/gld deficientes en FasL, 
re-estimuladas en presencia del inhibidor 
de muerte celular.
 Nuestro análisis de la respuesta 
proliferativa tanto de células T nativas 
como de memoria, excluyó la posibilidad 
de que la hiper-proliferación de células 
T B6/lpr fuera debida a diferencias en el 
estatus activación / memoria antes de la 
segunda estimulación, o de condiciones 
artefactuales de cultivo que favorezcan 
la selección de clones deficientes en Fas 
con mayor capacidad proliferativa inicial.
 Los resultados también implican 
que la ausencia de Fas en las células 
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T re-est imuladas conduce a una 
mayor activación de las cascadas de 
señalización NF-κB y ERK 1/2 y que 
Fas controla la activación y proliferación 
de células T mediante regulación 
negativa de la actividad de caspasa-8 
en su forma completa.  Caspasa-8 
sin procesar controla la activación del 
complejo CBM, y la proliferación de 
las células T re-estimuladas, tanto en 
B6 como en B6/lpr, independiente de 
su función pro-apoptótica.  Además, 
encontramos que tras re-estimulación del 
TCR en condiciones libres de apoptosis, 
caspasa-8 se localiza en diferentes 
regiones celulares en las células T 
deficientes en Fas que en controles. 
Esto sugiere que Fas es necesario para 
la internalización de la porción pro-
proliferativa de caspasa-8.
 Nuestros datos también indican 
que Fas es un regulador de los eventos 
proximales de la señalización del TCR, 
incluyendo la fosforilación de Lck, ZAP70 
y PKC; la deficiencia de Fas conduce 
a una amplificación de estas señales. 
Además, la ausencia de Fas durante 
la re-estimulación de células T, resulta 
en la inhibición de la internalización del 
TCR.  Una internalización deficiente del 
TCR en células T B6/lpr podría resultar 
en una activación prolongada de las 
cascadas de señalización, originando 
una hiper-activación de NF-κB y ERK 
1/2, y finalmente, la hiper-activación e 
hiper-proliferación de las células T.
 Vimos que en las células T con-
trol, Fas co-localiza con el TCR antes y 
después de una segunda estimulación, lo 
cual podría permitir una influencia direc-
ta de Fas en la internalización del TCR 
y otras señales dependientes del mismo. 
Además, Fas es reclutado al complejo 
TCR después de una re-estimulación, 
posiblemente impidiendo la agregación 
de proteínas importantes en las casca-
das de señalización iniciadas por el TCR; 
la pérdida de este impedimento podría 
por otra parte, resultar en señales prolife-
rativas hiper-activadas, como es el caso 
en células T B6/lpr deficientes en Fas.
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          Conclusiones
1. Fas, además de un papel pro-apoptótico, tiene una función alternativa en la 
homeostasis de las células T, controlando su activación y proliferación.  El efecto 
regulador de proliferación de Fas es fisiológicamente relevante, ya que la sobre-
expresión de p21 no afecta al defecto apoptótico de las células B6/lpr, pero reduce la 
linfoadenopatía que muestran los ratones B6/lpr, mediante la reducción de la hiper-
proliferación de sus células T.
2. La señalización deficiente por Fas, resulta en hiper-proliferación de células T B6/lpr 
in vitro re-estimuladas vía TCR, sugiriendo una importante función anti-proliferativa de 
Fas tras una estimulación secundaria, e independiente de su rol pro-apoptótico.
3. La interacción de Fas con su ligando es esencial para la inhibición de la hiper-
proliferación tras re-estimulación, pero este fenómeno es independiente de la inducción 
de apoptosis.
4. La hiper-proliferación de las células T B6/lpr resulta de su hiper-activación. Fas actúa 
como un regulador negativo de la activación y proliferación de células T mediante el 
control negativo de eventos proximales en la señalización del TCR, así como de la 
activación del complejo CBM, NF-κB y ERK 1/2.
5. Una correcta internalización del TCR es esencial para la terminación de la 
señalización y el control de la proliferación.  La reducción del TCR en la superficie de 
las células T B6/lpr es defectuosa debido a una internalización impedida.
6.Fas interacciona directamente con el complejo TCR en el control negativo de la 
activación y proliferación de células T.
7. La función anti-proliferativa de Fas, junto con la inducción de apoptosis, son 
fundamentales en el control de la homeostasis inmunológica y tolerancia periférica.
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 En esta tesis, examinamos la naturaleza de las células T deficientes en Fas hiper-
proliferativas y estudiamos su implicación en una enfermedad tipo lupus en ratones 
B6/lpr.  Hemos visto que la reducción de la hiper-proliferación de células T, de hecho, 
atenúa las manifestaciones de la enfermedad en estos animales, e identifica a Fas 
como un potente regulador negativo de la proliferación de las células T pre-activadas. 
Nuestros datos indican que Fas se asocia con el complejo TCR y afecta a su inter-
nalización así como a otros eventos de señalización tempranos.  Basados en estos 
descubrimientos, proponemos un mecanismo de homeostasis de las células T que 
implica esta alternativa a la función pro-apoptótica de Fas.
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